U.S. patent application number 09/773658 was filed with the patent office on 2001-10-04 for omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors.
Invention is credited to Dumas, Jaques, Khire, Uday, Lowinger, Timothy B., Monahan, Mary-Katherine, Natero, Reina, Renick, Joel, Riedl, Bernd, Scott, William J., Sibley, Robert N., Smith, Roger A., Wood, Jill E..
Application Number | 20010027202 09/773658 |
Document ID | / |
Family ID | 56290111 |
Filed Date | 2001-10-04 |
United States Patent
Application |
20010027202 |
Kind Code |
A1 |
Riedl, Bernd ; et
al. |
October 4, 2001 |
Omega-carboxyaryl substituted disphenyl ureas as raf kinase
inhibitors
Abstract
This invention relates to the use of a group of aryl ureas in
treating raf mediated diseases, and pharmaceutical compositions for
use in such therapy.
Inventors: |
Riedl, Bernd; (Wuppertal,
DE) ; Dumas, Jaques; (Orange, CT) ; Khire,
Uday; (Hamden, CT) ; Lowinger, Timothy B.;
(Nishinomiya City, JP) ; Scott, William J.;
(Guilford, CT) ; Smith, Roger A.; (Madison,
CT) ; Wood, Jill E.; (Hamden, CT) ; Monahan,
Mary-Katherine; (Hamden, CT) ; Natero, Reina;
(Hamden, CT) ; Renick, Joel; (Milford, CT)
; Sibley, Robert N.; (Noth Haven, CT) |
Correspondence
Address: |
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I, Suite 1400
2200 Clarendon Boulevard
Arlington
VA
22201
US
|
Family ID: |
56290111 |
Appl. No.: |
09/773658 |
Filed: |
February 2, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09773658 |
Feb 2, 2001 |
|
|
|
09425228 |
Oct 22, 1999 |
|
|
|
09425228 |
Oct 22, 1999 |
|
|
|
09257266 |
Feb 25, 1999 |
|
|
|
60115877 |
Jan 13, 1999 |
|
|
|
Current U.S.
Class: |
514/354 ;
514/256; 544/326; 546/291 |
Current CPC
Class: |
C07C 275/40 20130101;
C07C 275/32 20130101; C07D 209/46 20130101; A61K 31/5375 20130101;
C07D 401/12 20130101; A61K 31/44 20130101; A61K 31/40 20130101;
A61K 31/4439 20130101; C07C 275/30 20130101; C07D 209/48 20130101;
C07D 295/135 20130101; A61K 31/17 20130101; C07C 275/36 20130101;
C07C 311/29 20130101; C07D 295/073 20130101; C07D 295/12 20130101;
C07D 295/13 20130101; C07F 7/1804 20130101; A61K 31/496 20130101;
C07D 213/80 20130101; C07D 213/81 20130101; A61K 31/18 20130101;
A61P 43/00 20180101; C07D 413/12 20130101; A61P 35/00 20180101;
C07C 275/28 20130101; A61K 31/341 20130101; A61K 31/4035 20130101;
C07C 317/22 20130101; C07D 295/18 20130101; C07D 295/192 20130101;
C07D 213/75 20130101; C07D 209/50 20130101; A61K 31/4453 20130101;
A61K 31/24 20130101; C07D 213/82 20130101; A61K 31/495 20130101;
A61K 31/5377 20130101 |
Class at
Publication: |
514/354 ;
514/256; 546/291; 544/326 |
International
Class: |
A61K 031/505; C07D
211/72; C07D 211/84; C07D 213/63; C07D 213/70; C07D 239/02; A61K
031/44 |
Claims
What is claimed is:
1. A compound of Formula I: A-D-B (I) or a pharmaceutically
acceptable salt thereof, wherein D is --NH--C(O)--NH--, A is a
substituted moiety of up to 40 carbon atoms of the formula:
-L-(M-L.sup.1).sub.q, where L is a 5 or 6 membered cyclic structure
bound directly to D, L.sup.1 comprises a substituted cyclic moiety
having at least 5 members, M is a bridging group having at least
one atom, q is an integer of from 1-3; and each cyclic structure of
L and L.sup.1 contains 0-4 members of the group consisting of
nitrogen, oxygen and sulfur, and B is a substituted or
unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to
30 carbon atoms with at least one 6-member cyclic structure bound
directly to D containing 0-4 members of the group consisting of
nitrogen, oxygen and sulfur, wherein L.sup.1 is substituted by at
least one substituent selected from the group consisting of
--SO.sub.2R.sub.x, --C(O)R.sub.x and --C(NR.sub.y)R.sub.z, R.sub.y
is hydrogen or a carbon based moiety of up to 24 carbon atoms
optionally containing heteroatoms selected from N, S and O and
optionally halosubstituted, up to per halo, R.sub.z is hydrogen or
a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen; R.sub.x
is R.sub.z or NR.sub.aR.sub.b where R.sub.a and R.sub.b are a)
independently hydrogen, a carbon based moiety of up to 30 carbon
atoms optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen, hydroxy and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen, or --OSi(R.sub.f).sub.3 where R.sub.f is hydrogen or a
carbon based moiety of up to 24 carbon atoms optionally containing
heteroatoms selected from N, S and O and optionally substituted by
halogen, hydroxy and carbon based substituents of up to 24 carbon
atoms, which optionally contain heteroatoms selected from N, S and
O and are optionally substituted by halogen; or b) R.sub.a and
R.sub.b together form a 5-7 member heterocyclic structure of 1-3
heteroatoms selected from N, S and O, or a substituted 5-7 member
heterocyclic structure of 1-3 heteroatoms selected from N, S and O
substituted by halogen, hydroxy or carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen; or c)
one of R.sub.a or R.sub.b is --C(O)--, a C.sub.1-C.sub.5 divalent
alkylene group or a substituted C.sub.1-C.sub.5 divalent alkylene
group bound to the moiety L to form a cyclic structure with at
least 5 members, wherein the substituents of the substituted
C.sub.1-C.sub.5 divalent alkylene group are selected from the group
consisting of halogen, hydroxy, and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen; where B
is substituted, L is substituted or L.sup.1 is additionally
substituted, the substituents are selected from the group
consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting
of --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7, --C(O)--R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7, --NR.sup.7R.sup.7,
--NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, -Q-Ar, and carbon
based moieties of up to 24 carbon atoms, optionally containing
heteroatoms selected from N, S and O and optionally substituted by
one or more substituents independently selected from the group
consisting of --CN, CO.sub.2R.sup.7, --C(O)R.sup.7,
--C(O)NR.sup.7R.sup.7, --OR.sup.7, --SR.sup.7, --NR.sup.7R.sup.7,
--NO.sub.2, --NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 and
halogen up to per-halo; with each R.sup.7 independently selected
from H or a carbon based moiety of up to 24 carbon atoms,
optionally containing heteroatoms selected from N, S and O and
optionally substituted by halogen, wherein Q is --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7- )--, --O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, and X.sup.a is
halogen; and Ar is a 5- or 6-member aromatic structure containing
0-2 members selected from the group consisting of nitrogen, oxygen
and sulfur, which is optionally substituted by halogen, up to
per-halo, and optionally substituted by Z.sub.n1, wherein n1 is 0
to 3 and each Z is independently selected from the group consisting
of --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7 --NR.sup.7R.sup.7,
--NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, and a carbon based
moiety of up to 24 carbon atoms, optionally containing heteroatoms
selected from N, S and O and optionally substituted by one or more
substituents selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --COR.sup.7, --C(O)NR.sup.7R.sup.7, --OR.sup.7,
--SR.sup.7, --NO.sub.2,--NR.sup.7R.sup- .7,--NR.sup.7C(O)R.sup.7,
and --NR.sup.7C(O)OR.sup.7, with R.sup.7 as defined above.
2. A compound as in claim 1 wherein: R.sub.y is hydrogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, C.sub.3-10 cycloalkyl having
0-3 heteroatoms, C.sub.2-10 alkenyl, C.sub.1-10 alkenoyl,
C.sub.6-12 aryl, C.sub.3-12 hetaryl having 1-3 heteroatoms selected
from N, S and O, C.sub.7-24 aralkyl, C.sub.7-24 alkaryl,
substituted C.sub.1-10 alkyl, substituted C.sub.1-10 alkoxy,
substituted C.sub.3-10 cycloalkyl having 0-3 heteroatoms selected
from N, S and O, substituted C.sub.6-C.sub.14 aryl, substituted
C.sub.3-12 hetaryl having 1-3 heteroatoms selected from N, S and O,
substituted C.sub.7-24 alkaryl or substituted C.sub.7-C.sub.24
aralkyl, where R.sub.y is a substituted group, it is substituted by
halogen up to per halo, R.sub.z is hydrogen, C.sub.1-10 alkyl,
C.sub.1-10 alkoxy, C.sub.3-10 cycloalkyl having 0-3 heteroatom,
C.sub.2-10 alkenyl, C.sub.1-10 alkenoyl, C.sub.6-12 aryl,
C.sub.3-C.sub.12 hetaryl having 1-3 heteroatoms selected from, S, N
and O, C.sub.7-24 alkaryl, C.sub.7-24 aralkyl, substituted
C.sub.1-10 alkyl, substituted C.sub.1-10 alkoxy, substituted
C.sub.6-C.sub.14 aryl, substituted C.sub.3-C.sub.10 cycloalkyl
having 0-3 heteroatoms selected from S, N and O, substituted
C.sub.3-12 hetaryl having 1-3 heteroatoms selected from S, N and O,
substituted C.sub.7-24 alkaryl or substituted C.sub.7-C.sub.24
aralkyl where R.sub.z is a substituted group, it is substituted by
halogen up to per halo, hydroxy, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl having 0-3 heteroatoms selected from O, S and N,
C.sub.3-12 hetaryl having 1-3 heteroatoms selected from N, S and O,
C.sub.1-10 alkoxy, C.sub.6-12 aryl, C.sub.1-6 halo substituted
alkyl up to per halo alkyl, C.sub.6-C.sub.12 halo substituted aryl
up to per halo aryl, C.sub.3-C.sub.12 halo substituted cycloalkyl
up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S
and O, halo substituted C.sub.3-C.sub.12 hetaryl up to per halo
hetaryl having 1-3 heteroatoms selected from O, N and S, halo
substituted C.sub.7-C.sub.24 aralkyl up to per halo aralkyl, halo
substituted C.sub.7-C.sub.24 alkaryl up to per halo alkaryl, and
--C(O)R.sub.g, R.sub.a and R.sub.b are, a) independently hydrogen,
a carbon based moiety selected from te group consisting of
C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.3-10
cycloalkyl, C.sub.2-10 alkenyl, C.sub.1-10 alkenoyl, C.sub.6-12
aryl, C.sub.3-12 hetaryl having 1-3 heteroatoms selected from O, N
and S, C.sub.3-12 cycloalkyl having 0-3 heteroatoms selected from
N, S and O, C.sub.7-24 aralkyl, C.sub.7-C.sub.24 alkaryl,
substituted C.sub.1-10 alkyl, substituted C.sub.1-10 alkoxy,
substituted C.sub.3-10 cycloalkyl, having 0-3 heteroatoms selected
from N, S and O, substituted C.sub.6-12 aryl, substituted
C.sub.3-12 hetaryl having 1-3 heteroatoms selected from N, S and O,
substituted C.sub.7-24 aralkyl, substituted C.sub.7-24 alkaryl,
where R.sub.a and R.sub.b are a substituted group, they are
substituted by halogen up to per halo, hydroxy, C.sub.1-10 alkyl,
C.sub.3-12 cycloalkyl having 0-3 heteroatoms selected from O, S and
N, C.sub.3-12 hetaryl having 1-3 heteroatoms selected from N, S and
O, C.sub.1-10 alkoxy, C.sub.6-12 aryl, C.sub.1-6 halo substituted
alkyl up to per halo alkyl, C.sub.6-C.sub.12 halo substituted aryl
up to per halo aryl, C.sub.3-C.sub.12 halo substituted cycloalkyl
having 0-3 heteroatoms selected from N, S and O, up to per halo
cycloalkyl, halo substituted C.sub.3-C.sub.12 hetaryl up to per
halo heteraryl, halo substituted C.sub.7-C.sub.24 aralkyl up to per
halo aralkyl, halo substituted C.sub.7-C.sub.24 alkaryl up to per
halo alkaryl, and --C(O)R.sub.g; or --OSi(R.sub.f).sub.3 where
R.sub.f is hydrogen, C.sub.1-10 alkyl, C.sub.1-10 alkoxy,
C.sub.3-C.sub.10 cycloalkyl having 0-3 heteroatoms selected from O,
S and N, C.sub.6-12 aryl, C.sub.3-C.sub.12 hetaryl having 1-3
heteroatoms selected from O, S and N, C.sub.7-24 aralkyl,
substituted C.sub.1-10 alkyl, substituted C.sub.1-C.sub.10 alkoxy,
substituted C.sub.3-C.sub.12 cycloalkyl having 0-3 heteroatoms
selected from O, S and N, substituted C.sub.3-C.sub.12 heteraryl
having 1-3 heteroatoms selected from O, S, and N, substituted
C.sub.6-12 aryl, and substituted C.sub.7-24 alkaryl, where R.sub.f
is a substituted group it is substituted halogen up to per halo,
hydroxy, C.sub.1-10 alkyl, C.sub.3-.sub.12 cycloalkyl having 0-3
heteroatoms selected from O, S and N, C.sub.3-12 hetaryl having 1-3
heteroatoms selected from N, S and O, C.sub.1-10 alkoxy, C.sub.6-12
aryl, C.sub.7-C.sub.24 alkaryl, C.sub.7-C.sub.24 aralkyl, C.sub.1-6
halo substituted alkyl up to per halo alkyl, C.sub.6-C.sub.12 halo
substituted aryl up to per halo aryl, C.sub.3-C.sub.12 halo
substituted cycloalkyl having 0-3 heteroatoms selected from N, S
and O, up to per halo cycloalkyl, halo substituted C.sub.3-C.sub.12
hetaryl up to per halo heteraryl, halo substituted C.sub.7-C.sub.24
aralkyl up to per halo aralkyl, halo substituted C.sub.7-C.sub.24
alkaryl up to per halo alkaryl, and --C(O)R.sub.g, or b) R.sub.a
and R.sub.b together form a 5-7 member heterocyclic structure of
1-3 heteroatoms selected from N, S and O, or a substituted 5-7
member heterocyclic structure of 1-3 heteroatoms selected from N, S
and O with substituents selected from the group consisting of
halogen up to per halo, hydroxy, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl having 0-3 heteroatoms selected from 0, S and N,
C.sub.3-12 hetaryl having 1-3 heteroatoms selected from N, S and O,
C.sub.1-10 alkoxy, C.sub.6-.sub.12 aryl, C.sub.7-C.sub.24 alkaryl,
C.sub.7-C.sub.24 aralkyl, halo substituted C.sub.1-6 alkyl up to
per halo alkyl, halo substituted C.sub.6-C.sub.12 aryl up to per
halo aryl, halo substituted C.sub.3-C.sub.12 cycloalkyl having 0-3
heteroatoms selected from N, S and O, up to per halo cycloalkyl,
halo substituted C.sub.3-C.sub.12 hetaryl up to per halo heteraryl,
halo substituted C.sub.7-C.sub.24 aralkyl up to per halo aralkyl,
halo substituted C.sub.7-C.sub.24 alkaryl up to per halo alkaryl,
and --C(O)R.sub.g, or c) one of R.sub.a or R.sub.b is --C(O)--, a
C.sub.1-C.sub.5 divalent alkylene group or a substituted
C.sub.1-C.sub.5 divalent alkylene group bound to the moiety L to
form a cyclic structure with at least 5 members, wherein the
substituents of the substituted C.sub.1-C.sub.5 divalent alkylene
group are selected from the group consisting of halogen, hydroxy,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl having 0-3 heteroatoms
selected from O, S and N, C.sub.3-12 hetaryl having 1-3 heteroatoms
selected from N, S and O, C.sub.1-10 alkoxy, C.sub.6-12 aryl,
C.sub.7-C.sub.24 alkaryl, C.sub.7-C.sub.24 aralkyl, C.sub.1-6 halo
substituted alkyl up to per halo alkyl, C.sub.6-C.sub.12 halo
substituted aryl up to per halo aryl, C.sub.3-C.sub.12 halo
substituted cycloalkyl having 0-3 heteroatoms selected from N, S
and O, up to per halo cycloalkyl, halo substituted C.sub.3-C.sub.12
hetaryl up to per halo heteraryl, halo substituted C.sub.7-C.sub.24
aralkyl up to per halo aralkyl, halo substituted C.sub.7-C.sub.24
alkaryl up to per halo alkaryl, and --C(O)R.sub.g, where R.sub.g is
C.sub.1-10 alkyl; --CN, --CO.sub.2R.sub.d, --OR.sub.d, --SR.sub.d,
--NO.sub.2, --C(O)R.sub.e, --NR.sub.dR.sub.e,
--NR.sub.dC(O)OR.sub.e and --NR.sub.dC(O)R.sub.e, and R.sub.d and
R.sub.e are independently selected from the group consisting of
hydrogen, C.sub.1-10, alkyl, C.sub.1-10 alkoxy, C.sub.3-10
cycloalkyl having 0-3 heteroatoms selected from O, N and S,
C.sub.6-12 aryl, C.sub.3- C.sub.12 hetaryl with 1-3 heteroatoms
selected from O, N and S and C.sub.7-C.sub.24 aralkyl,
C.sub.7-C.sub.24 alkaryl, up to per halo substituted
C.sub.1-C.sub.10 alkyl, up to per halo substituted C.sub.3-C.sub.10
cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to
per halo substituted C.sub.6-C.sub.14 aryl, up to per halo
substituted C.sub.3-C.sub.12 hetaryl having 1-3 heteroatoms
selected from O, N, and S, halo substituted C.sub.7-C.sub.24
alkaryl up to per halo alkaryl, and up to per halo substituted
C.sub.7-C.sub.24 aralkyl, W is independently selected from the
group consisting of --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7,
--C(O)--R.sup.7, --NO.sub.2, --OR.sup.7, --SR.sup.7,
--NR.sup.7R.sup.7, --NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7,
C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10
alkenyl, C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl
having 0-3 heteroatoms selected from O, S and N, C.sub.6-C.sub.14
aryl, C.sub.7-C.sub.24 alkaryl, C.sub.7-C.sub.24 aralkyl,
C.sub.3-C.sub.12 heteroaryl having 1-3 heteroatoms selected from O,
N and S, C.sub.4-C.sub.23 alkheteroaryl having 1-3 heteroatoms
selected from O, N and S, substituted C.sub.1-C.sub.10 alkyl,
substituted C.sub.1-C.sub.10 alkoxy, substituted C.sub.2-C.sub.10
alkenyl, substituted C.sub.1-C.sub.10 alkenoyl, substituted
C.sub.3-C.sub.10 cycloalkyl having 0-3 heteroatoms selected from O,
N and S, substituted C.sub.6-C.sub.12 aryl, substituted
C.sub.3-C.sub.12 hetaryl having 1-3 heteroatoms selected from O, N
and S, substituted C.sub.7-C.sub.24 aralkyl, substituted
C.sub.7-C.sub.24 alkaryl, substituted C.sub.4-C.sub.23
alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and
-Q-Ar; R.sup.7 is independently selected from H, C.sub.1-C.sub.10
alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10 alkenyl,
C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl having 0-3
heteroatoms selected from O, S and N, C.sub.6-C.sub.14 aryl,
C.sub.3-C.sub.13 hetaryl having 1-3 heteroatoms selected from O, N
and S, C.sub.7-C.sub.1 4 alkaryl, C.sub.7-C.sub.24 aralkyl,
C.sub.4-C.sub.23 alkheteroaryl having 1-3 heteroatoms selected from
O, N and S, up to per-halosubstituted C.sub.1-C.sub.10 alkyl, up to
per-halosubstituted C.sub.3-C.sub.10 cycloalkyl having 0-3
heteroatoms selected from O, N and S, up to per-halosubstituted
C.sub.6-C.sub.1 4 aryl, up to per-halosubstituted C.sub.3-C.sub.13
hetaryl having 1-3 heteroatoms selected from O, N and S, up to
per-halosubstituted C.sub.7-C.sub.24 aralkyl, up to
per-halosubstituted C.sub.7-C.sub.24 alkaryl, and up to
per-halosubstituted C.sub.4-C.sub.23 alkheteroaryl; and each Z is
independently selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7 --NR.sup.7R.sup.7,
--NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, C.sub.1-C.sub.10
alkyl, C.sub.1-C.sub.10 alkoxy, C.sub.2-C.sub.10 alkenyl,
C.sub.1-C.sub.10 alkenoyl, C.sub.3-C.sub.10 cycloalkyl having 0-3
heteroatoms selected from O, N and S, C.sub.6-C.sub.14 aryl,
C.sub.3-C.sub.1 3 hetaryl having 1-3 heteroatoms selected from O, N
and S, C.sub.7-C.sub.24 alkaryl, C.sub.7-C.sub.24 aralkyl,
C.sub.4-C.sub.23 alkheteroaryl having 1-3 heteroatoms selected from
O, N and S, substituted C.sub.1-C.sub.10 alkyl, substituted
C.sub.1-C.sub.10 alkoxy, substituted C.sub.2-C.sub.10 alkenyl,
substituted C.sub.1-C.sub.10 alkenoyl, substituted C.sub.3-C.sub.10
cycloalkyl having 0-3 heteroatoms selected from O, N and S,
substituted C.sub.6-C.sub.12 aryl, substituted C.sub.7-C.sub.24
alkaryl, substituted C.sub.7-C.sub.24 aralkyl and substituted
C.sub.4-C.sub.23 alkheteroaryl having 1-3 heteroatoms selected from
O, N and S; wherein if Z is a substituted group, the one or more
substituents are selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --COR.sup.7, --C(O)NR.sup.7R.sup.7, --OR.sup.7,
--SR.sup.7, --NO.sub.2, --NR.sup.7R.sup.7, --NR.sup.7C(O)R.sup.7,
and --NR.sup.7C(O)OR.sup.7.
3. A compound as in claim 1 wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7)--, --O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is halogen and
R.sup.7is as defined in claim 1.
4. A compound as in claim 1 wherein the cyclic structures of B and
L bound directly to D are not substituted in the ortho position by
--OH.
5. A compound as in claim 1 wherein the cyclic structures of B and
L bound directly to D are not substituted in the ortho position by
a moiety having an ionizable hydrogen and a pKa of 10 or less.
6. A compound of claim 1 wherein B of Formula I is a substituted or
unsubstituted six member aryl moiety or six member hetaryl moiety,
said hetaryl moiety having 1 to 4 members selected from the group
of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the
balance of the hetaryl moiety being carbon.
7. A compound of claim 1 wherein B of Formula I is an unsubstituted
phenyl group, an unsubstituted pyridyl group, an unsubstituted
pyrimidinyl, a phenyl group substituted by a substituent selected
from the group consisting of halogen and Wn wherein W and n are as
defined in claim 1, a pyrimidinyl group substituted by a
substituent selected from the group constituting of halogen and Wn,
whereas W and n are as defined in claim 1, or a substituted pyridyl
group substituted by a substituent selected from the group
consisting of halogen and Wn wherein W and n are as defined in
claim 1.
8. A compound of claim 6 wherein B of Formula I is a substituted
phenyl group, a substituted pyrimidinyl group, or substituted
pyrridyl group substituted 1 to 3 times by 1 or more substituents
selected from the group consisting of --CN, halogen,
C.sub.1-C.sub.10 alkyl, C.sub.1-C.sub.10 alkoxy, --OH, up to per
halo substituted C.sub.1-C.sub.10 alkyl, up to per halo substituted
C.sub.1-C.sub.10 alkoxy or phenyl substituted by halogen up to per
halo.
9. A compound of claim 1, wherein L, the six member cyclic
structure bound directly to D, is a substituted or unsubstituted 6
member aryl moiety or a substituted or unsubstituted 6 member
hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members
selected from the group of heteroatoms consisting of nitrogen,
oxygen and sulfur with the balance of said hetaryl moiety being
carbon, wherein the one or more substituents are selected from the
group consisting of halogen and Wn wherein W and n are as defined
in claim 1.
10. A compound of claim 8, wherein L, the 6 member cyclic structure
bound directly to D, is a substituted phenyl, unsubstituted phenyl,
substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted
pyridyl or unsubstituted pyridyl group.
11. A compound of claim 1, wherein said substituted cyclic moiety
L.sup.1 comprises a 5 to 6 membered aryl moiety or hetaryl moiety,
wherein said heteraryl moiety comprises 1 to 4 members selected
from the group of heteroatoms consisting of nitrogen, oxygen and
sulfur.
12. A compound of claim 1, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
13. A compound of claim 3, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
14. A compound of claim 6, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
15. A compound of claim 8, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
16. A compound of claim 9, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
17. A compound of claim 10, wherein said substituted cyclic moiety
L.sup.1 is phenyl, pyridinyl or pyrimidinyl.
18. A compound of claim 14, wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7)--, O(CH.sub.2).sub.m--CHX.sup.a--,
CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is halogen and
R.sup.7 is hydrogen or a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen up to per halo.
19. A compound of claim 15, wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7)--, O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is halogen and
R.sup.7 is hydrogen or a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen up to per halo.
20. A compound of claim 16, wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7)--, --O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is halogen and
R.sup.7 is hydrogen or a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen up to per halo.
21. A compound of claim 17, wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.nN(R.sup.7)--, --O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is halogen and
R.sup.7 is hydrogen or a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen up to per halo.
22. A compound of claim 1 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
23. A compound of claim 13 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
24. A compound of claim 18 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
25. A compound of claim 19 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
26. A compound of claim 20 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
27. A compound of claim 21 wherein L.sup.1 is additionally
substituted 1 to 3 times by one or more substituents selected from
the group consisting of C.sub.1-C.sub.10 alkyl, up to per halo
substituted C.sub.1-C.sub.10 alkyl, --CN, --OH, halogen,
C.sub.1-C.sub.10 alkoxy and up to per halo substituted
C.sub.1-C.sub.10 alkoxy.
28. A compound of claim 1 wherein L.sup.1 is substituted by
--C(O)R.sub.x.
29. A compound of claim 1 wherein L.sup.1 is substituted by
--SO.sub.2R.sub.x.
30. A compound of claim 1 wherein L.sup.1 is substituted only by
--C(O)R.sub.x.
31. A compound of claim 1 wherein L.sup.1 is substituted only by
--SO.sub.2R.sub.x.
32. A compound of claim 1 wherein L.sup.1 is substituted by
--C(O)R.sub.x or --SO.sub.2R.sub.x, wherein R.sub.x is
NR.sub.aR.sub.b.
33. A compound of claim 13 wherein L.sup.1 is substituted by
--C(O)R.sub.x or --SO.sub.2R.sub.x, wherein R.sub.x is
NR.sub.aR.sub.b, and R.sub.a and R.sub.b are a) independently
hydrogen, a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen, or
--OSi(R.sub.f).sub.3 where R.sub.f is hydrogen or a carbon based
moiety of up to 24 carbon atoms optionally containing heteroatoms
selected from N, S and O and optionally substituted by halogen,
hydroxy and carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen; or b) R.sub.a and R.sub.b
together form a 5-7 member heterocyclic structure of 1-3
heteroatoms selected from N, S and O, or a substituted 5-7 member
heterocyclic structure of 1-3 heteroatoms selected from N, S and O
substituted by halogen, hydroxy or carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen; or c)
one of R.sub.a or R.sub.b is --C(O)--, a C.sub.1-C.sub.5 divalent
alkylene group or a substituted C.sub.1-C.sub.5 divalent alkylene
group bound to the moiety L to form a cyclic structure with at
least 5 members, wherein the substituents of the substituted
C.sub.1-C.sub.5 divalent alkylene group are selected from the group
consisting of halogen, hydroxy, and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen.
34. A compound of claim 18 wherein L.sup.1 is substituted by
--C(O)R.sub.x or --SO.sub.2R.sub.x, wherein R.sub.x is
NR.sub.aR.sub.b and R.sub.a and R.sub.b are independently hydrogen
or a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen.
35. A compound of claim 19 wherein L.sup.1 is substituted by
--C(O)R.sub.x , wherein R.sub.x is NR.sub.aR.sub.b and R.sub.a and
R.sub.b are independently hydrogen or a carbon based moiety of up
to 30 carbon atoms optionally containing heteroatoms selected from
N, S and O and optionally substituted by halogen, hydroxy and
carbon based substituents of up to 24 carbon atoms, which
optionally contain heteroatoms selected from N, S and O and are
optionally substituted by halogen.
36. A compound of claim 20 wherein L.sup.1 is substituted by
--C(O)R.sub.x or --SO.sub.2R.sub.x, wherein R.sub.x is
NR.sub.aR.sub.b and R.sub.a and R.sub.b are independently hydrogen
or a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen.
37. A compound of claim 21 wherein L.sup.1 is substituted by
--C(O)R.sub.x or --SO.sub.2R.sub.x, wherein R.sub.x is
NR.sub.aR.sub.b and R.sub.a and R.sub.b are independently hydrogen
or a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen.
38. A compound of Formula I: A-D-B (I) or a pharmaceutically
acceptable salt thereof, wherein D is --NH--C(O)--NH--, A is a
substituted moiety of up to 40 carbon atoms of the formula:
-L-(M-L.sup.1 ).sub.q, where L is a 6 membered aryl moiety or a 6
membered hetaryl moiety bound directly to D, L.sup.1 comprises a
substituted cyclic moiety having at least 5 members, M is a
bridging group having at least one atom, q is an integer of from
1-3; and each cyclic structure of L and L.sup.1 contains 0-4
members of the group consisting of nitrogen, oxygen and sulfur, and
B is a substituted or unsubstituted, up to tricyclic aryl or
heteroaryl moiety of up to 30 carbon atoms with at least one
6-member cyclic structure bound directly to D containing 0-4
members of the group consisting of nitrogen, oxygen and sulfur,
wherein L.sup.1 is substituted by at least one substituent selected
from the group consisting of --SO.sub.2R.sub.x, --C(O)R.sub.x and
--C(NR.sub.y)R.sub.z, R.sub.y is hydrogen or a carbon based moiety
of up to 24 carbon atoms optionally containing heteroatoms selected
from N, S and O and optionally halosubstituted, up to per halo,
R.sub.z is hydrogen or a carbon based moiety of up to 30 carbon
atoms optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen, hydroxy and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen; R.sub.x is R.sub.z or NR.sub.aR.sub.b where R.sub.a and
R.sub.b are a) independently hydrogen, a carbon based moiety of up
to 30 carbon atoms optionally containing heteroatoms selected from
N, S and O and optionally substituted by halogen, hydroxy and
carbon based substituents of up to 24 carbon atoms, which
optionally contain heteroatoms selected from N, S and O and are
optionally substituted by halogen, or --OSi(R.sub.f).sub.3 where
R.sub.f is hydrogen or a carbon based moiety of up to 24 carbon
atoms optionally containing heteroatoms selected from N, S and O
and optionally substituted by halogen, hydroxy and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen; or b) R.sub.a and R.sub.b together form a 5-7 member
heterocyclic structure of 1-3 heteroatoms selected from N, S and O,
or a substituted 5-7 member heterocyclic structure of 1-3
heteroatoms selected from N, S and O substituted by halogen,
hydroxy or carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen; or c) one of R.sub.a or
R.sub.b is --C(O)--, a C.sub.1-C.sub.5 divalent alkylene group or a
substituted C.sub.1-C.sub.5 divalent alkylene group bound to the
moiety L to form a cyclic structure with at least 5 members,
wherein the substituents of the substituted C.sub.1-C.sub.5
divalent alkylene group are selected from the group consisting of
halogen, hydroxy, and carbon based substituents of up to 24 carbon
atoms, which optionally contain heteroatoms selected from N, S and
O and are optionally substituted by halogen; where B is
substituted, L is substituted or L.sup.1 is additionally
substituted, the substituents are selected from the group
consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting
of --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7, --C(O)--R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7,
--NR.sup.7R.sup.7--NR.sup.7C(O)OR.sup.7,
--NR.sup.7C(O)R.sup.7-Q-Ar, and carbon based moieties of up to 24
carbon atoms, optionally containing heteroatoms selected from N, S
and O and optionally substituted by one or more substituents
independently selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7,
--OR.sup.7, --SR.sup.7, --NR.sup.7R.sup.7, --NO.sub.2,
--NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 and halogen up to
per-halo; with each R.sup.7 independently selected from H or a
carbon based moiety of up to 24 carbon atoms, optionally containing
heteroatoms selected from N, S and O and optionally substituted by
halogen, wherein Q is --O--, --S--, --N(R.sup.7)--,
--(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--, --(CH.sub.2).sub.mO--,
--(CH.sub.2).sub.mS--, --(CH.sub.2).sub.mN(R.sup.7)--,
--O(CH.sub.2).sub.m--CHX.sup.a--, --CX.sup.a.sub.2--,
--S--(CH.sub.2).sub.m-- and --N(R.sup.7)(CH.sub.2).su- b.m--, where
m=1-3, and X.sup.a is halogen; Ar is a 5- or 6-member aromatic
structure containing 0-2 members selected from the group consisting
of nitrogen, oxygen and sulfur, which is optionally substituted by
halogen, up to per-halo, and optionally substituted by Z.sub.n1,
wherein n1 is 0 to 3 and each Z is independently selected from the
group consisting of --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7,
--C(O)NR.sup.7R.sup.7, --NO.sub.2, --OR.sup.7,
--SR.sup.7--NR.sup.7R.sup.- 7, --NR.sup.7C(O)OR.sup.7,
--NR.sup.7C(O)R.sup.7, and a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by one or more substituents are selected
from the group consisting of --CN, --CO.sub.2R.sup.7, --COR.sup.7,
--C(O)NR.sup.7R.sup.7, --OR.sup.7, --SR.sup.7, --NO.sub.2,
--NR.sup.7R.sup.7, --NR.sup.7C(O)R.sup.7, and
--NR.sup.7C(O)R.sup.7, with R.sup.7 as defined above; and wherein M
is one or more bridging groups selected from the group consisting
of --O--, --S--, --N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--,
--CH(OH)--, --(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7- )--, --O(CH.sub.2).sub.m--CHX.sup.a--,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).sub.m--, where m=1-3, X.sup.a is
halogen.
39. A compound of Formula I: A-D-B (I) or a pharmaceutically
acceptable salt thereof, wherein D is --NH--C(O)--NH--, A is a
substituted moiety of up to 40 carbon atoms of the formula:
-L-(M-L.sup.1).sub.q, where L is a substituted or unsubstituted
phenyl or peritoneal moiety bound directly to D, L.sup.1 comprises
a substituted phenyl, peritoneal or pyrimidinyl moiety, M is a
bridging group having at least one atom, q is an integer of from
1-3; and B is a substituted or unsubstituted phenyl or pyridine
group bound directly to D, wherein L.sup.1 is substituted by at
least one substituent selected from the group consisting of
--SO.sub.2R.sub.x, --C(O)R.sub.x and --C(NR.sub.y)R.sub.z, R.sub.y
is hydrogen or a carbon based moiety of up to 24 carbon atoms
optionally containing heteroatoms selected from N, S and O and
optionally halosubstituted, up to per halo, and; R.sub.z is
hydrogen or a carbon based moiety of up to 30 carbon atoms
optionally containing heteroatoms selected from N, S and O and
optionally substituted by halogen, hydroxy and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen; R.sub.x is R.sub.z or NR.sub.aR.sub.b where R.sub.a and
R.sub.b are a) independently hydrogen, a carbon based moiety of up
to 30 carbon atoms optionally containing heteroatoms selected from
N, S and O and optionally substituted by halogen, hydroxy and
carbon based substituents of up to 24 carbon atoms, which
optionally contain heteroatoms selected from N, S and O and are
optionally substituted by halogen, or --OSi(R.sub.f)3 where R.sub.f
is hydrogen or a carbon based moiety of up to 24 carbon atoms
optionally containing heteroatoms selected from N, S and O and
optionally substituted by halogen, hydroxy and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen; or b) R.sub.a and R.sub.b together form a 5-7 member
heterocyclic structure of 1-3 heteroatoms selected from N, S and O,
or a substituted 5-7 member heterocyclic structure of 1-3
heteroatoms selected from N, S and O substituted by halogen,
hydroxy or carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen; or c) one of R.sub.a or
R.sub.b is --C(O)--, a C.sub.1-C.sub.5 divalent alkylene group or a
substituted C.sub.1-C.sub.5 divalent alkylene group bound to the
moiety L to form a cyclic structure with at least 5 members,
wherein the substituents of the substituted C.sub.1-C.sub.5
divalent alkylene group are selected from the group consisting of
halogen, hydroxy, and carbon based substituents of up to 24 carbon
atoms, which optionally contain heteroatoms selected from N, S and
O and are optionally substituted by halogen; where B is
substituted, L is substituted or L.sup.1 is additionally
substituted, the substituents are selected from the group
consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting
of --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7, --C(O)--R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7, --NR.sup.7R.sup.7,
--NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, -Q-Ar, and carbon
based moieties of up to 24 carbon atoms, optionally containing
heteroatoms selected from N, S and O and optionally substituted by
one or more substituents independently selected from the group
consisting of --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7,
--C(O)NR.sup.7R.sup.7, --OR.sup.7, --OR.sup.7, --NR.sup.7R.sup.7,
--NO.sub.2, --NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 and
halogen up to per-halo; with each R.sup.7 independently selected
from H or a carbon based moiety of up to 24 carbon atoms,
optionally containing heteroatoms selected from N, S and O and
optionally substituted by halogen, wherein Q is --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2)CH.sub.2).sub.m- --CHX.sup.a--, --CX.sup.a.sub.2--,
--S--(CH.sub.2).sub.m-- and --N(R.sup.7)(CH.sub.2).sub.m--, where
m=1-3, and X.sup.a is halogen; Ar is a 5- or 6-member aromatic
structure containing 0-2 members selected from the group consisting
of nitrogen, oxygen and sulfur, which is optionally substituted by
halogen, up to per-halo, and optionally substituted by Z.sub.n1,
wherein n1 is 0 to 3 and each Z is independently selected from the
group consisting of --CN, --CO.sub.2R.sup.7, --C(O)R.sup.7,
--C(O)NR.sup.7R.sup.7, --NO.sub.2, --OR.sup.7,
--SR.sup.7--NR.sup.7R.sup.7, --NR.sup.7C(O)OR.sup.7,
--NR.sup.7C(O)R.sup.7, and a carbon based moiety of up to 24 carbon
atoms, optionally containing heteroatoms selected from N, S and O
and optionally substituted by one or more substituents selected
from the group consisting of --CN, --CO.sub.2R.sup.7, --COR.sup.7,
--C(O)NR.sup.7R.sup.7, --OR.sup.7, --SR.sup.7, --NO.sub.2,
--NR.sup.7R.sup.7, --NR.sup.7C(O)R.sup.7, and
--NR.sup.7C(O)OR.sup.7; and wherein M is one or more bridging
groups selected from the group consisting of --O--, --S--,
--N(R.sup.7)--, --(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--,
--(CH.sub.2).sub.mO--, --(CH.sub.2).sub.mS--,
--(CH.sub.2).sub.mN(R.sup.7)--, --O(CH.sub.2).sub.m--CHX.sup.a,
--CX.sup.a.sub.2--, --S--(CH.sub.2).sub.m-- and
--N(R.sup.7)(CH.sub.2).su- b.m--, where m=1-3, X.sup.a is
halogen.
40. A compound as in claim 38 wherein the cyclic structures of B
and L bound directly to D are not substituted in the ortho position
by --OH.
41. A compound as in claim 38 wherein the cyclic structures of B
and L bound directly to D are not substituted in the ortho position
by a moiety having an ionizable hydrogen and a pKa of 10 or
less.
42. A compound as in claim 39 wherein the cyclic structures of B
and L bound directly to D are not substituted in the ortho position
by --OH.
43. A compound as in claim 39 wherein the cyclic structures of B
and L bound directly to D are not substituted in the ortho position
by a moiety having an ionizable hydrogen and a pKa of 10 or
less.
44. A compound as in claim 38 wherein substituents for B and L and
additional substituents for L , are selected from the group
consisting of C.sub.1-C.sub.10 alkyl up to per halo substituted
C.sub.1-C.sub.10 alkyl, CN, OH, halogen, C.sub.1-C.sub.10 alkoxy
and up to per halo substituted C.sub.1-C.sub.10 alkoxy.
45. A compound as in claim 39 wherein substituents for B and L and
additional substituents for L.sup.1, are selected from the group
consisting of C.sub.1-C.sub.10 alkyl up to per halo substituted
C.sub.1-C.sub.10 alkyl, CN, OH, halogen, C.sub.1-C.sub.10 alkoxy
and up to per halo substituted C.sub.1-C.sub.10 alkoxy.
46. A compound of claim 38 wherein L.sup.1 is substituted by C(O)RX
or SO.sub.2R.sub.x.
47. A compound of claim 39 wherein L.sup.1 is substituted by
C(O)R.sub.x or SO.sub.2R.sub.x.
48. A compound of claim 46 wherein R.sub.x is NR.sub.aR.sub.b and
R.sub.a and R.sub.b are independently hydrogen and a carbon based
moiety of up to 30 carbon atoms optionally containing heteroatoms
selected from N, S and O and optionally substituted by halogen,
hydroxy and carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen.
49. A compound of claim 47 wherein R.sub.x is NR.sub.aR.sub.b and
R.sub.a and R.sub.b are independently hydrogen and a carbon based
moiety of up to 30 carbon atoms optionally containing heteroatoms
selected from N, S and O and optionally substituted by halogen,
hydroxy and carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen.
50. A compound of claim 1 which is a pharmaceutically acceptable
salt of a compound of formula I selected from the group consisting
of a) basic salts of organic acids and inorganic acids selected
from the group consisting of hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, methanesulphonic acid,
trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic
acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene
sulfonic acid, acetic acid, trifluoroacetic acid, malic acid,
tartaric acid, citric acid, lactic acid, oxalic acid, succinic
acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
phenylacetic acid, and mandelic acid; and b) acid salts of organic
and inorganic bases containing cations selected from the group
consisting of alkaline cations, alkaline earth cations, the
ammonium cation, aliphatic substituted ammonium cations and
aromatic substituted ammonium cations.
51. A compound of claim 2 which is a pharmaceutically acceptable
salt of a compound of formula I selected from the group consisting
of a) basic salts of organic acids and inorganic acids selected
from the group consisting of hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, methanesulphonic acid,
trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic
acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene
sulfonic acid, acetic acid, trifluoroacetic acid, malic acid,
tartaric acid, citric acid, lactic acid, oxalic acid, succinic
acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
phenylacetic acid, and mandelic acid; and b) acid salts of organic
and inorganic bases containing cations selected from the group
consisting of alkaline cations, alkaline earth cations, the
ammonium cation, aliphatic substituted ammonium cations and
aromatic substituted ammonium cations.
52. A compound of claim 33 which is a pharmaceutically acceptable
salt of a compound of formula I selected from the group consisting
of a) basic salts of organic acids and inorganic acids selected
from the group consisting of hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, methanesulphonic acid,
trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic
acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene
sulfonic acid, acetic acid, trifluoroacetic acid, malic acid,
tartaric acid, citric acid, lactic acid, oxalic acid, succinic
acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
phenylacetic acid, and mandelic acid; and b) acid salts of organic
and inorganic bases containing cations selected from the group
consisting of alkaline cations, alkaline earth cations, the
ammonium cation, aliphatic substituted ammonium cations and
aromatic substituted ammonium cations.
53. A compound of claim 38 which is a pharmaceutically acceptable
salt of a compound of formula I selected from the group consisting
of a) basic salts of organic acids and inorganic acids selected
from the group consisting of hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, methanesulphonic acid,
trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic
acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene
sulfonic acid, acetic acid, trifluoroacetic acid, malic acid,
tartaric acid, citric acid, lactic acid, oxalic acid, succinic
acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
phenylacetic acid, and mandelic acid; and b) acid salts of organic
and inorganic bases containing cations selected from the group
consisting of alkaline cations, alkaline earth cations, the
ammonium cation, aliphatic substituted ammonium cations and
aromatic substituted ammonium cations.
54. A compound of claim 39 which is a pharmaceutically acceptable
salt of a compound of formula I selected from the group consisting
of a) basic salts of organic acids and inorganic acids selected
from the group consisting of hydrochloric acid, hydrobromic acid,
sulphuric acid, phosphoric acid, methanesulphonic acid,
trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic
acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene
sulfonic acid, acetic acid, trifluoroacetic acid, malic acid,
tartaric acid, citric acid, lactic acid, oxalic acid, succinic
acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
phenylacetic acid, and mandelic acid; and b) acid salts of organic
and inorganic bases containing cations selected from the group
consisting of alkaline cations, alkaline earth cations, the
ammonium cation, aliphatic substituted ammonium cations and
aromatic substituted ammonium cations.
55. A pharmaceutical composition comprising a compound of claim 1
or a pharmaceutically acceptable salt of a compound of formula I,
and a physiologically acceptable carrier.
56. A pharmaceutical composition comprising a compound of claim 2
consistent with formula I or a pharmaceutically acceptable salt
thereof, and a physiologically acceptable carrier.
57. A pharmaceutical composition comprising a compound of claim 33
consistent with formula I or a pharmaceutically acceptable salt
thereof, and a physiologically acceptable carrier.
58. A pharmaceutical composition comprising a compound of claim 38
consistent with formula I or a pharmaceutically acceptable salt
thereof, and a physiologically acceptable carrier.
59. A pharmaceutical composition comprising a compound of claim 39
consistent with formula I or a pharmaceutically acceptable salt
thereof and a physiologically acceptable carrier.
60. A compound selected from the group consisting of 3-tert butyl
phenyl ureas of Table 1 above; 5-tert butyl-2-methoxyphenyl ureas
of Table 2 above; 5-(trifluoromethyl)-2 phenyl ureas of Table 3
above; 3-(trifluoromethyl)-4 chlorophenyl ureas of Table 4 above;
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;
5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6
above; and ureas 101-103 in Table 7 above.
61. A compound selected from the group consisting of the 3-tert
butyl phenyl ureas:
N-(3-tert-butylphenyl)-N'-(4-(3-(N-methylcarbamoyl)phenoxy)- phenyl
urea and N-(3-tert-butylphenyl)-N'-(4-(4-acetylphenoxy)phenyl urea;
the 5-tert-butyl-2-methoxyphenyl ureas:
N-(5-tert-butyl-2-methoxyphenyl)--
N'-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxy-
phenyl)-N'-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N
'-(4-(4-methoxy-3-(N-methylcarbamoyl)p- henoxy)phenyl) urea and
N-(5-tert-butyl-2-methoxyphenyl)-N'-(4-(3-(N-methy-
lcarbamoyl)phenoxy)phenyl) urea; the
2-methoxy-5-trifluoromethyl)phenyl ureas:
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-(2-carbamoyl-4-pyrid-
yloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-me-
thylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)-
phenyl)-N-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py-
ridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-
-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(2-methoxy-5-(trifluoromet-
hyl)phenyl)-N'-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl)
urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-met-
hylcarbamoyl)(4-pyridyloxy))phenyl) urea; the
4-chloro-3-(trifluoromethyl)- phenyl ureas:
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(3-(2-carbamoyl-4--
pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(3-(2-(-
N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluorometh-
yl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr-
idyloxy)phenyl) urea. the 4-romo-3-(trifluoromethyl)phenyl ureas:
N-(4-bromo-3-(trifluoromethyl)phenyl)-N
'-(3-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-me-
thylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)ph-
enyl)-N'-(3-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(2-chloro-4-(2-(N-methylcarbamoy-
l)(4-pyridyloxy))phenyl) urea and
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-
-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and
the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbam-
oyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)p-
henyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(2-chloro-4-(2-(N-met-
hylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-4-chloro-5-(trif-
luoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))ph-
enyl) urea.
62. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administering a compound of Formula I of
claim 1.
63. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administering a compound of Formula I of
claim 33.
64. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administering a compound of Formula I of
claim 38.
65. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administering a compound of Formula I of
claim 39.
66. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administrating a compound selected from
the group consisting of 3-tert butyl phenyl ureas of Table 1 above;
5-tert butyl-2-methoxyphenyl ureas of Table 2 above;
5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;
3-(trifluoromethyl) -4 chlorophenyl ureas of Table 4 above;
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;
5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6
above; and ureas 101-103 in Table 7 above.
67. A method for the treatment of a cancerous cell growth mediated
by raf kinase, comprising administrating a compound selected from
the group consisting of the 3-tert butyl phenyl ureas:
N-(3-tert-butylphenyl)-N'-(4- -(3-(N-methylcarbamoyl)phenoxy)phenyl
urea and N-(3-tert-butylphenyl)-N'-(- 4-(4-acetylphenoxy)phenyl
urea; the 5-tert-butyl-2-methoxyphenyl ureas:
N-(5-tert-butyl-2-methoxyphenyl)-N'-(4-(1,3-dioxoisoindolin-5-yloxy)pheny-
l) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N'-(4-(1-oxoisoindolin-5-yloxy)p-
henyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N'-(4-(4-methoxy-3-(N-methyl-
carbamoyl)phenoxy)phenyl) urea and
N-(5-tert-butyl-2-methoxyphenyl)-N'-(4--
(3-(N-methylcarbamoyl)phenoxy)phenyl) urea; the
2-methoxy-5-trifluoromethy- l)phenyl ureas:
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-(2-carbamoyl-
-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3--
(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluor-
omethyl)phenyl)-N'-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py-
ridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-
-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(2-methoxy-5-(trifluoromet-
hyl)phenyl)-N'-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl)
urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-met-
hylcarbamoyl)(4-pyridyloxy))phenyl) urea; the
4-chloro-3-(trifluoromethyl)- phenyl ureas:
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(3-(2-carbamoyl-4--
pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(3-(2-(-
N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluorometh- yl)phenyl)-N'-(4-(2-carbamoyl-
4-pyridyloxy)phenyl) urea and
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr-
idyloxy)phenyl) urea; the 4-romo-3-(trifluoromethyl)phenyl ureas:
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl
)-4-pyridyl oxy )phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(-
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl)-4-pyri-
dylthio)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(2-chloro-4-
-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-methylcarbamoy-
l)(4-pyridyloxy))phenyl) urea; and the
2-methoxy-4-chloro-5-(trifluorometh- yl)phenyl ureas:
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(3-(2-
-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(t-
rifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)
urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N'-(2-chloro-4-(2--
(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-4-chloro-5-
-(trifluoromethyl)phenyl)-N'-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridylo-
xy))phenyl) urea.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation of Ser. No. 09/425,228 filed Oct. 22,
1999, which is a continuation-in-part of Ser. No. 09/257,266 filed
Feb. 25, 1999 and claims priority to provisional application Serial
No. 60/115,877 filed Jan. 13, 1999.
FIELD OF THE INVENTION
[0002] This invention relates to the use of a group of aryl ureas
in treating raf mediated diseases, and pharmaceutical compositions
for use in such therapy.
BACKGROUND OF THE INVENTION
[0003] The p21.sup.ras oncogene is a major contributor to the
development and progression of human solid cancers and is mutated
in 30% of all human cancers (Bolton et al. Ann. Rep. Med. Chem.
1994, 29, 165-74; Bos. Cancer Res. 1989, 49, 4682-9). In its
normal, unmutated form, the ras protein is a key element of the
signal transduction cascade directed by growth factor receptors in
almost all tissues (Avruch et al. Trends Biochem. Sci. 1994, 19,
279-83). Biochemically, ras is a guanine nucleotide binding
protein, and cycling between a GTP-bound activated and a GDP-bound
resting form is strictly controlled by ras' endogenous GTPase
activity and other regulatory proteins. In the ras mutants in
cancer cells, the endogenous GTPase activity is alleviated and,
therefore, the protein delivers constitutive growth signals to
downstream effectors such as the enzyme raf kinase. This leads to
the cancerous growth of the cells which carry these mutants
(Magnuson et al. Semin. Cancer Biol. 1994, 5, 247-53). It has been
shown that inhibiting the effect of active ras by inhibiting the
raf kinase signaling pathway by administration of deactivating
antibodies to raf kinase or by co-expression of dominant negative
raf kinase or dominant negative MEK, the substrate of raf kinase,
leads to the reversion of transformed cells to the normal growth
phenotype (see: Daum et al. Trends Biochem. Sci. 1994, 19, 474-80;
Fridman et al. J. Biol. Chem. 1994, 269, 30105-8. Kolch et al.
(Nature 1991, 349, 426-28) have further indicated that inhibition
of raf expression by antisense RNA blocks cell proliferation in
membrane-associated oncogenes. Similarly, inhibition of raf kinase
(by antisense oligodeoxynucleotides) has been correlated in vitro
and in vivo with inhibition of the growth of a variety of human
tumor types (Monia et al., Nat. Med. 1996, 2, 668-75).
SUMMARY OF THE INVENTION
[0004] The present invention provides compounds which are
inhibitors of the enzyme raf kinase. Since the enzyme is a
downstream effector of p21.sup.ras, the inhibitors are useful in
pharmaceutical compositions for human or veterinary use where
inhibition of the raf kinase pathway is indicated, e.g., in the
treatment of tumors and/or cancerous cell growth mediated by raf
kinase. In particular, the compounds are useful in the treatment of
human or animal solid cancers, e.g., murine cancer, since the
progression of these cancers is dependent upon the ras protein
signal transduction cascade and therefore susceptible to treatment
by interruption of the cascade, i.e., by inhibiting raf kinase.
Accordingly, the compounds of the invention are useful in treating
cancers, including solid cancers, such as, for example, carcinomas
(e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid
disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon
adenoma).
[0005] The present invention therefore provides compounds generally
described as aryl ureas, including both aryl and heteroaryl
analogues, which inhibit the raf kinase pathway. The invention also
provides a method for treating a raf mediated disease state in
humans or mammals. Thus, the invention is directed to compounds
which inhibit the enzyme raf kinase and also compounds,
compositions and methods for the treatment of cancerous cell growth
mediated by raf kinase wherein a compound of Formula I is
administered or pharmaceutically acceptable salt thereof.
A-D-B (I)
[0006] In formula I, D is --NH--C(O)--NH--,
[0007] A is a substituted moiety of up to 40 carbon atoms of the
formula: -L-(M-L.sup.1).sub.q, where L is a 5 or 6 membered cyclic
structure bound directly to D, L.sup.1 comprises a substituted
cyclic moiety having at least 5 members, M is a bridging group
having at least one atom, q is an integer of from 1-3; and each
cyclic structure of L and L.sup.1 contains 0-4 members of the group
consisting of nitrogen, oxygen and sulfur, and
[0008] B is a substituted or unsubstituted, up to tricyclic aryl or
heteroaryl moiety of up to 30 carbon atoms with at least one
6-member cyclic structure bound directly to D containing 0-4
members of the group consisting of nitrogen, oxygen and sulfur,
[0009] wherein L.sup.1 is substituted by at least one substituent
selected from the group consisting of --SO.sub.2R.sub.x,
--C(O)R.sub.x and --C(NR.sub.y) R.sub.z,
[0010] R.sub.y is hydrogen or a carbon based moiety of up to 24
carbon atoms optionally containing heteroatoms selected from N, S
and O and optionally halosubstituted, up to per halo,
[0011] R.sub.z is hydrogen or a carbon based moiety of up to 30
carbon atoms optionally containing heteroatoms selected from N, S
and O and optionally substituted by halogen, hydroxy and carbon
based substituents of up to 24 carbon atoms, which optionally
contain heteroatoms selected from N, S and O and are optionally
substituted by halogen;
[0012] R.sub.x is R.sub.z or NR.sub.aR.sub.b where R.sub.a and
R.sub.b are
[0013] a) independently hydrogen,
[0014] a carbon based moiety of up to 30 carbon atoms optionally
containing heteroatoms selected from N, S and O and optionally
substituted by halogen, hydroxy and carbon based substituents of up
to 24 carbon atoms, which optionally contain heteroatoms selected
from N, S and O and are optionally substituted by halogen, or
[0015] --OSi(R.sub.f).sub.3 where R.sub.f is hydrogen or a carbon
based moiety of up to 24 carbon atoms optionally containing
heteroatoms selected from N, S and O and optionally substituted by
halogen, hydroxy and carbon based substituents of up to 24 carbon
atoms, which optionally contain heteroatoms selected from N, S and
O and are optionally substituted by halogen; or
[0016] b) R.sub.a and R.sub.b together form a 5-7 member
heterocyclic structure of 1-3 heteroatoms selected from N, S and O,
or a substituted 5-7 member heterocyclic structure of 1-3
heteroatoms selected from N, S and O substituted by halogen,
hydroxy or carbon based substituents of up to 24 carbon atoms,
which optionally contain heteroatoms selected from N, S and O and
are optionally substituted by halogen; or
[0017] c) one of R.sub.a or R.sub.b is --C(O)--, a C.sub.1-C.sub.5
divalent alkylene group or a substituted C.sub.1-C.sub.5 divalent
alkylene group bound to the moiety L to form a cyclic structure
with at least 5 members, wherein the substituents of the
substituted C.sub.1-C.sub.5 divalent alkylene group are selected
from the group consisting of halogen, hydroxy, and carbon based
substituents of up to 24 carbon atoms, which optionally contain
heteroatoms selected from N, S and O and are optionally substituted
by halogen;
[0018] where B is substituted, L is substituted or L.sup.1 is
additionally substituted, the substituents are selected from the
group consisting of halogen, up to per-halo, and Wn, where n is
0-3;
[0019] wherein each W is independently selected from the group
consisting of --CN, --CO.sub.2R.sup.7, --C(O)NR.sup.7R.sup.7,
--C(O)--R.sup.7, --NO.sub.2, --OR.sup.7, --SR.sup.7,
--NR.sup.7R.sup.7, --NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7,
-Q-Ar, and carbon based moieties of up to 24 carbon atoms,
optionally containing heteroatoms selected from N, S and O and
optionally substituted by one or more substituents independently
selected from the group consisting of --CN, --CO.sub.2R.sup.7,
--C(O)R.sup.7, --C(O)NR R, --OR, --SR.sup.7, --NR.sup.7R.sup.7,
--NO.sub.2, --NR.sup.7C(O)R.sup.7, --NR.sup.7C(O)OR.sup.7 and
halogen up to per-halo; with each R.sup.7 independently selected
from H or a carbon based moiety of up to 24 carbon atoms,
optionally containing heteroatoms selected from N, S and O and
optionally substituted by halogen,
[0020] wherein Q is --O--, --S--, --N(R.sup.7)--,
--(CH.sub.2).sub.m--, --C(O)--, --CH(OH)--, --(CH.sub.2).sub.mO--,
--(CH.sub.2).sub.mS--, --(CH.sub.2).sub.nN(R.sup.7)--,
--O(CH.sub.2).sub.m--CHX.sup.a--, --CX.sup.a.sub.2--,
--S--(CH.sub.2).sub.m-- and --N(R.sup.7)(CH.sub.2).su- b.m--, where
m=1-3, and X.sup.a is halogen; and
[0021] Ar is a 5- or 6-member aromatic structure containing 0-2
members selected from the group consisting of nitrogen, oxygen and
sulfur, which is optionally substituted by halogen, up to per-halo,
and optionally substituted by Z.sub.n1,wherein n1 is 0 to 3 and
each Z is independently selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --C(O)R.sup.7, --C(O)NR.sup.7R.sup.7,
--NO.sub.2, --OR.sup.7, --SR.sup.7--NR.sup.7R.sup.7,
--NR.sup.7C(O)OR.sup.7, --NR.sup.7C(O)R.sup.7, and a carbon based
moiety of up to 24 carbon atoms, optionally containing heteroatoms
selected from N, S and O and optionally substituted by one or more
substituents selected from the group consisting of --CN,
--CO.sub.2R.sup.7, --COR.sup.7, --C(O)NR.sup.7R.sup.7, --OR.sup.7,
--SR.sup.7, --NO.sub.2, --NR.sup.7R.sup.7, --NR.sup.7C(O)R.sup.7,
and --NR.sup.7C(O)OR.sup.7, with R.sup.7 as defined above.
[0022] In formula I, suitable hetaryl groups include, but are not
limited to, 5-12 carbon-atom aromatic rings or ring systems
containing 1-3 rings, at least one of which is aromatic, in which
one or more, e.g., 1-4 carbon atoms in one or more of the rings can
be replaced by oxygen, nitrogen or sulfur atoms. Each ring
typically has 3-7 atoms. For example, B can be 2- or 3-furyl, 2- or
3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or
5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-,
4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl,
1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1-
or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or
-5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl,
1,3,4-thiadiazol-2- or -5-yl, 1,3,4-thiadiazol-3- or -5-yl,
1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl,
2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-,
4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl,
1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or
5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-,
5-, 6- or 7-benzoxazolyl, 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-,
3-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or
7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-1,3-oxadiazolyl, 2-,
3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-
isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-,
6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,
or additionally optionally substituted phenyl, 2- or 3-thienyl,
1,3,4-thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or
5-thiazolyl, etc. For example, B can be 4-methyl-phenyl,
5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl,
1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or
5-methyl-1,2,4-thiadiazol-2-yl.
[0023] Suitable alkyl groups and alkyl portions of groups, e.g.,
alkoxy, etc. throughout include methyl, ethyl, propyl, butyl, etc.,
including all straight-chain and branched isomers such as
isopropyl, isobutyl, sec-butyl, tert-butyl, etc.
[0024] Suitable aryl groups which do not contain heteroatoms
include, for example, phenyl and 1- and 2-naphthyl.
[0025] The term "cycloalkyl", as used herein, refers to cyclic
structures with or without alkyl substituents such that, for
example, "C.sub.4 cycloalkyl" includes methyl substituted
cyclopropyl groups as well as cyclobutyl groups. The term
"cycloalkyl", as used herein also includes saturated heterocyclic
groups.
[0026] Suitable halogen groups include F, Cl, Br, and/or I, from
one to per-substitution (i.e. all H atoms on a group replaced by a
halogen atom) being possible where an alkyl group is substituted by
halogen, mixed substitution of halogen atom types also being
possible on a given moiety.
[0027] The invention also relates to compounds per se, of formula
I.
[0028] The present invention is also directed to pharmaceutically
acceptable salts of formula I. Suitable pharmaceutically acceptable
salts are well known to those skilled in the art and include basic
salts of inorganic and organic acids, such as hydrochloric acid,
hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic
acid, trifluoromethanesulfonic acid, benzenesulfonic acid,
p-toluenesulfonic acid, 1-naphthalenesulfonic acid,
2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid,
malic acid, tartaric acid, citric acid, lactic acid, oxalic acid,
succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic
acid, phenylacetic acid, and mandelic acid. In addition,
pharmaceutically acceptable salts include acid salts of inorganic
bases, such as salts containing alkaline cations (e.g., Li.sup.+
Na.sup.+ or K.sup.+), alkaline earth cations (e.g., Mg.sup.+2,
Ca.sup.+2 or Ba.sup.+2), the ammonium cation, as well as acid salts
of organic bases, including aliphatic and aromatic substituted
ammonium, and quaternary ammonium cations, such as those arising
from protonation or peralkylation of triethylamine,
N,N-diethylamine, N,N-dicyclohexylamine, lysine, pyridine,
N,N-dimethylaminopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane
(DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
[0029] A number of the compounds of Formula I possess asymmetric
carbons and can therefor exist in racemic and optically active
forms. Methods of separation of enantiomeric and diastereomeric
mixtures are well known to one skilled in the art. The present
invention encompasses any isolated racemic or optically active form
of compounds described in Formula I which possess raf inhibitory
activity.
General Preparative Methods
[0030] The compounds of Formula I may be prepared by the use of
known chemical reactions and procedures, some from starting
materials which are commercially available. Nevertheless, general
preparative methods are provided below to aid one skilled in the
art in synthesizing these compounds, with more detailed examples
being provided in the Experimental section which follows.
[0031] Substituted anilines may be generated using standard methods
(March. Advanced Organic Chemistry, 3.sup.rd Ed.; John Wiley: New
York (1985). Larock. Comprehensive Organic Transformations; VCH
Publishers: New York (1989)). As shown in Scheme I, aryl amines are
commonly synthesized by reduction of nitroaryls using a metal
catalyst, such as Ni, Pd, or Pt, and H.sub.2 or a hydride transfer
agent, such as formate, cyclohexadiene, or a borohydride (Rylander.
Hydrogenation Methods; Academic Press: London, UK (1985)).
Nitroaryls may also be directly reduced using a strong hydride
source, such as LiAlH.sub.4 (Seyden-Penne. Reductions by the
Alumino- and Borohydrides in Organic Synthesis; VCH Publishers: New
York (1991)), or using a zero valent metal, such as Fe, Sn or Ca,
often in acidic media. Many methods exist for the synthesis of
nitroaryls (March. Advanced Organic Chemistry, 3.sup.rd Ed.; John
Wiley: New York (1985). Larock. Comprehensive Organic
Transformations; VCH Publishers: New York (1989)). 1
[0032] Nitroaryls are commonly formed by electrophilic aromatic
nitration using HNO.sub.3, or an alternative NO.sub.2.sup.+ source.
Nitroaryls may be further elaborated prior to reduction. Thus,
nitroaryls substituted with 2
[0033] potential leaving groups (e.g. F, Cl, Br, etc.) may undergo
substitution reactions on treatment with nucleophiles, such as
thiolate (exemplified in Scheme II) or phenoxide. Nitroaryls may
also undergo Ullman-type coupling reactions (Scheme II). 3
[0034] Nitroaryls may also undergo transition metal mediated cross
coupling reactions. For example, nitroaryl electrophiles, such as
nitroaryl bromides, iodides or triflates, undergo palladium
mediated cross coupling reactions with aryl nucleophiles, such as
arylboronic acids (Suzuki reactions, exemplified below), aryltins
(Stille reactions) or arylzincs (Negishi reaction) to afford the
biaryl (5). 4
[0035] Either nitroaryls or anilines may be converted into the
corresponding arenesulfonyl chloride (7) on treatment with
chlorosulfonic acid. Reaction of the sulfonyl chloride with a
fluoride source, such as KF then affords sulfonyl fluoride (8).
Reaction of sulfonyl fluoride 8 with trimethylsilyl
trifluoromethane in the presence of a fluoride source, such as
tris(dimethylamino)sulfonium difluorotrimethylsiliconate (TASF)
leads to the corresponding trifluoromethylsulfone (9).
Alternatively, sulfonyl chloride 7 may be reduced to the arenethiol
(10), for example with zinc amalgum. Reaction of thiol 10 with
CHClF.sub.2 in the presence of base gives the difluoromethyl
mercaptam (11), which may be oxidized to the sulfone (12) with any
of a variety of oxidants, including CrO.sub.3-acetic anhydride
(Sedova et al. Zh. Org. Khim. 1970, 6, (568). 5
[0036] As shown in Scheme IV, non-symmetrical urea formation may
involve reaction of an aryl isocyanate (14) with an aryl amine
(13). The heteroaryl isocyanate may be synthesized from a
heteroaryl amine by treatment with phosgene or a phosgene
equivalent, such as trichloromethyl chloroformate (diphosgene),
bis(trichloromethyl) carbonate (triphosgene), or
N,N'-carbonyldiimidazole (CDI). The isocyanate may also be derived
from a heterocyclic carboxylic acid derivative, such as an ester,
an acid halide or an anhydride by a Curtius-type rearrangement.
Thus, reaction of acid derivative 16 with an azide source, followed
by rearrangement affords the isocyanate. The corresponding
carboxylic acid (17) may also be subjected to Curtius-type
rearrangements using diphenylphosphoryl azide (DPPA) or a similar
reagent. 6
[0037] Finally, ureas may be further manipulated using methods
familiar to those skilled in the art.
[0038] The invention also includes pharmaceutical compositions
including a compound of Formula I, and a physiologically acceptable
carrier.
[0039] The compounds may be administered orally, topically,
parenterally, by inhalation or spray or rectally in dosage unit
formulations. The term `administration by injection` includes
intravenous, intramuscular, subcutaneous and parenteral injections,
as well as use of infusion techniques. One or more compounds may be
present in association with one or more non-toxic pharmaceutically
acceptable carriers and if desired other active ingredients.
[0040] Compositions intended for oral use may be prepared according
to any suitable method known to the art for the manufacture of
pharmaceutical compositions. Such compositions may contain one or
more agents selected from the group consisting of diluents,
sweetening agents, flavoring agents, coloring agents and preserving
agents in order to provide palatable preparations. Tablets contain
the active ingredient in admixture with non-toxic pharmaceutically
acceptable excipients which are suitable for the manufacture of
tablets. These excipients may be, for example, inert diluents, such
as calcium carbonate, sodium carbonate, lactose, calcium phosphate
or sodium phosphate; granulating and disintegrating agents, for
example, corn starch, or alginic acid; and binding agents, for
example magnesium stearate, stearic acid or talc. The tablets may
be uncoated or they may be coated by known techniques to delay
disintegration and adsorption in the gastrointestinal tract and
thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or
glyceryl distearate may be employed. These compounds may also be
prepared in solid, rapidly released form.
[0041] Formulations for oral use may also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin or olive oil.
[0042] Aqueous suspensions contain the active materials in
admixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose, hydroxypropyl
methylcellulose, sodium alginate, polyvinylpyrrolidone, gum
tragacanth and gum acacia; dispersing or wetting agents may be a
naturally occurring phosphatide, for example, lecithin, or
condensation products or an alkylene oxide with fatty acids, for
example polyoxyethylene stearate, or condensation products of
ethylene oxide with long chain aliphatic alcohols, for example
heptadecaethylene oxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and hexitol such
as polyoxyethylene sorbitol monooleate, or condensation products of
ethylene oxide with partial esters derived from fatty acids and
hexitol anhydrides, for example polyethylene sorbitan monooleate.
The aqueous suspensions may also contain one or more preservatives,
for example ethyl, or n-propyl p-hydroxybenzoate, one or more
coloring agents, one or more flavoring agents, and one or more
sweetening agents, such as sucrose or saccharin.
[0043] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients, for example,
sweetening, flavoring and coloring agents, may also be present.
[0044] The compounds may also be in the form of non-aqueous liquid
formulations, e.g., oily suspensions which may be formulated by
suspending the active ingredients in a vegetable oil, for example
arachis oil, olive oil, sesame oil or peanut oil, or in a mineral
oil such as liquid paraffin. The oily suspensions may contain a
thickening agent, for example beeswax, hard paraffin or cetyl
alcohol. Sweetening agents such as those set forth above, and
flavoring agents may be added to provide palatable oral
preparations. These compositions may be preserved by the addition
of an anti-oxidant such as ascorbic acid.
[0045] Pharmaceutical compositions of the invention may also be in
the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, for example olive oil or arachis oil, or a mineral
oil, for example liquid paraffin or mixtures of these. Suitable
emulsifying agents may be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol anhydrides, for example sorbitan
monooleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan
monooleate. The emulsions may also contain sweetening and flavoring
agents.
[0046] Syrups and elixirs may be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol or sucrose. Such
formulations may also contain a demulcent, a preservative and
flavoring and coloring agents.
[0047] The compounds may also be administered in the form of
suppositories for rectal administration of the drug. These
compositions can be prepared by mixing the drug with a suitable
non-irritating excipient which is solid at ordinary temperatures
but liquid at the rectal temperature and will therefore melt in the
rectum to release the drug. Such materials include cocoa butter and
polyethylene glycols.
[0048] For all regimens of use disclosed herein for compounds of
Formula I, the daily oral dosage regimen will preferably be from
0.01 to 200 mg/Kg of total body weight. The daily dosage for
administration by injection, including intravenous, intramuscular,
subcutaneous and parenteral injections, and use of infusion
techniques will preferably be from 0.01 to 200 mg/Kg of total body
weight. The daily rectal dosage regime will preferably be from 0.01
to 200 mg/Kg of total body weight. The daily topical dosage regime
will preferably be from 0.1 to 200 mg administered between one to
four times daily. The daily inhalation dosage regime will
preferably be from 0.01 to 10 mg/Kg of total body weight.
[0049] It will be appreciated by those skilled in the art that the
particular method of administration will depend on a variety of
factors, all of which are considered routinely when administering
therapeutics. It will also be appreciated by one skilled in the art
that the specific dose level for a given patient depends on a
variety of factors, including specific activity of the compound
administered, age, body weight, health, sex, diet, time and route
of administration, rate of excretion, etc. It will be further
appreciated by one skilled in the art that the optimal course of
treatment, ie., the mode of treatment and the daily number of doses
of a compound of Formula I or a pharmaceutically acceptable salt
thereof given for a defined number of days, can be ascertained by
those skilled in the art using conventional treatment tests.
[0050] It will be understood, however, that the specific dose level
for any particular patient will depend upon a variety of factors,
including the activity of the specific compound employed, the age,
body weight, general health, sex, diet, time of administration,
route of administration, and rate of excretion, drug combination
and the severity of the condition undergoing therapy.
[0051] The entire disclosure of all applications, patents and
publications cited above and below are hereby incorporated by
reference, including provisional application Serial No. 60/115,877,
filed Jan. 13, 1999 and non-provisional application Ser. No.
09/257,266 filed Feb. 25, 1999.
[0052] The compounds can be produced from known compounds (or from
starting materials which, in turn, can be produced from known
compounds), e.g., through the general preparative methods shown
below. The activity of a given compound to inhibit raf kinase can
be routinely assayed, e.g., according to procedures disclosed
below. The following examples are for illustrative purposes only
and are not intended, nor should they be construed to limit the
invention in any way.
EXAMPLES
[0053] All reactions were performed in flame-dried or oven-dried
glassware under a positive pressure of dry argon or dry nitrogen,
and were stirred magnetically unless otherwise indicated. Sensitive
liquids and solutions were transferred via syringe or cannula, and
introduced into reaction vessels through rubber septa. Unless
otherwise stated, the term `concentration under reduced pressure`
refers to use of a Buchi rotary evaporator at approximately 15
mmHg. Unless otherwise stated, the term `under high vacuum` refers
to a vacuum of 0.4-1.0 mmHg.
[0054] All temperatures are reported uncorrected in degrees Celsius
(.degree. C.). Unless otherwise indicated, all parts and
percentages are by weight.
[0055] Commercial grade reagents and solvents were used without
further purification.
N-cyclohexyl-N'-(methylpolystyrene)carbodiimide was purchased from
Calbiochem-Novabiochem Corp. 3-tert-Butylaniline,
5-tert-butyl-2-methoxyaniline, 4-bromo-3-(trifluoromethyl)aniline,
4-chloro-3-(trifluoromethyl)aniline
2-methoxy-5-(trifluoromethyl)aniline, 4-tert-butyl-2-nitroaniline,
3-amino-2-naphthol, ethyl 4-isocyanatobenzoate,
N-acetyl-4-chloro-2-methoxy-5-(trifluoromethyl)anil- ine and
4-chloro-3-(trifluoromethyl)phenyl isocyanate were purchased and
used without further purification. Syntheses of
3-amino-2-methoxyquinolin- e (E. Cho et al. WO 98/00402; A. Cordi
et al. EP 542,609; IBID Bioorg. Med. Chem., 3, 1995, 129),
4-(3-carbamoylphenoxy)-1-nitrobenzene (K. Ikawa Yakugaku Zasshi 79,
1959, 760; Chem. Abstr. 53, 1959, 12761b), 3-tert-butylphenyl
isocyanate (O. Rohr et al. DE 2,436,108) and
2-methoxy-5-(trifluoromethyl)phenyl isocyanate (K. Inukai et al. JP
42,025,067; IBID Kogyo Kagaku Zasshi 70, 1967, 491) have previously
been described.
[0056] Thin-layer chromatography (TLC) was performed using
Whatman.RTM. pre-coated glass-backed silica gel 60A F-254 250 .mu.m
plates. Visualization of plates was effected by one or more of the
following techniques: (a) ultraviolet illumination, (b) exposure to
iodine vapor, (c) immersion of the plate in a 10% solution of
phosphomolybdic acid in ethanol followed by heating, (d) immersion
of the plate in a cerium sulfate solution followed by heating,
and/or (e) immersion of the plate in an acidic ethanol solution of
2,4-dinitrophenylhydrazine followed by heating. Column
chromatography (flash chromatography) was performed using 230-400
mesh EM Science.RTM. silica gel.
[0057] Melting points (mp) were determined using a Thomas-Hoover
melting point apparatus or a Mettler FP66 automated melting point
apparatus and are uncorrected. Fourier transform infrared spectra
were obtained using a Mattson 4020 Galaxy Series spectrophotometer.
Proton (.sup.1H) nuclear magnetic resonance (NMR) spectra were
measured with a General Electric GN-Omega 300 (300 MHz)
spectrometer with either Me.sub.4Si (.delta.0.00) or residual
protonated solvent (CHCl.sub.3 .delta.7.26; MeOH .delta.3.30; DMSO
.delta.2.49) as standard. Carbon (.sup.13C) NMR spectra were
measured with a General Electric GN-Omega 300 (75 MHz) spectrometer
with solvent (CDCl.sub.3 .delta.77.0; MeOD-d.sub.3; .delta.49.0;
DMSO-d.sub.6 .delta.39.5) as standard. Low resolution mass spectra
(MS) and high resolution mass spectra (HRMS) were either obtained
as electron impact (EI) mass spectra or as fast atom bombardment
(FAB) mass spectra. Electron impact mass spectra (EI-MS) were
obtained with a Hewlett Packard 5989A mass spectrometer equipped
with a Vacumetrics Desorption Chemical Ionization Probe for sample
introduction. The ion source was maintained at 250.degree. C.
Electron impact ionization was performed with electron energy of 70
eV and a trap current of 300 .mu.A. Liquid-cesium secondary ion
mass spectra (FAB-MS), an updated version of fast atom bombardment
were obtained using a Kratos Concept 1-H spectrometer. Chemical
ionization mass spectra (CI-MS) were obtained using a Hewlett
Packard MS-Engine (5989A) with methane or ammonia as the reagent
gas (1.times.10.sup.-4 torr to 2.5.times.10.sup.-4 torr). The
direct insertion desorption chemical ionization (DCI) probe
(Vaccumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held
at 10 amps until all traces of the sample disappeared (.about.1-2
min). Spectra were scanned from 50-800 amu at 2 sec per scan.
HPLC--electrospray mass spectra (HPLC ES-MS) were obtained using a
Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a
variable wavelength detector, a C-18 column, and a Finnigan LCQ ion
trap mass spectrometer with electrospray ionization. Spectra were
scanned from 120-800 amu using a variable ion time according to the
number of ions in the source. Gas chromatography--ion selective
mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas
chromatograph equipped with an HP-1 methyl silicone column (0.33 mM
coating; 25 m.times.0.2 mm) and a Hewlett Packard 5971 Mass
Selective Detector (ionization energy 70 eV). Elemental analyses
are conducted by Robertson Microlit Labs, Madison N.J.
[0058] All compounds displayed NMR spectra, LRMS and either
elemental analysis or HRMS consistent with assigned structures.
1 List of Abbreviations and Acronyms: AcOH acetic acid anh
anhydrous atm atmosphere(s) BOC tert-butoxycarbonyl CDI
1,1'-carbonyl diimidazole conc concentrated d day(s) dec
decomposition DMAC N,N-dimethylacetamide DMPU
1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-- pyrimidinone DMF
N,N-dimethylformamide DMSO dimethylsulfoxide DPPA
diphenylphosphoryl azide EDCI
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide EtOAc ethyl acetate
EtOH ethanol (100%) Et.sub.2O diethyl ether Et.sub.3N triethylamine
h hour(s) HOBT 1-hydroxybenzotriazole m-CPBA 3-chloroperoxybenzoic
acid MeOH methanol pet. ether petroleum ether (boiling range
30-60.degree. C.) temp. temperature THF tetrahydrofuran TFA
trifluoroAcOH Tf trifluoromethanesulfonyl
[0059] A. General Methods for Synthesis of Substituted Anilines
[0060] A1. General Method for Aryl Amine Formation via Ether
Formation Followed by Ester Saponification, Curtius Rearrangement,
and Carbamate Deprotection. Synthesis of
2-Amino-3-methoxynaphthalene. 7
[0061] Step 1. Methyl 3-methoxy-2-naphthoate
[0062] A slurry of methyl 3-hydroxy-2-naphthoate (10.1 g, 50.1
mmol) and K.sub.2CO.sub.3 (7.96 g, 57.6 mmol) in DMF (200 mL) was
stirred at room temp. for 15 min., then treated with iodomethane
(3.43 mL, 55.1 mmol). The mixture was allowed to stir at room temp.
overnight, then was treated with water (200 mL). The resulting
mixture was extracted with EtOAc (2.times.200 mL). The combined
organic layers were washed with a saturated NaCl solution (100 mL),
dried (MgSO.sub.4), concentrated under reduced pressure
(approximately 0.4 mmHg overnight) to give methyl
3-methoxy-2-naphthoate as an amber oil (10.30 g): .sup.1H-NMR
(DMSO-d.sub.6) .delta.2.70 (s, 3H), 2.85 (s, 3H), 7.38 (app t,
J=8.09 Hz, 1H), 7.44 (s, 1H), 7.53 (app t, J=8.09 Hz, 1H), 7.84 (d,
J=8.09 Hz, 1H), 7.90 (s, 1H), 8.21 (s, 1H). 8
[0063] Step 2. 3-Methoxy-2-naphthoic acid
[0064] A solution of methyl 3-methoxy-2-naphthoate (6.28 g, 29.10
mmol) and water (10 mL) in MeOH (100 mL) at room temp. was treated
with a 1 N NaOH solution (33.4 mL, 33.4 mmol). The mixture was
heated at the reflux temp. for 3 h, cooled to room temp., and made
acidic with a 10% citric acid solution. The resulting solution was
extracted with EtOAc (2.times.100 mL). The combined organic layers
were washed with a saturated NaCl solution, dried (MgSO.sub.4) and
concentrated under reduced pressure. The residue was triturated
with hexane then washed several times with hexane to give
3-methoxy-2-naphthoic acid as a white solid (5.40 g, 92%):
.sup.1H-NMR (DMSO-d.sub.6) .delta.3.88 (s, 3H), 7.34-7.41 (m, 2H),
7.49-7.54 (m, 1H), 7.83 (d, J=8.09 Hz, 1H), 7.91 (d, J=8.09 Hz,
1H), 8.19 (s, 1H), 12.83 (br s, 1H). 9
[0065] Step 3. 2-(N-(Carbobenzyloxy)amino-3-methoxynaphthalene
[0066] A solution of 3-methoxy-2-naphthoic acid (3.36 g, 16.6 mmol)
and Et.sub.3N (2.59 mL, 18.6 mmol) in anh toluene (70 mL) was
stirred at room temp. for 15 min., then treated with a solution of
DPPA (5.12 g, 18.6 mmol) in toluene (10 mL) via pipette. The
resulting mixture was heated at 80.degree. C. for 2 h. After
cooling the mixture to room temp., benzyl alcohol (2.06 mL, 20
mmol) was added via syringe. The mixture was then warmed to
80.degree. C. overnight. The resulting mixture was cooled to room
temp., quenched with a 10% citric acid solution, and extracted with
EtOAc (2.times.100 mL). The combined organic layers were washed
with a saturated NaCl solution, dried (MgSO.sub.4) and concentrated
under reduced pressure. The residue was purified by column
chromatography (14% EtOAc/86% hexane) to give
2-(N-(carbobenzyloxy)amino-3-methoxynaphthalene as a pale yellow
oil (5.1 g, 100%): .sup.1H-NMR (DMSO-d.sub.6) .delta.3.89 (s, 3H),
5.17 (s, 2H), 7.27-7.44 (m, 8H), 7.72-7.75 (m, 2H), 8.20 (s, 1H),
8.76 (s, 1H). 10
[0067] Step 4. 2-Amino-3-methoxynaphthalene
[0068] A slurry of 2-(N-(carbobenzyloxy)amino-3-methoxynaphthalene
(5.0 g, 16.3 mmol) and 10% Pd/C (0.5 g) in EtOAc (70 mL) was
maintained under a H.sub.2 atm (balloon) at room temp. overnight.
The resulting mixture was filtered through Celite.RTM. and
concentrated under reduced pressure to give
2-amino-3-methoxynaphthalene as a pale pink powder (2.40 g, 85%):
.sup.1H-NMR (DMSO-d.sub.6) .delta.3.86 (s, 3H), 6.86 (s, 2H),
7.04-7.16 (m, 2H), 7.43 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.0 Hz, 1H);
EI-MS m/z 173 (M.sup.+).
[0069] A2. Synthesis of .omega.-Carbamyl Anilines via Formation of
a Carbamylpyridine Followed by Nucleophilic Coupling with an Aryl
Amine. Synthesis of 4-(2-N-Methylcarbamyl-4-pyridyloxy)aniline
11
[0070] Step 1a. Synthesis of
4-chloro-N-methyl-2-pyridinecarboxamide via the Menisci
reaction
[0071] Caution: this is a highly hazardous, potentially explosive
reaction. To a stirring solution of 4-chloropyridine (10.0 g) in
N-methylformamide (250 mL) at room temp. was added conc.
H.sub.2SO.sub.4 (3.55 mL) to generate an exotherm. To this mixture
was added H.sub.2O.sub.2 (30% wt in H.sub.2O, 17 mL) followed by
FeSO.sub.4.7H.sub.2O (0.56 g) to generate another exotherm. The
resulting mixture was stirred in the dark at room temp. for 1 h,
then warmed slowly over 4 h to 45.degree. C. When bubbling had
subsided, the reaction was heated at 60.degree. C. for 16 h. The
resulting opaque brown solution was diluted with H.sub.2O (700 mL)
followed by a 10% NaOH solution (250 mL). The resulting mixture was
extracted with EtOAc (3.times.500 mL). The organic phases were
washed separately with a saturated NaCl solution (3.times.150 mL),
then they were combined, dried (MgSO.sub.4) and filtered through a
pad of silica gel with the aid of EtOAc. The resulting brown oil
was purified by column chromatography (gradient from 50% EtOAc/50%
hexane to 80% EtOAc/20% hexane). The resulting yellow oil
crystallized at 0.degree. C. over 72 h to give
4-chloro-N-methyl-2-pyridi- necarboxamide (0.61 g, 5.3%): TLC (50%
EtOAc/50% hexane) R.sub.f 0.50; .sup.1H NMR (CDCl.sub.3)
.delta.3.04 (d, J=5.1 Hz, 3H), 7.43 (dd, J=5.4, 2.4 Hz, 1H), 7.96
(br s, 1H), 8.21 (s, 1H), 8.44 (d, J=5.1 Hz, 1 H); CI-MS m/z 171
((M+H).sup.+). 12
[0072] Step 1b. Synthesis of 4-chloropyridine-2-carbonyl chloride
HCl salt via picolinic acid
[0073] Anhydrous DMF (6.0 mL) was slowly added to SOCl.sub.2 (180
mL) between 40.degree. and 50.degree. C. The solution was stirred
in that temperature range for 10 min. then picolinic acid (60.0 g,
487 mmol) was added in portions over 30 min. The resulting solution
was heated at 72.degree. C. (vigorous SO.sub.2 evolution) for 16 h
to generate a yellow solid precipitate. The resulting mixture was
cooled to room temp., diluted with toluene (500 mL) and
concentrated to 200 mL. The toluene addition/concentration process
was repeated twice. The resulting nearly dry residue was filtered
and the solids were washed with toluene (2.times.200 mL) and dried
under high vacuum for 4 h to afford 4-chloropyridine-2-carbonyl
chloride HCl salt as a yellow-orange solid (92.0 g, 89%). 13
[0074] Step 2. Synthesis of methyl 4-chloropyridine-2-carboxylate
HCl salt
[0075] Anh DMF (10.0 mL) was slowly added to SOCl.sub.2 (300 mL) at
40-48.degree. C. The solution was stirred at that temp. range for
10 min., then picolinic acid (100 g, 812 mmol) was added over 30
min. The resulting solution was heated at 72.degree. C. (vigorous
SO.sub.2 evolution) for 16 h to generate a yellow solid. The
resulting mixture was cooled to room temp., diluted with toluene
(500 mL) and concentrated to 200 mL. The toluene
addition/concentration process was repeated twice. The resulting
nearly dry residue was filtered, and the solids were washed with
toluene (50 mL) and dried under high vacuum for 4 hours to afford
4-chloropyridine-2-carbonyl chloride HCl salt as an off-white solid
(27.2 g, 16%). This material was set aside.
[0076] The red filtrate was added to MeOH (200 mL) at a rate which
kept the internal temperature below 55.degree. C. The contents were
stirred at room temp. for 45 min., cooled to 5.degree. C. and
treated with Et.sub.2O (200 mL) dropwise. The resulting solids were
filtered, washed with Et.sub.2O (200 mL) and dried under reduced
pressure at 35.degree. C. to provide methyl
4-chloropyridine-2-carboxylate HCl salt as a white solid (110 g,
65%): mp 108-112.degree. C.; .sup.1H-NMR (DMSO-d.sub.6) .delta.3.88
(s, 3H); 7.82 (dd, J=5.5, 2.2 Hz, 1H); 8.08 (d, J=2.2 Hz, 1H); 8.68
(d, J=5.5 Hz, 1H); 10.68 (br s, 1H); HPLC ES-MS m/z 172
((M+H).sup.+). 14
[0077] Step 3a. Synthesis of
4-chloro-N-methyl-2-pyridinecarboxamide from methyl
4-chloropyridine-2-carboxylate
[0078] A suspension of methyl 4-chloropyridine-2-carboxylate HCl
salt (89.0 g, 428 mmol) in MeOH (75 mL) at 0.degree. C. was treated
with a 2.0 M methylamine solution in THF (1 L) at a rate which kept
the internal temp. below 5.degree. C. The resulting mixture was
stored at 3.degree. C. for 5 h, then concentrated under reduced
pressure. The resulting solids were suspended in EtOAc (1 L) and
filtered. The filtrate was washed with a saturated NaCl solution
(500 mL), dried (Na.sub.2SO.sub.4) and concentrated under reduced
pressure to afford 4-chloro-N-methyl-2-pyridin- ecarboxamide as
pale-yellow crystals (71.2 g, 97%): mp 41-43.degree. C.;
.sup.1H-NMR (DMSO-d.sub.6) .delta.2.81 (s, 3H), 7.74 (dd, J=5.1,
2.2 Hz, 1H), 8.00 (d, J=2.2, 1H), 8.61 (d, J=5.1 Hz, 1H), 8.85 (br
d, 1H); CI-MS m/z 171 ((M+H).sup.+). 15
[0079] Step 3b. Synthesis of
4-chloro-N-methyl-2-pyridinecarboxamide from
4-chloropyridine-2-carbonyl chloride
[0080] 4-Chloropyridine-2-carbonyl chloride HCl salt (7.0 g, 32.95
mmol) was added in portions to a mixture of a 2.0 M methylamine
solution in THF (100 mL) and MeOH (20 mL) at 0.degree. C. The
resulting mixture was stored at 3.degree. C. for 4 h, then
concentrated under reduced pressure. The resulting nearly dry
solids were suspended in EtOAc (100 mL) and filtered. The filtrate
was washed with a saturated NaCl solution (2.times.100 mL), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure to
provide 4-chloro-N-methyl-2-pyridinecarboxamide as a yellow,
crystalline solid (4.95 g, 88%): mp 37-40.degree. C. 16
[0081] Step 4. Synthesis of
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline
[0082] A solution of 4-aminophenol (9.60 g, 88.0 mmol) in anh. DMF
(150 mL) was treated with potassium tert-butoxide (10.29 g, 91.7
mmol), and the reddish-brown mixture was stirred at room temp. for
2 h. The contents were treated with
4-chloro-N-methyl-2-pyridinecarboxamide (15.0 g, 87.9 mmol) and
K.sub.2CO.sub.3 (6.50 g, 47.0 mmol) and then heated at 80.degree.
C. for 8 h. The mixture was cooled to room temp. and separated
between EtOAc (500 mL) and a saturated NaCl solution (500 mL). The
aqueous phase was back-extracted with EtOAc (300 mL). The combined
organic layers were washed with a saturated NaCl solution
(4.times.1000 mL), dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure. The resulting solids were dried under reduced
pressure at 35.degree. C. for 3 h to afford
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline as a light-brown
solid 17.9 g, 84%): .sup.1H-NMR (DMSO-d.sub.6) .delta.2.77 (d,
J=4.8 Hz, 3H), 5.17 (br s, 2H), 6.64, 6.86 (AA'BB' quartet, J=8.4
Hz, 4H), 7.06 (dd, J=5.5, 2.5 Hz, 1H), 7.33 (d, J=2.5 Hz, 1H), 8.44
(d, J=5.5 Hz, 1H), 8.73 (br d, 1H); HPLC ES-MS m/z 244
((M+H).sup.+).
[0083] A3. General Method for the Synthesis of Anilines by
Nucleophilic Aromatic Addition Followed by Nitroarene Reduction.
Synthesis of 5-(4-Aminophenoxy)isoindoline-1,3-dione 17
[0084] Step 1. Synthesis of 5-hydroxyisoindoline-1,3-dione
[0085] To a mixture of ammonium carbonate (5.28 g, 54.9 mmol) in
conc. AcOH (25 mL) was slowly added 4-hydroxyphthalic acid (5.0 g,
27.45 mmol). The resulting mixture was heated at 120.degree. C. for
45 min., then the clear, bright yellow mixture was heated at
160.degree. C. for 2 h. The resulting mixture was maintained at
160.degree. C. and was concentrated to approximately 15 mL, then
was cooled to room temp. and adjusted pH 10 with a 1N NaOH
solution. This mixture was cooled to 0.degree. C. and slowly
acidified to pH 5 using a 1N HCl solution. The resultant
precipitate was collected by filtration and dried under reduced
pressure to yield 5-hydroxyisoindoline-1,3-dione as a pale yellow
powder as product (3.24 g, 72%): .sup.1H NMR (DMSO-d.sub.6)
.delta.7.00-7.03 (m, 2H), 7.56 (d, J=9.3Hz, 1H). 18
[0086] Step 2. Synthesis of
5-(4-nitrophenoxy)isoindoline-1,3-dione
[0087] To a stirring slurry of NaH (1.1 g, 44.9 mmol) in DMF (40
mL) at 0.degree. C. was added a solution of
5-hydroxyisoindoline-1,3-dione (3.2 g, 19.6 mmol) in DMF (40 mL)
dropwise. The bright yellow-green mixture was allowed to return to
room temp. and was stirred for 1 h, then 1-fluoro-4-nitrobenzene
(2.67 g, 18.7 mmol) was added via syringe in 3-4 portions. The
resulting mixture was heated at 70.degree. C. overnight, then
cooled to room temp. and diluted slowly with water (150 mL), and
extracted with EtOAc (2.times.100 mL). The combined organic layers
were dried (MgSO.sub.4) and concentrated under reduced pressure to
give 5-(4-nitrophenoxy)isoindoline-1,3-dione as a yellow solid (3.3
g, 62%): TLC (30% EtOAc/70% hexane) R.sub.f 0.28; 1H NMR
(DMSO-d.sub.6) .delta.7.32 (d, J=12 Hz, 2H), 7.52-7.57 (m, 2H),
7.89(d, J=7.8 Hz, 1H), 8.29 (d, J=9 Hz, 2H), 11.43 (br s, 1H);
CI-MS m/z 285 ((M+H).sup.+, 100%). 19
[0088] Step 3. Synthesis of
5-(4-aminophenoxy)isoindoline-1,3-dione
[0089] A solution of 5-(4-nitrophenoxy)isoindoline-1,3-dione (0.6
g, 2.11 mmol) in conc. AcOH (12 mL) and water (0.1 mL) was stirred
under stream of argon while iron powder (0.59 g, 55.9 mmol) was
added slowly. This mixture stirred at room temp. for 72 h, then was
diluted with water (25 mL) and extracted with EtOAc (3.times.50
mL). The combined organic layers were dried (MgSO.sub.4) and
concentrated under reduced pressure to give
5-(4-aminophenoxy)isoindoline-1,3-dione as a brownish solid (0.4 g,
75%): TLC (50% EtOAc/50% hexane) R.sub.f 0.27; .sup.1H NMR
(DMSO-d.sub.6) .delta.5.14 (br s, 2H), 6.62 (d, J=8.7 Hz, 2H), 6.84
(d, J=8.7 Hz, 2H), 7.03 (d, J=2.1 Hz, 1H), 7.23 (dd, 1H), 7.75 (d,
J=8.4 Hz, 1H), 11.02 (s, 1H); HPLC ES-MS m/z 255 ((M+H).sup.+,
100%).
[0090] A4. General Method for the Synthesis of Pyrrolylanilines.
Synthesis of 5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline 20
[0091] Step 1. Synthesis of
1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyr- role
[0092] To a stirring solution of 2-nitro-4-tert-butylaniline (0.5
g, 2.57 mmol) in cyclohexane (10 mL) was added AcOH (0.1 mL) and
acetonylacetone (0.299 g, 2.63 mmol) via syringe. The reaction
mixture was heated at 120.degree. C. for 72 h with azeotropic
removal of volatiles. The reaction mixture was cooled to room
temp., diluted with CH.sub.2Cl.sub.2 (10 mL) and sequentially
washed with a 1N HCl solution (15 mL), a 1N NaOH solution (15 mL)
and a saturated NaCl solution (15 mL), dried (MgSO.sub.4) and
concentrated under reduced pressure. The resulting orange-brown
solids were purified via column chromatography (60 g SiO.sub.2;
gradient from 6% EtOAc/94% hexane to 25% EtOAc/75% hexane) to give
1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyrrole as an
orange-yellow solid (0.34 g, 49%): TLC (15% EtOAc/85% hexane)
R.sub.f 0.67; .sup.1H NMR (CDCl.sub.3) d 1.34 (s, 9H), 1.89 (s,
6H), 5.84 (s, 2H), 7.19-7.24 (m, 1H), 7.62 (dd, 1H), 7.88 (d, J=2.4
Hz, 1H); CI-MS m/z 273 ((M+H).sup.+, 50%). 21
[0093] Step 2. Synthesis of
5-tert--Butyl-2-(2,5-dimethylpyrrolyl)aniline
[0094] A slurry of
1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyrrole (0.341 g, 1.25
mmol), 10% Pd/C (0.056 g) and EtOAc (50 mL) under an H.sub.2
atmosphere (balloon) was stirred for 72 h, then filtered through a
pad of Celite.RTM.. The filtrate was concentrated under reduced
pressure to give 5-tert--butyl-2-(2,5-dimethylpyrrolyl)aniline as
yellowish solids (0.30 g, 99%): TLC (10% EtOAc/90% hexane) R.sub.f
0.43; .sup.1H NMR (CDCl.sub.3) .delta.1.28 (s, 9H), 1.87-1.91 (m,
8H), 5.85 (br s, 2H), 6.73-6.96 (m, 3H), 7.28 (br s, 1H).
[0095] A5. General Method for the Synthesis of Anilines from
Anilines by Nucleophilic Aromatic Substitution. Synthesis of
4-(2-(N-Methylcarbamoyl)- -4-pyridyloxy)-2-methylaniline HCl Salt
22
[0096] A solution of 4-amino-3-methylphenol (5.45 g, 44.25 mmol) in
dry dimethylacetamide (75 mL) was treated with potassium
tert-butoxide (10.86 g, 96.77 mmol) and the black mixture was
stirred at room temp. until the flask had reached room temp. The
contents were then treated with
4-chloro-N-methyl-2-pyridinecarboxamide (Method A2, Step 3b; 7.52
g, 44.2 mmol) and heated at 110.degree. C. for 8 h. The mixture was
cooled to room temp. and diluted with water (75 mL). The organic
layer was extracted with EtOAc (5.times.100 mL). The combined
organic layers were washed with a saturated NaCl solution (200 mL),
dried (MgSO.sub.4) and concentrated under reduced pressure. The
residual black oil was treated with Et.sub.2O (50 mL) and
sonicated. The solution was then treated with HCl (1 M in
Et.sub.2O; 100 mL) and stirred at room temp. for 5 min. The
resulting dark pink solid (7.04 g, 24.1 mmol) was removed by
filtration from solution and stored under anaerobic conditions at
0.degree. C. prior to use: .sup.1H NMR (DMSO-d.sub.6) .delta.2.41
(s, 3H), 2.78 (d, J=4.4 Hz, 3H), 4.93 (br s, 2H), 7.19 (dd, J=8.5,
2.6 Hz, 1H), 7.23 (dd, J=5.5, 2.6 Hz, 1H), 7.26 (d, J=2.6 Hz, 1H),
7.55 (d, J=2.6 Hz, 1H), 7.64 (d, J=8.8 Hz, 1H), 8.55 (d, J=5.9 Hz,
1H), 8.99 (q, J=4.8 Hz, 1H).
[0097] A6. General Method for the Synthesis of Anilines from
Hydroxyanilines by N-Protection, Nucleophilic Aromatric
Substitution and Deprotection. Synthesis of
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlor- oaniline 23
[0098] Step 1: Synthesis of
3-Chloro-4-(2,2,2-trifluoroacetylamino)phenol
[0099] Iron (3.24 g, 58.00 mmol) was added to stirring TFA (200
mL). To this slurry was added 2-chloro-4-nitrophenol (10.0 g, 58.0
mmol) and trifluoroacetic anhydride (20 mL). This gray slurry was
stirred at room temp. for 6 d. The iron was filtered from solution
and the remaining material was concentrated under reduced pressure.
The resulting gray solid was dissolved in water (20 mL). To the
resulting yellow solution was added a saturated NaHCO.sub.3
solution (50 mL). The solid which precipitated from solution was
removed. The filtrate was slowly quenched with the sodium
bicarbonate solution until the product visibly separated from
solution (determined was using a mini work-up vial). The slightly
cloudy yellow solution was extracted with EtOAc (3.times.125 mL).
The combined organic layers were washed with a saturated NaCl
solution (125 mL), dried (MgSO.sub.4) and concentrated under
reduced pressure. The .sup.1H NMR (DMSO-d.sub.6) indicated a 1:1
ratio of the nitrophenol starting material and the intended product
3-chloro-4-(2,2,2-trifluoroace- tylamino)phenol. The crude material
was taken on to the next step without further purification. 24
[0100] Step 2: Synthesis of
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlor- ophenyl
(222-trifluoro)acetamide
[0101] A solution of crude
3-chloro-4-(2,2,2-trifluoroacetylamino)phenol (5.62 g, 23.46 mmol)
in dry dimethylacetamide (50 mL) was treated with potassium
tert-butoxide (5.16 g, 45.98 mmol) and the brownish black mixture
was stirred at room temp. until the flask had cooled to room temp.
The resulting mixture was treated with
4-chloro-N-methyl-2-pyridine- carboxamide (Method A2, Step 3b; 1.99
g, 11.7 mmol) and heated at 100.degree. C. under argon for 4 d. The
black reaction mixture was cooled to room temp. and then poured
into cold water (100 mL). The mixture was extracted with EtOAc
(3.times.75 mL) and the combined organic layers were concentrated
under reduced pressure. The residual brown oil was purified by
column chromatography (gradient from 20% EtOAc/pet. ether to 40%
EtOAc/pet. ether) to yield
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlor- ophenyl
(222-trifluoro)acetamide as a yellow solid (8.59 g, 23.0 mmol).
25
[0102] Step 3. Synthesis of
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlor- oaniline
[0103] A solution of crude
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloro- phenyl
(222-trifluoro)acetamide (8.59 g, 23.0 mmol) in dry 4-dioxane (20
mL) was treated with a 1N NaOH solution (20 mL). This brown
solution was allowed to stir for 8 h. To this solution was added
EtOAc (40 mL). The green organic layer was extracted with EtOAc
(3.times.40 mL) and the solvent was concentrated to yield
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-- 2-chloroaniline as a green
oil that solidified upon standing (2.86 g, 10.30 mmol): .sup.1H NMR
(DMSO-d.sub.6) .delta.2.77 (d, J=4.8 Hz, 3H), 5.51 (s, 2H), 6.60
(dd, J=8.5, 2.6 Hz, 1H), 6.76 (d, J=2.6 Hz, 1H), 7.03 (d, J=8.5 Hz,
1H), 7.07 (dd, J=5.5, 2.6, Hz, 1H), 7.27 (d, J=2.6 Hz, 1H), 8.46
(d, J=5.5 Hz, 1H), 8.75 (q, J=4.8, 1H).
[0104] A7. General Method for the Deprotection of an Acylated
Aniline. Synthesis of 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline
26
[0105] A suspension of
3-chloro-6-(N-acetyl)-4-(trifluoromethyl)anisole (4.00 g, 14.95
mmol) in a 6M HCl solution (24 mL) was heated at the reflux temp.
for 1 h. The resulting solution was allowed to cool to room temp.
during which time it solidified slightly. The resulting mixture was
diluted with water (20 mL) then treated with a combination of solid
NaOH and a saturated NaHCO.sub.3 solution until the solution was
basic. The organic layer was extracted with CH.sub.2Cl.sub.2
(3.times.50 mL). The combined organics were dried (MgSO.sub.4) and
concentrated under reduced pressure to yield
4-chloro-2-methoxy-5-(trifluoromethyl)aniline as a brown oil (3.20
g, 14.2 mmol): .sup.1H NMR (DMSO-d.sub.6) .delta.3.84 (s, 3H), 5.30
(s, 2H), 7.01 (s, 2H).
[0106] A8. General Method for Synthesis of
.omega.-Alkoxy-.omega.-carboxyp- henyl Anilines. Synthesis of
4-(3-(N-Methylcarbamoly)-4-methoxyphenoxy)ani- line. 27
[0107] Step 1.
4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene:
[0108] To a solution of
4-(3-carboxy-4-hydroxyphenoxy)-1-nitrobenzene (prepared from
2,5-dihydroxybenzoic acid in a manner analogous to that described
in Method A13, Step 1, 12 mmol) in acetone (50 mL) was added
K.sub.2CO.sub.3 (5 g) and dimethyl sulfate (3.5 mL). The resulting
mixture was heated at the reflux temp. overnight, then cooled to
room temp. and filtered through a pad of Celite.RTM.. The resulting
solution was concentrated under reduced pressure, absorbed onto
SiO.sub.2, and purified by column chromatography (50% EtOAc/50%
hexane) to give
4-(3-methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene as a yellow
powder (3 g): mp 115-118.degree. C. 28
[0109] Step 2. 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene:
[0110] A mixture of
4-(3-methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene (1.2 g), KOH
(0.33 g) and water (5 mL) in MeOH (45 mL) was stirred at room temp.
overnight and then heated at the reflux temp. for 4 h. The
resulting mixture was cooled to room temp. and concentrated under
reduced pressure. The residue was dissolved in water (50 mL), and
the aqueous mixture was made acidic with a 1N HCl solution. The
resulting mixture was extracted with EtOAc (50 mL). The organic
layer was dried (MgSO.sub.4) and concentrated under reduced
pressure to give 4-(3-carboxy-4-methoxyphe- noxy)-1-nitrobenzene
(1.04 g). 29
[0111] Step 3.
4-(3-(N-Methylcarbamoly)-4-methoxyphenoxy)-1-nitrobenzene:
[0112] To a solution of
4-(3-carboxy-4-methoxyphenoxy)-1-nitrobenzene (0.50 g, 1.75 mmol)
in CH.sub.2Cl.sub.2 (12 mL) was added SOCl.sub.2 (0.64 mL, 8.77
mmol) in portions. The resulting solution was heated at the reflux
temp. for 18 h, cooled to room temp., and concentrated under
reduced pressure. The resulting yellow solids were dissolved in
CH.sub.2Cl.sub.2 (3 mL) then the resulting solution was treated
with a methylamine solution (2.0 M in THF, 3.5 mL, 7.02 mmol) in
portions (CAUTION: gas evolution), and stirred at room temp. for 4
h. The resulting mixture was treated with a 1N NaOH solution, then
extracted with CH.sub.2Cl.sub.2 (25 mL). The organic layer was
dried (Na.sub.2SO.sub.4) and concentrated under reduced pressure to
give 4-(3-(N-methylcarbamoly)-4-methoxyphenoxy)-1-nitrobenzene as a
yellow solid (0.50 g, 95%). 30
[0113] Step 4.
4-(3-(N-Methylcarbamoly)-4-methoxyphenoxy)aniline:
[0114] A slurry of
4-(3-(N-methylcarbamoly)-4-methoxyphenoxy)-1-nitrobenze- ne (0.78
g, 2.60 mmol) and 10% Pd/C (0.20 g) in EtOH (55 mL) was stirred
under 1 atm of H.sub.2 (balloon) for 2.5 d, then was filtered
through a pad of Celite.RTM.. The resulting solution was
concentrated under reduced pressure to afford
4-(3-(N-methylcarbamoly)-4-methoxyphenoxy)aniline as an off-white
solid (0.68 g, 96%): TLC (0.1% Et.sub.3N/99.9% EtOAc) R.sub.f
0.36.
[0115] A9. General Method for Preparation of
.omega.-Alkylphthalimide-cont- aining Anilines. Synthesis of
5-(4-Aminophenoxy)-2-methylisoindoline-1,3-d- ione 31
[0116] Step 1. Synthesis of
5-(4-Nitrophenoxy)-2-methylisoindoline-1,3-dio- ne:
[0117] A slurry of 5-(4-nitrophenoxy)isoindoline-1,3-dione (A3 Step
2; 1.0 g, 3.52 mmol) and NaH (0.13 g, 5.27 mmol) in DMF (15 mL) was
stirred at room temp. for 1 h, then treated with methyl iodide (0.3
mL, 4.57 mmol). The resulting mixture was stirred at room temp.
overnight, then was cooled to .degree. C. and treated with water
(10 mL). The resulting solids were collected and dried under
reduced pressure to give
5-(4-nitrophenoxy)-2-methylisoindoline-1,3-dione as a bright yellow
solid (0.87 g, 83%): TLC (35% EtOAc/65% hexane) R.sub.f 0.61.
32
[0118] Step 2. Synthesis of
5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dio- ne:
[0119] A slurry of nitrophenoxy)-2-methylisoindoline-1,3-dione
(0.87 g, 2.78 mmol) and 10% Pd/C (0.10 g) in MeOH was stirred under
1 atm of H.sub.2 (balloon) overnight. The resulting mixture was
filtered through a pad of Celite.RTM. and concentrated under
reduced pressure. The resulting yellow solids were dissolved in
EtOAc (3 mL) and filtered through a plug of SiO.sub.2 (60%
EtOAc/40% hexane) to afford 5-(4-aminophenoxy)-2-methyl-
isoindoline-1,3-dione as a yellow solid (0.67 g, 86%): TLC (40%
EtOAc/60% hexane) R.sub.f 0.27.
[0120] A10. General Method for Synthesis of .omega.-Carbamoylaryl
Anilines Through Reaction of .omega.-Alkoxycarbonylaryl Precursors
with Amines. Synthesis of
4-(2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline 33
[0121] Step 1. Synthesis of
4-Chloro-2-(N-(2-morpholin-4-ylethyl)carbamoyl- )pyridine
[0122] To a solution of methyl 4-chloropyridine-2-carboxylate HCl
salt (Method A2, Step 2; 1.01 g, 4.86 mmol) in THF (20 mL) was
added 4-(2-aminoethyl)morpholine (2.55 mL, 19.4 mmol) dropwise and
the resulting solution was heated at the reflux temp. for 20 h,
cooled to room temp., and treated with water (50 mL). The resulting
mixture was extracted with EtOAc (50 mL). The organic layer was
dried (MgSO.sub.4) and concentrated under reduced pressure to
afford 4-chloro-2-(N-(2-morpho- lin-4-ylethyl)carbamoyl)pyridine as
a yellow oil (1.25 g, 95%): TLC (10% MeOH/90% EtOAc) R.sub.f 0.50.
34
[0123] Step 2. Synthesis of
4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyrid- yloxy)aniline.
[0124] A solution of 4-aminophenol (0.49 g, 4.52 mmol) and
potassium tert-butoxide (0.53 g, 4.75 mol) in DMF (8 mL) was
stirred at room temp. for 2 h, then was sequentially treated with
4-chloro-2-(N-(2-morpholin-4-- ylethyl)carbamoyl)pyridine (1.22 g,
4.52 mmol) and K.sub.2CO.sub.3 (0.31 g, 2.26 mmol). The resulting
mixture was heated at 75.degree. C. overnight, cooled to room
temp., and separated between EtOAc (25 mL) and a saturated NaCl
solution (25 mL). The aqueous layer was back extracted with EtOAc
(25 mL). The combined organic layers were washed with a saturated
NaCl solution (3.times.25 mL) and concentrated under reduced
pressure. The resulting brown solids were purified by column
chromatography (58 g; gradient from 100% EtOAc to 25% MeOH/75%
EtOAc) to afford
4-(2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline (1.0 g,
65%): TLC (10% MeOH/90% EtOAc) R.sub.f 0.32.
[0125] A11. General Method for the Reduction of Nitroarenes to
Arylamines. Synthesis of 4-(3-Carboxyphenoxy)aniline. 35
[0126] A slurry of 4-(3-carboxyphenoxy)-1-nitrobenzene (5.38 g,
20.7 mmol) and 10% Pd/C (0.50 g) in MeOH (120 mL) was stirred under
an H.sub.2 atmosphere (balloon) for 2 d. The resulting mixture was
filtered through a pad of Celite.RTM., then concentrated under
reduced pressure to afford 4-(3-carboxyphenoxy)aniline as a brown
solid (2.26 g, 48%): TLC (10% MeOH/90% CH.sub.2Cl.sub.2) R.sub.f
0.44 (streaking).
[0127] A12. General Method for the Synthesis of
Isoindolinone-Containing Anilines. Synthesis of
4-(1-Oxoisoindolin-5-yloxy)aniline. 36
[0128] Step 1. Synthesis of 5-hydroxyisoindolin-1-one
[0129] To a solution of 5-hydroxyphthalimide (19.8 g, 121 mmol) in
AcOH (500 mL) was slowly added zinc dust (47.6 g, 729 mmol) in
portions, then the mixture was heated at the reflux temp. for 40
min., filtered hot, and concentrated under reduced pressure. The
reaction was repeated on the same scale and the combined oily
residue was purified by column chromatography (1.1 Kg SiO.sub.2;
gradient from 60% EtOAc/40% hexane to 25% MeOH/75% EtOAc) to give
5-hydroxyisoindolin-1-one (3.77 g): TLC (100% EtOAc) R.sub.f 0.17;
HPLC ES-MS m/z 150 ((M+H).sup.+). 37
[0130] Step 2. Synthesis of
4-(1-isoindolinon-5-yloxy)-1-nitrobenzene
[0131] To a slurry of NaH (0.39 g, 16.1 mmol) in DMF at 0.degree.
C. was added 5-hydroxyisoindolin-1-one (2.0 g, 13.4 mmol) in
portions. The resulting slurry was allowed to warm to room temp.
and was stirred for 45 min., then 4-fluoro-1-nitrobenzene was added
and then mixture was heated at 70.degree. C. for 3 h. The mixture
was cooled to 0.degree. C. and treated with water dropwise until a
precipitate formed. The resulting solids were collected to give
4-(1-isoindolinon-5-yloxy)-1-nitrobenzene as a dark yellow solid
(3.23 g, 89%): TLC (100% EtOAc) R.sub.f 0.35. 38
[0132] Step 3. Synthesis of 4-(1-oxoisoindolin-5-yloxy)aniline
[0133] A slurry of 4-(1-isoindolinon-5-yloxy)-1-nitrobenzene (2.12
g, 7.8 mmol) and 10% Pd/C (0.20 g) in EtOH (50 mL) was stirred
under an H.sub.2 atmosphere (balloon) for 4 h, then filtered
through a pad of Celite.RTM.. The filtrate was concentrated under
reduced pressure to afford 4-(1-oxoisoindolin-5-yloxy)aniline as a
dark yellow solid: TLC (100% EtOAc) R.sub.f 0.15.
[0134] A13. General Method for the Synthesis of .omega.-Carbamoyl
Anilines via EDCI-Mediated Amide Formation Followed by Nitroarene
Reduction. Synthesis of 4-(3-N-Methylcarbamoylphenoxy)aniline.
39
[0135] Step 1. Synthesis of
4-(3-ethoxycarbonylphenoxy)-1-nitrobenzene
[0136] A mixture of 4-fluoro-1-nitrobenzene (16 mL, 150 mmol),
ethyl 3-hydroxybenzoate 25 g, 150 mmol) and K.sub.2CO.sub.3 (41 g,
300 mmol) in DMF (125 mL) was heated at the reflux temp. overnight,
cooled to room temp. and treated with water (250 mL). The resulting
mixture was extracted with EtOAc (3.times.150 mL). The combined
organic phases were sequentially washed with water (3.times.100 mL)
and a saturated NaCl solution (2.times.100 mL), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. The
residue was purified by column chromatography (10% EtOAc/90%
hexane) to afford 4-(3-ethoxycarbonylphenoxy)-1-nitrobenze- ne as
an oil (38 g). 40
[0137] Step 2. Synthesis of 4-(3-carboxyphenoxy)-1-nitrobenzene
[0138] To a vigorously stirred mixture of
4-(3-ethoxycarbonylphenoxy)-1-ni- trobenzene (5.14 g, 17.9 mmol) in
a 3:1 THF/water solution (75 mL) was added a solution LiOH.H.sub.2O
(1.50 g, 35.8 mmol) in water (36 mL). The resulting mixture was
heated at 50.degree. C. overnight, then cooled to room temp.,
concentrated under reduced pressure, and adjusted to pH 2 with a 1M
HCl solution. The resulting bright yellow solids were removed by
filtration and washed with hexane to give
4-(3-carboxyphenoxy)-1-nitro- benzene (4.40 g, 95%). 41
[0139] Step 3. Synthesis of
4-(3-(N-methylcarbamoyl)phenoxy)-1-nitrobenzen- e
[0140] A mixture of 4-(3-carboxyphenoxy)-1-nitrobenzene (3.72 g,
14.4 mmol), EDCI.HCl (3.63 g, 18.6 mmol), N-methylmorpholine (1.6
mL, 14.5 mmol) and methylamine (2.0 M in THF; 8 mL, 16 mmol) in
CH.sub.2Cl.sub.2 (45 mL) was stirred at room temp. for 3 d, then
concentrated under reduced pressure. The residue was dissolved in
EtOAc (50 mL) and the resulting mixture was extracted with a 1M HCl
solution (50 mL). The aqueous layer was back-extracted with EtOAc
(2.times.50 mL). The combined organic phases were washed with a
saturated NaCl solution (50 mL), dried (Na.sub.2SO.sub.4), and
concentrated under reduced pressure to give
4-(3-(N-methylcarbamoyl)phenoxy)-1-nitrobenzene as an oil (1.89 g).
42
[0141] Step 4. Synthesis of
4-(3-(N-methylcarbamoyl)phenoxy)aniline
[0142] A slurry of 4-(3-(N-methylcarbamoyl)phenoxy)-1-nitrobenzene
(1.89 g, 6.95 mmol) and 5% Pd/C (0.24 g) in EtOAc (20 mL) was
stirred under an H.sub.2 atm (balloon) overnight. The resulting
mixture was filtered through a pad of Celite.RTM. and concentrated
under reduced pressure. The residue was purified by column
chromatography (5% MeOH/95% CH.sub.2Cl.sub.2). The resulting oil
solidified under vacuum overnight to give
4-(3-(N-methylcarbamoyl)phenoxy)aniline as a yellow solid (0.95 g,
56%).
[0143] A14. General Method for the Synthesis of .omega.-Carbamoyl
Anilines via EDCI-Mediated Amide Formation Followed by Nitroarene
Reduction. Synthesis of 4-3-(5-Methylcarbamoyl)pyridyloxy)aniline
43
[0144] Step 1. Synthesis of
4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitroben- zene
[0145] To a slurry of NaH (0.63 g, 26.1 mmol) in DMF (20 mL) was
added a solution of methyl 5-hydroxynicotinate (2.0 g, 13.1 mmol)
in DMF (10 mL). The resulting mixture was added to a solution of
4-fluoronitrobenzene (1.4 mL, 13.1 mmol) in DMF (10 mL) and the
resulting mixture was heated at 70.degree. C. overnight, cooled to
room temp., and treated with MeOH (5 mL) followed by water (50 mL).
The resulting mixture was extracted with EtOAc (100 mL). The
organic phase was concentrated under reduced pressure. The residue
was purified by column chromatography (30% EtOAc/70% hexane) to
afford 4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobe- nzene (0.60
g). 44
[0146] Step 2. Synthesis of
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline
[0147] A slurry of
4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobenzene (0.60 g, 2.20
mmol) and 10% Pd/C in MeOH/EtOAc was stirred under an H.sub.2
atmosphere (balloon) for 72 h. The resulting mixture was filtered
and the filtrate was concentrated under reduced pressure. The
residue was purified by column chromatography (gradient from 10%
EtOAc/90% hexane to 30% EtOAc/70% hexane to 50% EtOAc/50% hexane)
to afford 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline (0.28 g, 60%):
.sup.1H NMR (CDCl.sub.3) .delta.3.92 (s, 3H), 6.71 (d, 2H), 6.89
(d, 2H), 7.73 (, 1H), 8.51 (d, 1H), 8.87 (d, 1H).
[0148] A15. Synthesis of an Aniline via Electrophilic Nitration
Followed by Reduction. Synthesis of
4-(3-Methylsulfamoylphenoxy)aniline. 45
[0149] Step 1. Synthesis of N-methyl-3-bromobenzenesulfonamide
[0150] To a solution of 3-bromobenzenesulfonyl chloride (2.5 g,
11.2 mmol) in THF (15 mL) at 0.degree. C. was added methylamine
(2.0 M in THF; 28 mL, 56 mmol). The resulting solution was allowed
to warm to room temp. and was stirred at room temp. overnight. The
resulting mixture was separated between EtOAc (25 mL) and a 1 M HCl
solution (25 mL). The aqueous phase was back-extracted with EtOAc
(2.times.25 mL). The combined organic phases were sequentially
washed with water (2.times.25 mL) and a saturated NaCl solution (25
mL), dried (MgSO.sub.4) and concentrated under reduced pressure to
give N-methyl-3-bromobenzenesulfonamide as a white solid (2.8 g,
99%). 46
[0151] Step 2. Synthesis of
4-(3-(N-methylsulfamoyl)phenyloxy)benzene
[0152] To a slurry of phenol (1.9 g, 20 mmol), K.sub.2CO.sub.3 (6.0
g, 40 mmol), and CuI (4 g, 20 mmol) in DMF (25 mL) was added
N-methyl-3-bromobenzenesulfonamide (2.5 g, 10mmol), and the
resulting mixture was stirred at the reflux temp. overnight, cooled
to room temp., and separated between EtOAc (50 mL) and a 1 N HCl
solution (50 mL). The aqueous layer was back-extracted with EtOAc
(2.times.50 mL). The combined organic phases were sequentially
washed with water (2.times.50 mL) and a saturated NaCl solution (50
mL), dried (MgSO.sub.4), and concentrated under reduced pressure.
The residual oil was purified by column chromatography (30%
EtOAc/70% hexane) to give 4-(3-(N-methylsulfamoyl)phe-
nyloxy)benzene (0.30 g). 47
[0153] Step 3. Synthesis of
4-(3-(N-methylsulfamoyl)phenyloxy)-1-nitrobenz- ene
[0154] To a solution of 4-(3-(N-methylsulfamoyl)phenyloxy)benzene
(0.30 g, 1.14 mmol) in TFA (6 mL) at -10.degree. C. was added
NaNO.sub.2 (0.097 g, 1.14 mmol) in portions over 5 min. The
resulting solution was stirred at -10.degree. C. for 1 h, then was
allowed to warm to room temp., and was concentrated under reduced
pressure. The residue was separated between EtOAc (10 mL) and water
(10 mL). The organic phase was sequentially washed with water (10
mL) and a saturated NaCl solution (10 mL), dried (MgSO.sub.4) and
concentrated under reduced pressure to give
4-(3-(N-methylsulfamoyl)phenyloxy)-1-nitrobenzene (0.20 g). This
material carried on to the next step without further purification.
48
[0155] Step 4. Synthesis of
4-(3-(N-methylsulfamoyl)phenyloxy)aniline
[0156] A slurry of
4-(3-(N-methylsulfamoyl)phenyloxy)-1-nitrobenzene (0.30 g) and 10%
Pd/C (0.030 g) in EtOAc (20 mL) was stirred under an H.sub.2
atmosphere (balloon) overnight. The resulting mixture was filtered
through a pad of Celite.RTM.. The filtrate was concentrated under
reduced pressure. The residue was purified by column chromatography
(30% EtOAc/70% hexane) to give
4-(3-(N-methylsulfamoyl)phenyloxy)aniline (0.070 g).
[0157] A16. Modification of .omega.-ketones. Synthesis of
4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt. 49
[0158] To a slurry of 4-(4-acetylphenoxy)aniline HCl salt (prepared
in a manner analogous to Method A13, step 4; 1.0 g, 3.89 mmol) in a
mixture of EtOH (10 mL) and pyridine (1.0 mL) was added
O-methylhydroxylamine HCl salt (0.65 g, 7.78 mmol, 2.0 equiv.). The
resulting solution was heated at the reflux temperature for 30 min,
cooled to room temperature and concentrated under reduced pressure.
The resulting solids were triturated with water (10 mL) and washed
with water to give 4-(4-(1-(N-methoxy)imino- ethyl) phenoxyaniline
HCl salt as a yellow solid (0.85 g): TLC (50% EtOAc/50% pet. ether)
R.sub.f 0.78; .sup.1H NMR (DMSO-d.sub.6) .delta.3.90 (s, 3H), 5.70
(s, 3H); HPLC-MS m/z 257 ((M+H).sup.+).
[0159] A17. Synthesis of N-(.omega.-Silyloxyalkyl)amides. Synthesis
of
4-(4-(2-(N-(2-Triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline.
50
[0160] Step 1.
4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxam-
ide
[0161] To a solution of
4-chloro-N-(2-hydroxyethyl)pyridine-2-carboxamide (prepared in a
manner analogous to Method A2, Step 3b; 1.5 g, 7.4 mmol) in anh DMF
(7 mL) was added triisopropylsilyl chloride (1.59 g, 8.2 mmol, 1.1
equiv.) and imidazole (1.12 g, 16.4 mmol, 2.2 equiv.). The
resulting yellow solution was stirred for 3 h at room temp, then
was concentrated under reduced pressure. The residue was separated
between water (10 mL) and EtOAc (10 mL). The aqueous layer was
extracted with EtOAc (3.times.10 mL). The combined organic phases
were dried (MgSO.sub.4), and concentrated under reduced pressure to
afford 4-chloro-2-(N-(2-triisoprop-
ylsilyloxy)ethyl)pyridinecarboxamide as an orange oil (2.32 g,
88%). This material was used in the next step without further
purification. 51
[0162] Step 2.
4-(4-(2-(N-(2-Triisopropylsilyloxy)ethylcarbamoyl)pyridylox-
yaniline
[0163] To a solution of 4-hydroxyaniline (0.70 g, 6.0 mmol) in anh
DMF (8 mL) was added potassium tert-butoxide (0.67 g, 6.0 mmol, 1.0
equiv.) in one portion causing an exotherm. When this mixture had
cooled to room temperature, a solution of
4-chloro-2-(N-(2-triisopropylsilyloxy)ethyl)py- ridinecarboxamide
(2.32 g, 6 mmol, 1 equiv.) in DMF (4 mL) was added followed by
K.sub.2CO.sub.3 (0.42 g, 3.0 mmol, 0.50 equiv.). The resulting
mixture was heated at 80.degree. C. overnight. An additional
portion of potassium tert-butoxide (0.34 g, 3 mmol, 0.5 equiv.) was
then added and the mixture was stirred at 80.degree. C. an
additional 4 h. The mixture was cooled to 0.degree. C. with an
ice/water bath, then water (approx. 1 mL) was slowly added
dropwise. The organic layer was extracted with EtOAc (3.times.10
mL). The combined organic layers were washed with a saturated NaCl
solution (20 mL), dried (MgSO.sub.4) and concentrated under reduced
pressure. The brown oily residue was purified by column
chromatography (SiO.sub.2; 30% EtOAc/ 70% pet ether) to afford
4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline
as a clear light brown oil (0.99 g, 38%).
[0164] A18. Synthesis of 2-Pryidinecarboxylate Esters via Oxidation
of 2-Methylpyridines. Synthesis of
4-(5-(2-methoxycarbonyl)pyridyloxy)anilin- e. 52
[0165] Step 1. 4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene.
[0166] A mixture of 5-hydroxy-2-methylpyridine (10.0 g, 91.6 mmol),
1-fluoro-4-nitrobenzene (9.8 mL, 91.6 mmol, 1.0 equiv.),
K.sub.2CO.sub.3 (25 g, 183 mmol, 2.0 equiv.) in DMF (100 mL) was
heated at the reflux temperature overnight. The resulting mixture
was cooled to room temperature, treated with water (200 mL), and
extracted with EtOAc (3.times.100 mL). The combined organic layers
were sequentially washed with water (2.times.100 mL) and a
saturated NaCl solution ((100 mL), dried (MgSO.sub.4) and
concentrated under reduced pressure to give
4-(5-(2-methyl)pyridyloxy)-1-nitrobenzene as a brown solid (12.3
g). 53
[0167] Step 2. Synthesis of
4-(5-(2-Methoxycarbonyl)pyridyloxy)-1-nitroben- zene.
[0168] A mixture of 4-(5-(2-methyl)pyridyloxy)-1-nitrobenzene (1.70
g, 7.39 mmol) and selenium dioxide (2.50 g, 22.2 mmol, 3.0 equiv.)
in pyridine (20 mL) was heated at the reflux temperature for 5 h,
then cooled to room temperature. The resulting slurry was filtered
, then concentrated under reduced pressure. The residue was
dissolved in MeOH (100 mL). The solution was treated with a conc
HCl solution (7 mL), then heated at the reflux temperature for 3 h,
cooled to room temperature and concentrated under reduced pressure.
The residue was separated between EtOAc (50 mL) and a 1N NaOH
solution (50 mL). The aqueous layer was extracted with EtOAc
(2.times.50 mL). The combined organic layers were sequentially
washed with water (2.times.50 mL) and a saturated NaCl solution (50
mL), dried (MgSO.sub.4) and concentrated under reduced pressure.
The residue was purified by column chromatography (SiO.sub.2; 50%
EtOAc/50% hexane) to afford
4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nit- robenzene (0.70 g).
54
[0169] Step 3. Synthesis of
4-(5-(2-Methoxycarbonyl)pyridyloxy)aniline.
[0170] A slurry of
4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nitrobenzene (0.50 g) and 10%
Pd/C (0.050 g) in a mixture of EtOAc (20 mL) and MeOH (5 mL) was
placed under a H.sub.2 atmosphere (balloon) overnight. The
resulting mixture was filtered through a pad of Celite.RTM., and
the filtrate was concentrated under reduced pressure. The residue
was purified by column chromatography (SiO.sub.2; 70% EtOAc/30%
hexane) to give 4-(5-(2-methoxycarbonyl)pyridyloxy)aniline (0.40
g).
[0171] A19. Synthesis of .omega.-Sulfonylphenyl Anilines. Synthesis
of 4-(4-Methylsulfonylphenyoxy)aniline. 55
[0172] Step 1. 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene:
[0173] To a solution of 4-(4-methylthiophenoxy)-1-nitrobenzene (2.0
g, 7.7 mmol) in CH.sub.2Cl.sub.2 (75 mL) at 0.degree. C. was slowly
added m-CPBA (57-86%, 4.0 g), and the reaction mixture was stirred
at room temperature for 5 h. The reaction mixture was treated with
a 1N NaOH solution (25 mL). The organic layer was sequentially
washed with a 1N NaOH solution (25 mL), water (25 mL) and a
saturated NaCl solution (25 mL), dried (MgSO.sub.4), and
concentrated under reduced pressure to give
4-(4-methylsulfonylphenoxy)-1-nitrobenzene as a solid (2.1 g).
[0174] Step 2. 4-(4-Methylsulfonylphenoxy)-1-aniline:
[0175] 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene was reduced to
the aniline in a manner analogous to that described in Method A18,
step 3.
[0176] B. Synthesis of Urea Precursors
[0177] B1. General Method for the Synthesis of Isocyanates from
Anilines Using CDI. Synthesis of 4-Bromo-3-(trifluoromethyl)phenyl
Isocyanate. 56
[0178] Step 1. Synthesis of 4-bromo-3-(trifluoromethyl)aniline HCl
salt
[0179] To a solution of 4-bromo-3-(trifluoromethyl)aniline (64 g,
267 mmol) in Et.sub.2O (500 mL) was added an HCl solution (1 M in
Et.sub.2O; 300 mL) dropwise and the resulting mixture was stirred
at room temp. for 16 h. The resulting pink-white precipitate was
removed by filtration and washed with Et.sub.2O (50 mL) and to
afford 4-bromo-3-(trifluoromethyl)an- iline HCl salt (73 g, 98%).
57
[0180] Step 2. Synthesis of 4-bromo-3-(trifluoromethyl)phenyl
isocyanate
[0181] A suspension of 4-bromo-3-(trifluoromethyl)aniline HCl salt
(36.8 g, 133 mmol) in toluene (278 mL) was treated with
trichloromethyl chloroformate dropwise and the resulting mixture
was heated at the reflux temp. for 18 h. The resulting mixture was
concentrated under reduced pressure. The residue was treated with
toluene (500 mL), then concentrated under reduced pressure. The
residue was treated with CH.sub.2Cl.sub.2 (500 mL), then
concentrated under reduced pressure. The CH.sub.2Cl.sub.2
treatment/concentration protocol was repeated and resulting amber
oil was stored at -20.degree. C. for 16 h, to afford
4-bromo-3-(trifluoromethyl)phenyl isocyanate as a tan solid (35.1
g, 86%): GC-MS m/z 265 (M.sup.+).
[0182] C. Methods of Urea Formation
[0183] C1a. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)p-
henyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
58
[0184] A solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate
(14.60 g, 65.90 mmol) in CH.sub.2Cl.sub.2 (35 mL) was added
dropwise to a suspension of
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (Method A2, Step 4;
16.0 g, 65.77 mmol) in CH.sub.2Cl.sub.2 (35 mL) at 0.degree. C. The
resulting mixture was stirred at room temp. for 22 h. The resulting
yellow solids were removed by filtration, then washed with
CH.sub.2Cl.sub.2 (2.times.30 mL) and dried under reduced pressure
(approximately 1 mmHg) to afford
N-(4-chloro-3-(trifluoromethyl)phenyl)-N-
'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as an
off-white solid (28.5 g, 93%): mp 207-209.degree. C.; .sup.1H-NMR
(DMSO-d.sub.6) .delta.2.77 (d, J=4.8 Hz, 3H), 7.16 (m, 3H), 7.37
(d, J=2.5 Hz, 1H), 7.62 (m, 4H), 8.11 (d, J=2.5 Hz, 1H), 8.49 (d,
J=5.5 Hz, 1H), 8.77 (br d, 1H), 8.99 (s, 1H), 9.21 (s, 1H); HPLC
ES-MS m/z 465 ((M+H).sup.+).
[0185] C1b. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Bromo-3-(trifluoromethyl)ph-
enyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea 59
[0186] A solution of 4-bromo-3-(trifluoromethyl)phenyl isocyanate
(Method B1, Step 2; 8.0 g, 30.1 mmol) in CH.sub.2Cl.sub.2 (80 mL)
was added dropwise to a solution of
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (Method A2, Step 4;
7.0 g, 28.8 mmol) in CH.sub.2Cl.sub.2 (40 mL) at 0.degree. C. The
resulting mixture was stirred at room temp. for 16 h. The resulting
yellow solids were removed by filtration, then washed with
CH.sub.2Cl.sub.2 (2.times.50 mL) and dried under reduced pressure
(approximately 1 mmHg) at 40.degree. C. to afford
N-(4-bromo-3-(trifluoro-
methyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)
urea as a pale-yellow solid (13.2 g, 90%): mp 203-205.degree. C.;
.sup.1H-NMR (DMSO-d.sub.6) .delta.2.77 (d, J=4.8 Hz, 3H), 7.16 (m,
3H), 7.37 (d, J=2.5 Hz, 1H), 7.58 (m, 3H), 7.77 (d, J=8.8 Hz, 1H),
8.11 (d, J=2.5 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.77 (br d, 1H),
8.99 (s, 1H), 9.21 (s, 1H); HPLC ES-MS m/z 509 ((M+H).sup.+).
[0187] C1c. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)p-
henyl)-N'-(2-methyl-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl)
Urea 60
[0188] A solution of
2-methyl-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))anili- ne (Method
A5; 0.11 g, 0.45 mmol) in CH.sub.2Cl.sub.2 (1 mL) was treated with
Et.sub.3N (0.16 mL) and 4-chloro-3-(trifluoromethyl)phenyl
isocyanate (0.10 g, 0.45 mmol). The resulting brown solution was
stirred at room temp. for 6 d, then was treated with water (5 mL).
The aqueous layer was back-extracted with EtOAc (3.times.5 mL). The
combined organic layers were dried (MgSO.sub.4) and concentrated
under reduced pressure to yield
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(2-methyl-4-(2-(N-methylc-
arbamoyl)(4-pyridyloxy))phenyl) urea as a brown oil (0.11 g, 0.22
mmol): .sup.1H NMR (DMSO-d.sub.6) .delta.2.27 (s, 3H), 2.77 (d,
J=4.8 Hz, 3H), 7.03 (dd, J=8.5, 2.6 Hz, 1H), 7.11 (d, J=2.9 Hz,
1H), 7.15 (dd, J=5.5, 2.6, Hz, 1H), 7.38 (d, J=2.6 Hz, 1H), 7.62
(app d, J=2.6 Hz, 2H), 7.84 (d, J=8.8 Hz, 1H), 8.12 (s, 1H), 8.17
(s, 1H); 8.50 (d, J=5.5 Hz, 1H), 8.78 (q, J=5.2, 1H), 9.52 (s, 1H);
HPLC ES-MS m/z 479 ((M+H).sup.+).
[0189] C1d. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)p- henyl)-N'-(4-aminophenyl) Urea
61
[0190] To a solution of 4-chloro-3-(trifluoromethyl)phenyl
isocyanate (2.27 g, 10.3 mmol) in CH.sub.2Cl.sub.2 (308 mL) was
added p-phenylenediamine (3.32 g, 30.7 mmol) in one part. The
resulting mixture was stirred at room temp. for 1 h, treated with
CH.sub.2Cl.sub.2 (100 mL), and concentrated under reduced pressure.
The resulting pink solids were dissolved in a mixture of EtOAc (110
mL) and MeOH (15 mL), and the clear solution was washed with a 0.05
N HCl solution. The organic layer was concentrated under reduced
pressure to afford impure
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-aminophenyl) urea (3.3
g): TLC (100% EtOAc) R.sub.f 0.72.
[0191] C1e. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)p-
henyl)-N'-(4-ethoxycarbonylphenyl) Urea 62
[0192] To a solution of ethyl 4-isocyanatobenzoate (3.14 g, 16.4
mmol) in CH.sub.2Cl.sub.2 (30 mL) was added
4-chloro-3-(trifluoromethyl)aniline (3.21 g, 16.4 mmol), and the
solution was stirred at room temp. overnight. The resulting slurry
was diluted with CH.sub.2Cl.sub.2 (50 mL) and filtered to afford
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-ethox-
ycarbonylphenyl) urea as a white solid (5.93 g, 97%): TLC (40%
EtOAc/60% hexane) R.sub.f 0.44.
[0193] C1f. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)p- henyl)-N'-(3-carboxyphenyl) Urea
63
[0194] To a solution of 4-chloro-3-(trifluoromethyl)phenyl
isocyanate (1.21 g, 5.46 mmol) in CH.sub.2Cl.sub.2 (8 mL) was added
4-(3-carboxyphenoxy)aniline (Method A11; 0.81 g, 5.76 mmol) and the
resulting mixture was stirred at room temp. overnight, then treated
with MeOH (8 mL), and stirred an additional 2 h. The resulting
mixture was concentrated under reduced pressure. The resulting
brown solids were triturated with a 1:1 EtOAc/hexane solution to
give N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(3-carboxyphenyl)
urea as an off-white solid (1.21 g, 76%).
[0195] C2a. General Method for Urea Synthesis by Reaction of an
Aniline with N,N'-Carbonyl Diimidazole Followed by Addition of a
Second Aniline. Synthesis of
N-(2-Methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylca-
rbamoyl)-4-pyridyloxy)phenyl) Urea 64
[0196] To a solution of 2-methoxy-5-(trifluoromethyl)aniline (0.15
g) in anh CH.sub.2Cl.sub.2 (15 mL) at 0.degree. C. was added CDI
(0.13 g). The resulting solution was allowed to warm to room temp.
over 1 h, was stirred at room temp. for 16 h, then was treated with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.18 g). The
resulting yellow solution was stirred at room temp. for 72 h, then
was treated with H.sub.2O (125 mL). The resulting aqueous mixture
was extracted with EtOAc (2.times.150 mL). The combined organics
were washed with a saturated NaCl solution (100 mL), dried
(MgSO.sub.4) and concentrated under reduced pressure. The residue
was triturated (90% EtOAc/10% hexane). The resulting white solids
were collected by filtration and washed with EtOAc. The filtrate
was concentrated under reduced pressure and the residual oil
purified by column chromatography (gradient from 33% EtOAc/67%
hexane to 50% EtOAc/50% hexane to 100% EtOAc) to give
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py-
ridyloxy)phenyl) urea as a light tan solid (0.098 g, 30%): TLC
(100% EtOAc) R.sub.f 0.62; .sup.1H NMR (DMSO-d.sub.6) .delta.2.76
(d, J=4.8 Hz, 3H), 3.96 (s, 3H), 7.1-7.6 and 8.4-8.6 (m, 11H), 8.75
(d, J=4.8 Hz, 1H), 9.55 (s, 1 H); FAB-MS m/z 461 ((M+H).sup.+).
[0197] C2b. General Method for Urea Synthesis by Reaction of an
Aniline with N,N'-Carbonyl Diimidazole Followed by Addition of a
Second Aniline. Symmetrical Urea's as Side Products of a
N,N'-Carbonyl Diimidazole Reaction Procedure. Synthesis of
Bis(4-(2-(N-methylcarbamoyl)-4-pyridylox- y)phenyl) Urea 65
[0198] To a stirring solution of 3-amino-2-methoxyquinoline (0.14
g) in anhydrous CH.sub.2Cl.sub.2 (15 mL) at 0 C. was added CDI
(0.13 g). The resulting solution was allowed to warm to room temp.
over 1 h then was stirred at room temp. for 16 h. The resulting
mixture was treated with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.18 g). The
resulting yellow solution stirred at room temp. for 72 h, then was
treated with water (125 mL). The resulting aqueous mixture was
extracted with EtOAc (2.times.150 mL). The combined organic phases
were washed with a saturated NaCl solution (100 ml), dried
(MgSO.sub.4) and concentrated under reduced pressure. The residue
was triturated (90% EtOAc/10% hexane). The resulting white solids
were collected by filtration and washed with EtOAc to give
bis(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)pheny- l) urea (0.081 g,
44%): TLC (100% EtOAc) R.sub.f 0.50; .sup.1H NMR (DMSO-d.sub.6)
.delta.2.76 (d, J=5.1 Hz, 6H), 7.1-7.6 (m, 12H), 8.48 (d, J=5.4 Hz,
1H), 8.75 (d, J=4.8 Hz, 2H), 8.86 (s, 2H); HPLC ES-MS m/z 513
((M+H).sup.+).
[0199] C2c. General Method for the Synthesis of Ureas by Reaction
of an Isocyanate with an Aniline. Synthesis of
N-(2-Methoxy-5-(trifluoromethyl)-
phenyl-N'-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) Urea 66
[0200] To a stirring solution of
2-methoxy-5-(trifluoromethyl)phenyl isocyanate (0.10 g, 0.47 mmol)
in CH.sub.2Cl.sub.2 (1.5 mL) was added
5-(4-aminophenoxy)isoindoline-1,3-dione (Method A3, Step 3; 0.12 g,
0.47 mmol) in one portion. The resulting mixture was stirred for 12
h, then was treated with CH.sub.2Cl.sub.2 (10 mL) and MeOH (5 mL).
The resulting mixture was sequentially washed with a 1N HCl
solution (15 mL) and a saturated NaCl solution (15 mL), dried
(MgSO.sub.4) and concentrated under reduced pressure to afford
N-(2-methoxy-5-(trifluoromethyl)phenyl-N-
'-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea as a white solid
(0.2 g, 96%): TLC (70% EtOAc/30% hexane) R.sub.f 0.50; .sup.1H NMR
(DMSO-d.sub.6) .delta.3.95 (s, 3H), 7.31-7.10 (m, 6H), 7.57 (d,
J=9.3Hz, 2H), 7.80 (d, J=8.7 Hz, 1H), 8.53 (br s, 2H), 9.57 (s,
1H), 11.27 (br s, 1H); HPLC ES-MS 472.0 ((M+H).sup.+, 100%).
[0201] C2d. General Method for Urea Synthesis by Reaction of an
Aniline with N,N'-Carbonyl Diimidazole Followed by Addition of a
Second Aniline. Synthesis of
N-(5-(tert-Butyl)-2-(2,5-dimethylpyrrolyl)phenyl)-N'-(4-(2-(-
N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea 67
[0202] To a stirring solution of CDI (0.21 g, 1.30 mmol) in
CH.sub.2Cl.sub.2 (2 mL) was added
5-(tert-butyl)-2-(2,5-dimethylpyrrolyl)- aniline (Method A4, Step
2; 0.30 g, 1.24 mmol) in one portion. The resulting mixture was
stirred at room temp. for 4 h, then
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.065 g, 0.267mmol)
was then added in one portion. The resulting mixture was heated at
36.degree. C. overnight, then cooled to room temp. and diluted with
EtOAc (5 mL). The resulting mixture was sequentially washed with
water (15 mL) and a 1N HCl solution (15 mL), dried (MgSO.sub.4),
and filtered through a pad of silica gel (50 g) to afford
N-(5-(tert-butyl)-2-(2,5-dimethylpyrrolyl)phe-
nyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as a
yellowish solid (0.033 g, 24%): TLC (40% EtOAc/60% hexane) R.sub.f
0.24; .sup.1H NMR (acetone-d.sub.6) .delta.1.37 (s, 9H), 1.89 (s,
6H), 2.89 (d, J=4.8Hz, 3H), 5.83 (s, 2H), 6.87-7.20 (m, 6H), 7.17
(dd, 1H), 7.51-7.58 (m, 3H), 8.43 (d, J=5.4Hz, 1H), 8.57 (d, J=2.1
Hz, 1H), 8.80 (br s, 1H); HPLC ES-MS 512 ((M+H).sup.+, 100%).
[0203] C3. Combinatorial Method for the Synthesis of Diphenyl Ureas
Using Triphosgene
[0204] One of the anilines to be coupled was dissolved in
dichloroethane (0.10 M). This solution was added to a 8 mL vial
(0.5 mL) containing dichloroethane (1 mL). To this was added a
bis(trichloromethyl) carbonate solution (0.12 M in dichloroethane,
0.2 mL, 0.4 equiv.), followed by diisopropylethylamine (0.35 M in
dichloroethane, 0.2 mL, 1.2 equiv.). The vial was capped and heat
at 80.degree. C. for 5 h, then allowed to cool to room temp for
approximately 10 h. The second aniline was added (0.10 M in
dichloroethane, 0.5 mL, 1.0 equiv.), followed by
diisopropylethylamine (0.35 M in dichloroethane, 0.2 mL, 1.2
equiv.). The resulting mixture was heated at 80.degree. C. for 4 h,
cooled to room temperature and treated with MeOH (0.5 mL). The
resulting mixture was concentrated under reduced pressure and the
products were purified by reverse phase HPLC.
[0205] C4. General Method for Urea Synthesis by Reaction of an
Aniline with Phosgene Followed by Addition of a Second Aniline.
Synthesis of
N-(2-Methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py-
ridyloxy)phenyl) Urea 68
[0206] To a stirring solution of phosgene (1.9 M in toluene; 2.07
mL 0.21 g, 1.30 mmol) in CH.sub.2Cl.sub.2 (20 mL) at 0.degree. C.
was added anh pyridine (0.32 mL) followed by
2-methoxy-5-(trifluoromethyl)aniline (0.75 g). The yellow solution
was allowed to warm to room temp during which a precipitate formed.
The yellow mixture was stirred for 1 h, then concentrated under
reduced pressure. The resulting solids were treated with anh
toluene (20 mL) followed by 4-(2-(N-methylcarbamoyl)-4-pyridylox-
y)aniline (prepared as described in Method A2; 0.30 g) and the
resulting suspension was heated at 80.degree. C. for 20 h, then
allowed to cool to room temp. The resulting mixture was diluted
with water (100 mL), then was made basic with a saturated
NaHCO.sub.3 solution (2-3 mL). The basic solution was extracted
with EtOAc (2.times.250 mL). The organic layers were separately
washed with a saturated NaCl solution, combined, dried
(MgSO.sub.4), and concentrated under reduced pressure. The
resulting pink-brown residue was dissolved in MeOH and absorbed
onto SiO.sub.2 (100 g). Column chromatography (300 g SiO.sub.2;
gradient from 1% Et.sub.3N/33% EtOAc/66% hexane to 1% Et.sub.3N/99%
EtOAc to 1% Et.sub.3N/20% MeOH/79% EtOAc) followed by concentration
under reduced pressure at 45.degree. C. gave a warm concentrated
EtOAc solution, which was treated with hexane (10 mL) to slowly
form crystals of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-py-
ridyloxy)phenyl) urea (0.44 g): TLC (1% Et.sub.3N/99% EtOAc)
R.sub.f 0.40.
[0207] D. Interconversion of Ureas
[0208] D1a. Conversion of .omega.-Aminophenyl Ureas into
.omega.-(Aroylamino)phenyl Ureas. Synthesis of
N-(4-Chloro-3-((trifluorom-
ethyl)phenyl)-N'-(4-(3-methoxycarbonylphenyl)carboxyaminophenyl)
Urea 69
[0209] To a solution of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-amin- ophenyl) urea
(Method C1d; 0.050 g, 1.52 mmol), mono-methyl isophthalate (0.25 g,
1.38 mmol), HOBT.H.sub.2O (0.41 g, 3.03 mmol) and
N-methylmorpholine (0.33 mL, 3.03 mmol) in DMF (8 mL) was added
EDCI.HCl (0.29 g, 1.52 mmol). The resulting mixture was stirred at
room temp. overnight, diluted with EtOAc (25 mL) and sequentially
washed with water (25 mL) and a saturated NaHCO.sub.3 solution (25
mL). The organic layer was dried (Na.sub.2SO.sub.4) and
concentrated under reduced pressure. The resulting solids were
triturated with an EtOAc solution (80% EtOAc/20% hexane) to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(3-methoxyc-
arbonylphenyl)carboxyaminophenyl) urea (0.27 g, 43%): mp 121-122;
TLC (80% EtOAc/20% hexane) R.sub.f 0.75.
[0210] D1b. Conversion of .omega.-Carboxyphenyl Ureas into
.omega.-(Arylcarbamoyl)phenyl Ureas. Synthesis of
N-(4-Chloro-3-((trifluo-
romethyl)phenyl)-N'-(4-(3-methylcarbamoylphenyl)carbamoylphenyl)
Urea 70
[0211] To a solution of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(3-m-
ethylcarbamoylphenyl) carboxyaminophenyl) urea (0.14 g, 0.48 mmol),
3-methylcarbamoylaniline (0.080 g, 0.53 mmol), HOBT.H.sub.2O (0.14
g, 1.07 mmol), and N-methylmorpholine (0.5 mL, 1.07 mmol) in DMF (3
mL) at 0.degree. C. was added EDCI-HCl (0.10 g, 0.53 mmol). The
resulting mixture was allowed to warm to room temp. and was stirred
overnight. The resulting mixture was treated with water (10 mL),
and extracted with EtOAc (25 mL). The organic phase was
concentrated under reduced pressure. The resulting yellow solids
were dissolved in EtOAc (3 mL) then filtered through a pad of
silica gel (17 g, gradient from 70% EtOAc/30% hexane to 10%
MeOH/90% EtOAc) to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-
-(3-methylcarbamoylphenyl)carbamoylphenyl) urea as a white solid
(0.097 g, 41%): mp 225-229; TLC (100% EtOAc) R.sub.f 0.23.
[0212] D1c. Combinatorial Approach to the Conversion of
.omega.-Carboxyphenyl Ureas into .omega.-(Arylcarbamoyl)phenyl
Ureas. Synthesis of
N-(4-Chloro-3-((trifluoromethyl)phenyl)-N'-(4-(N-(3-(N-(3-py-
ridyl)carbamoyl)phenyl)carbamoyl)phenyl) Urea 71
[0213] A mixture of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(3-carboxyp- henyl) urea
(Method C1f; 0.030 g, 0.067 mmol) and N-cyclohexyl-N'-(methylp-
olystyrene)carbodiimide (55 mg) in 1,2-dichloroethane (1 mL) was
treated with a solution of 3-aminopyridine in CH.sub.2Cl.sub.2 (1
M; 0.074 mL, 0.074 mmol). (In cases of insolubility or turbidity, a
small amount of DMSO was also added.) The resulting mixture was
heated at 36.degree. C. overnight. Turbid reactions were then
treated with THF (1 mL) and heating was continued for 18 h. The
resulting mixtures were treated with
poly(4-(isocyanatomethyl)styrene) (0.040 g) and the resulting
mixture was stirred at 36.degree. C. for 72 h, then cooled to room
temp. and filtered. The resulting solution was filtered through a
plug of silica gel (1 g). Concentration under reduced pressure
afforded
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(N-(3-(N-(3-pyridyl)carbamo-
yl)phenyl)carbamoyl)phenyl) urea (0.024 g, 59%): TLC (70% EtOAc/30%
hexane) R.sub.f 0.12.
[0214] D2. Conversion of .omega.-Carboalkoxyaryl Ureas into
.omega.-Carbamoylaryl Ureas. Synthesis of
N-(4-Chloro-3-((trifluoromethyl-
)phenyl)-N'-(4-(3-methylcarbamoylphenyl)carboxyaminophenyl) Urea
72
[0215] To a sample of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(3-car-
bomethoxyphenyl) carboxyaminophenyl) urea (0.17 g, 0.34 mmol) was
added methylamine (2 M in THF; 1 mL, 1.7 mmol) and the resulting
mixture was stirred at room temp. overnight, then concentrated
under reduced pressure to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(3-methylcarbamoylp-
henyl)carboxyaminophenyl) urea as a white solid: mp 247; TLC (100%
EtOAc) R.sub.f 0.35.
[0216] D3. Conversion of (.omega.-Carboalkoxyaryl Ureas into
.omega.-Carboxyaryl Ureas. Synthesis of
N-(4-Chloro-3-((trifluoromethyl)p- henyl)-N'-(4-carboxyphenyl) Urea
73
[0217] To a slurry of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-ethoxy-
carbonylphenyl) urea (Method C1e; 5.93 g, 15.3 mmol) in MeOH (75
mL) was added an aqueous KOH solution (2.5 N, 10 mL, 23 mmol). The
resulting mixture was heated at the reflux temp. for 12 h, cooled
to room temp., and concentrated under reduced pressure. The residue
was diluted with water (50 mL), then treated with a 1 N HCl
solution to adjust the pH to 2 to 3. The resulting solids were
collected and dried under reduced pressure to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-carboxyphe- nyl) urea
as a white solid (5.05 g, 92%).
[0218] D4. General Method for the Conversion of .omega.-Alkoxy
Esters into .omega.-Alkyl Amides. Synthesis of
N-(4-Chloro-3-((trifluoromethyl)phenyl-
)-N'-((4-(3-(5-(2-dimethylaminoethyl)carbamoyl)pyridyl)oxyphenyl)
Urea 74
[0219] Step 1. Synthesis of
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-((4--
(3-(5-carboxypyridyl) oxyphenyl) Urea
[0220]
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-((4-(3-(5-methoxycarbonyl-
pyridyl)oxyphenyl) urea was synthesized from
4-chloro-3-(trifluoromethyl)p- henyl isocyanate and
4-(3-(5-methoxycarbonylpyridyl) oxyaniline (Method A14, Step 2) in
a manner analogous to Method C1a. A suspension of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-((4-(3-(5-methoxycarbonylpyridy-
l)oxyphenyl) urea (0.26 g, 0.56 mmol) in MeOH (10 mL) was treated
with a solution of KOH (0.14 g, 2.5 mmol) in water (1 mL) and was
stirred at room temp. for 1 h. The resulting mixture was adjusted
to pH 5 with a 1 N HCl solution. The resulting precipitate was
removed by filtration and washed with water. The resulting solids
were dissolved in EtOH (10 mL) and the resulting solution was
concentrated under reduced pressure. The EtOH/concentration
procedure was repeated twice to give
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-((4-(3-(5-carboxypyridyl)
oxyphenyl) urea (0.18 g, 71%). 75
[0221] Step 2. Synthesis of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-((4--
(3-(5-(2-dimethylaminoethyl)carbamoyl)pyridyl)oxyphenyl) urea
[0222] A mixture of
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-((4-(3-(5-ca-
rboxypyridyl)oxyphenyl) urea (0.050 g, 0.011 mmol),
N,N-dimethylethylenediamine (0.22 mg, 0.17 mmol), HOBT (0.028 g,
0.17 mmol), N-methylmorpholine (0.035 g, 0.28 mmol), and EDCI.HCl
(0.032 g, 0.17 mmol) in DMF (2.5 mL) was stirred at room temp.
overnight. The resulting solution was separated between EtOAc (50
mL) and water (50 mL). The organic phase was washed with water (35
mL), dried (MgSO.sub.4) and concentrated under reduced pressure.
The residue was dissolved in a minimal amount of CH.sub.2Cl.sub.2
(approximately 2 mL). The resulting solution was treated with
Et.sub.2O dropwise to give
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-((4-(3-(5-(2-dimethylaminoethyl-
)carbamoyl)pyridyl)oxyphenyl) urea as a white precipitate (0.48 g,
84%: .sup.1H NMR (DMSO-d.sub.6) .delta.2.10 s, 6H), 3.26 (s, H),
7.03 (d, 2H), 7.52 (d, 2H), 7.60 (m, 3H), 8.05 (s, 1H), 8.43 (s,
1H), 8.58 (t, 1H), 8.69 (s, 1H), 8.90 (s, 1H), 9.14 (s, 1H); HPLC
ES-MS m/z 522 ((M+H).sup.+).
[0223] D5. General Method for the Deprotection of
N-(.omega.-Silyloxyalkyl- )amides. Synthesis of
N-(4-Chloro-3-((trifluoromethyl)phenyl)-N'-(4-(4-(2--
(N-(2-hydroxy)ethylcarbamoyl)pyridyloxyphenyl) Urea. 76
[0224] To a solution of
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(4-(-
2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyphenyl) urea
(prepared in a manner analogous to Method C1a; 0.25 g, 0.37 mmol)
in anh THF (2 mL) was tetrabutylammonium fluoride (1.0 M in THF; 2
mL). The mixture was stirred at room temperature for 5 min, then
was treated with water (10 mL). The aqueous mixture was extracted
with EtOAc (3.times.10 mL). The combined organic layers were dried
(MgSO.sub.4) and concentrated under reduced pressure. The residue
was purified by column chromatography (SiO.sub.2; gradient from
100% hexane to 40% EtOAc/60% hexane) to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(4-(2-(N-(2-hydroxy)ethylca-
rbamoyl)pyridyloxyphenyl) urea as a white solid (0.019 g, 10%).
[0225] Listed below are compounds listed in the Tables below which
have been synthesized according to the Detailed Experimental
Procedures given above:
Syntheses of Exemplified Compounds
(See Tables for Compound Characterization)
[0226] Entry 1: 4-(3-N-Methylcarbamoylphenoxy)aniline was prepared
according to Method A13. According to Method C3,
3-tert-butylaniline was reacted with bis(trichloromethyl)carbonate
followed by 4-(3-N-Methylcarbamoylphenoxy)aniline to afford the
urea.
[0227] Entry 2: 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone
were reacted according to Method A13, Step 1 to afford the
4-(4-acetylphenoxy)-1-nitrobenzene.
4-(4-Acetylphenoxy)-1-nitrobenzene was reduced according to Method
A13, Step 4 to afford 4-(4-acetylphenoxy)aniline. According to
Method C3, 3-tert-butylaniline was reacted with
bis(trichloromethyl) carbonate followed by
4-(4-acetylphenoxy)aniline to afford the urea.
[0228] Entry 3: According to Method C2d, 3-tert-butylaniline was
treated with CDI, followed by
4-(3-N-methylcarbamoyl)-4-methoxyphenoxy)aniline, which had been
prepared according to Method A8, to afford the urea.
[0229] Entry 4: 5-tert-Butyl-2-methoxyaniline was converted to
5-tert-butyl-2-methoxyphenyl isocyanate according to Method B1.
4-(3-N-Methylcarbamoylphenoxy)aniline, prepared according to Method
A13, was reacted with the isocyanate according to Method C1a to
afford the urea.
[0230] Entry 5: According to Method C2d,
5-tert-butyl-2-methoxyaniline was reacted with CDI followed by
4-(3-N-methylcarbamoyl)-4-methoxyphenoxy)ani- line, which had been
prepared according to Method A8, to afford the urea.
[0231] Entry 6: 5-(4-Aminophenoxy)isoindoline-1,3-dione was
prepared according to Method A3. According to Method 2d,
5-tert-butyl-2-methoxyani- line was reacted with CDI followed by
5-(4-aminophenoxy)isoindoline-1,3-di- one to afford the urea.
[0232] Entry 7: 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized
according to Method A12. According to Method 2d,
5-tert-butyl-2-methoxyan- iline was reacted with CDI followed by
4-(1-oxoisoindolin-5-yloxy)aniline to afford the urea.
[0233] Entry 8: 4-(3-N-Methylcarbamoylphenoxy)aniline was
synthesized according to Method A13. According to Method C2a,
2-methoxy-5-(trifluorom- ethyl)aniline was reacted with CDI
followed by 4-(3-N-methylcarbamoylpheno- xy)aniline to afford the
urea.
[0234] Entry 9: 4-Hydroxyacetophenone was reacted with
2-chloro-5-nitropyridine to give
4-(4-acetylphenoxy)-5-nitropyridine according to Method A3, Step 2.
According to Method A8, Step 4, 4-(4-acetylphenoxy)-5-nitropyridine
was reduced to 4-(4-acetylphenoxy)-5-aminopyridine.
2-Methoxy-5-(trifluoromethyl)aniline was converted to
2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method
B1. The isocyanate was reacted with 4-(4-acetylphenoxy)-5-amino-
pyridine according to Method C1a to afford the urea.
[0235] Entry 10: 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone
were reacted according to Method A13, Step 1 to afford the
4-(4-acetylphenoxy)-1-nitrobenzene.
4-(4-Acetylphenoxy)-1-nitrobenzene was reduced according to Method
A13, Step 4 to afford 4-(4-acetylphenoxy)aniline. According to
Method C3, 5-(trifluoromethyl)-2-methoxybutylaniline was reacted
with bis(trichloromethyl) carbonate followed by
4-(4-acetylphenoxy)aniline to afford the urea.
[0236] Entry 11: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was
synthesized according to Method A2, Step 3a, was reacted with
3-aminophenol according to Method A2, Step 4 using DMAC in place of
DMF to give 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
According to Method C4, 2-methoxy-5-(trifluoromethyl)aniline was
reacted with phosgene followed by
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0237] Entry 12: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with ammonia according to Method A2, Step 3b to form
4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was
reacted with 3-aminophenol according to Method A2, Step 4 using
DMAC in place of DMF to give 3-(2-carbamoyl-4-pyridyloxy)aniline.
According to Method C2a, 2-methoxy-5-(trifluoromethyl)aniline was
reacted with phosgene followed by
3-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
[0238] Entry 13: 4-Chloro-N-methyl-2-pyridinecarboxamide was
synthesized according to Method A2, Step 3b.
4-Chloro-N-methyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 using DMAC in place of
DMF to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
According to Method C2a, 2-methoxy-5-(trifluoromethyl)aniline was
reacted with CDI followed by
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0239] Entry 14: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with ammonia according to Method A2, Step 3b to form
4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was
reacted with 4-aminophenol according to Method A2, Step 4 using
DMAC in place of DMF to give 4-(2-carbamoyl-4-pyridyloxy)aniline.
According to Method C4, 2-methoxy-5-(trifluoromethyl)aniline was
reacted with phosgene followed by
4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
[0240] Entry 15: According to Method C2d,
5-(triflouromethyl)-2-methoxyani- line was reacted with CDI
followed by 4-(3-N-methylcarbamoyl)-4-methoxyphe- noxy)aniline,
which had been prepared according to Method A8, to afford the
urea.
[0241] Entry 16:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was
synthesized according to Method A5.
5-(Trifluoromethyl)-2-methoxyanil- ine was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. The isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-methylaniline according to
Method C1c to afford the urea.
[0242] Entry 17:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was
synthesized according to Method A6.
5-(Trifluoromethyl)-2-methoxyanil- ine was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline according to
Method C1a to afford the urea.
[0243] Entry 18: According to Method A2, Step 4,
5-amino-2-methylphenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline according to
Method C1a to afford the urea.
[0244] Entry 19: 4-Chloropyridine-2-carbonyl chloride was reacted
with ethylamine according to Method A2, Step 3b. The resulting
4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-ethylcarbamoyl)-4-pyridylo- xy)aniline.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B 1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted
with 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline according to
Method C1a to afford the urea.
[0245] Entry 20: According to Method A2, Step 4,
4-amino-2-chlorophenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline according to
Method C1a to afford the urea.
[0246] Entry 21: 4-(4-Methylthiophenoxy)-1-nitrobenzene was
oxidized according to Method A19, Step 1 to give
4-(4-methylsulfonylphenoxy)-1-nit- robenzene. The nitrobenzene was
reduced according to Method A19, Step 2 to give
4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1a,
5-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(4-methylsulfonylphenoxy)-1-aniline to afford the urea.
[0247] Entry 22: 4-(3-carbamoylphenoxy)-1-nitrobenzene was reduced
to 4-(3-carbamoylphenoxy)aniline according to Method A15, Step 4.
According to Method C1a, 5-(trifluoromethyl)-2-methoxyphenyl
isocyanate was reacted with 4-(3-carbamoylphenoxy)aniline to afford
the urea.
[0248] Entry 23: 5-(4-Aminophenoxy)isoindoline-1,3-dione was
synthesized according to Method A3.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
5-(4-aminophenoxy)isoindoline-1,3-dione according to Method C1a to
afford the urea.
[0249] Entry 24: 4-Chloropyridine-2-carbonyl chloride was reacted
with dimethylamine according to Method A2, Step 3b. The resulting
4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline according to
Method C1a to afford the urea.
[0250] Entry 25: 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized
according to Method A12. 5-(Trifluoromethyl)-2-methoxyaniline was
treated with CDI, followed by 4-(1-oxoisoindolin-5-yloxy)aniline
according to Method C2d to afford the urea.
[0251] Entry 26: 4-Hydroxyacetophenone was reacted with
4-fluoronitrobenzene according to Method A13, Step 1 to give
4-(4-acetylphenoxy)nitrobenzene. The nitrobenzene was reduced
according to Method A13, Step 4 to afford
4-(4-acetylphenoxy)aniline, which was converted to the
4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt according to
Method A16. 5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B 1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted
with 4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt to
Method C1a to afford the urea.
[0252] Entry 27: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 4-aminothiophenol according to Method A2, Step 4
to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
5-(Trifluoromethyl)-2-meth- oxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline according to Method
C1a to afford the urea.
[0253] Entry 28: 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione
was synthesized according to Method A9.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione according to
Method C1a to afford the urea.
[0254] Entry 29: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 3-aminothiophenol according to Method A2, Step 4
to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
5-(Trifluoromethyl)-2-meth- oxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline according to Method
C1a to afford the urea.
[0255] Entry 30: 4-Chloropyridine-2-carbonyl chloride was reacted
with isopropylamine according to Method A2, Step 3b. The resulting
4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-isopropylcarbamoyl)-4-pyri- dyloxy)aniline.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline according to
Method C1a to afford the urea.
[0256] Entry 31: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a
to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N'-
-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified
according to Method D4, Step 1, and the corresponding acid was
coupled with 4-(2-aminoethyl)morpholine to afford the amide
according to Method D4, Step 2.
[0257] Entry 32: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a
to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N'-
-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified
according to Method D4, Step 1, and the corresponding acid was
coupled with methylamine according to Method D4, Step 2 to afford
the amide.
[0258] Entry 33: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
5-(Trifluoromethyl)-2-methoxyaniline was converted into
5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method
B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a
to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N'-
-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified
according to Method D4, Step 1, and the corresponding acid was
coupled with N,N-dimethylethylenediamine according to Method D4,
Step 2 to afford the amide.
[0259] Entry 34: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with 3-aminopyridine according to Method D1c.
[0260] Entry 35: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with N-(4-fluorophenyl)piperazine according to
Method D1c.
[0261] Entry 36: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with 4-fluoroaniline according to Method D1c.
[0262] Entry 37: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with 4-(dimethylamino)aniline according to Method
D1c.
[0263] Entry 38: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with 5-amino-2-methoxypyridine according to
Method D1c.
[0264] Entry 39: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with 4-morpholinoaniline according to Method
D1c.
[0265] Entry 40: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was
converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate
according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted
with 5-(trifluoromethyl)-2-methox- yphenyl isocyanate according to
Method C1f to afford
N-(5-(trifluoromethyl)-2-methoxyphenyl)-N'-(3-carboxyphenyl) urea,
which was coupled with N-(2-pyridyl)piperazine according to Method
D1c.
[0266] Entry 41: 4-(3-(N-Methylcarbamoyl)phenoxy)aniline was
synthesized according to Method A13. According to Method C3,
4-chloro-3-(trifluoromet- hyl)aniline was converted to the
isocyanate, then reacted with
4-(3-(N-Methylcarbamoyl)phenoxy)aniline to afford the urea.
[0267] Entry 42: 4-(2-N-Methylcarbamyl-4-pyridyloxy)aniline was
synthesized according to Method A2.
4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(2-N-methylcarbamyl-4-pyridyloxy)aniline according to Method C1a
to afford the urea.
[0268] Entry 43: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with ammonia according to Method A2, Step 3b to form
4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was
reacted with 4-aminophenol according to Method A2, Step 4 to form
4-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
[0269] Entry 44: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with ammonia according to Method A2, Step 3b to form
4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was
reacted with 3-aminophenol according to Method A2, Step 4 to form
3-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
3-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
[0270] Entry 45: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was
synthesized according to Method A2, Step 3a, was reacted with
3-aminophenol according to Method A2, Step 4 to form
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. According to Method
C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0271] Entry 46: 5-(4-Aminophenoxy)isoindoline-1,3-dione was
synthesized according to Method A3. According to Method C1a,
4-chloro-3-(trifluoromet- hyl)phenyl isocyanate was reacted with
5-(4-aminophenoxy)isoindoline-1,3-d- ione to afford the urea.
[0272] Entry 47:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was
synthesized according to Method A5. According to Method C1c,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
5-(4-aminophenoxy)isoindoline-1,3-dione to afford the urea.
[0273] Entry 48: 4-(3-N-Methylsulfamoyl)phenyloxy)aniline was
synthesized according to Method A15. According to Method C1a,
4-chloro-3-(trifluorome- thyl)phenyl isocyanate was reacted with
4-(3-N-methylsulfamoyl)phenyloxy)a- niline to afford the urea.
[0274] Entry 49:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was
synthesized according to Method A6. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline to afford
the urea.
[0275] Entry 50: According to Method A2, Step 4,
5-amino-2-methylphenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. According
to Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was
reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline
to afford the urea.
[0276] Entry 51: 4-Chloropyridine-2-carbonyl chloride was reacted
with ethylamine according to Method A2, Step 3b. The resulting
4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-ethylcarbamoyl)-4-pyridylo- xy)aniline. According to Method
C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0277] Entry 52: According to Method A2, Step 4,
4-amino-2-chlorophenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. According
to Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was
reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline
to afford the urea.
[0278] Entry 53: 4-(4-Methylthiophenoxy)-1-nitrobenzene was
oxidized according to Method A19, Step 1 to give
4-(4-methylsulfonylphenoxy)-1-nit- robenzene. The nitrobenzene was
reduced according to Method A19, Step 2 to give
4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(4-methylsulfonylphenoxy)-1-aniline to afford the urea.
[0279] Entry 54: 4-Bromobenzenesulfonyl chloride was reacted with
methylamine according to Method A15, Step 1 to afford
N-methyl-4-bromobenzenesulfonamide.
N-Methyl-4-bromobenzenesulfonamide was coupled with phenol
according to Method A15, Step 2 to afford
4-(4-(N-methylsulfamoyl)phenoxy)benzene.
4-(4-(N-Methylsulfamoyl)phenoxy)- benzene was converted into
4-(4-(N-methylsulfamoyl)phenoxy)-1-nitrobenzene according to Method
A15, Step 3. 4-(4-(N-Methylsulfamoyl)phenoxy)-1-nitro- benzene was
reduced to 4-(4-N-methylsulfamoyl)phenyloxy)aniline according to
Method A15, Step 4. According to Method C1a,
4-chloro-3-(trifluorometh- yl)phenyl isocyanate was reacted with
4-(3-N-methylsulfamoyl)phenyloxy)ani- line to afford the urea.
[0280] Entry 55: 5-Hydroxy-2-methylpyridine was coupled with
1-fluoro-4-nitrobenzene according to Method A18, Step 1 to give
4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene. The methylpyridine was
oxidized according to the carboxylic acid, then esterified
according to Method A18, Step 2 to give
4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nitroben- zene. The
nitrobenzene was reduced according the Method A18, Step 3 to give
4-(5-(2-methoxycarbonyl)pyridyloxy)aniline. The aniline was reacted
with 4-chloro-3-(trifluoromethyl)phenyl isocyanate according to
Method C1a to afford the urea.
[0281] Entry 56: 5-Hydroxy-2-methylpyridine was coupled with
1-fluoro-4-nitrobenzene according to Method A18, Step 1 to give
4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene. The methylpyridine was
oxidized according to the carboxylic acid, then esterified
according to Method A18, Step 2 to give
4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nitroben- zene. The
nitrobenzene was reduced according the Method A18, Step 3 to give
4-(5-(2-methoxycarbonyl)pyridyloxy)aniline. The aniline was reacted
with 4-chloro-3-(trifluoromethyl)phenyl isocyanate according to
Method C1a to give
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(methoxycarbo-
nyl)-5-pyridyloxy)phenyl) urea. The methyl ester was reacted with
methylamine according to Method D2 to afford
N-(4-chloro-3-(trifluorometh-
yl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-5-pyridyloxy)phenyl)
urea.
[0282] Entry 57:
N-(4-Chloro-3-(trifluoromethyl)phenyl-N'-(4-aminophenyl) urea was
prepared according to Method C1d. N-(4-Chloro-3-(trifluoromethyl-
)phenyl-N'-(4-aminophenyl) urea was coupled with mono-methyl
isophthalate according to Method D1a to afford the urea.
[0283] Entry 58:
N-(4-Chloro-3-(trifluoromethyl)phenyl-N'-(4-aminophenyl) urea was
prepared according to Method C1d. N-(4-Chloro-3-(trifluoromethyl-
)phenyl-N'-(4-aminophenyl) urea was coupled with mono-methyl
isophthalate according to Method D1a to afford
N-(4-chloro-3-(trifluoromethyl)phenyl-N-
'-(4-(3-methoxycarbonylphenyl)carboxyaminophenyl) urea. According
to Method D2,
N-(4-chloro-3-(trifluoromethyl)phenyl-N'-(4-(3-methoxycarbonyl-
phenyl)carboxyaminophenyl) urea was reacted with methylamine to
afford the corresponding methyl amide.
[0284] Entry 59: 4-Chloropyridine-2-carbonyl chloride was reacted
with dimethylamine according to Method A2, Step 3b. The resulting
4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline. According to
Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was
reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to
afford the urea.
[0285] Entry 60: 4-Hydroxyacetophenone was reacted with
4-fluoronitrobenzene according to Method A13, Step 1 to give
4-(4-acetylphenoxy)nitrobenzene. The nitrobenzene was reduced
according to Method 13, Step 4 to afford
4-(4-acetylphenoxy)aniline, which was converted to the
4-(4-(1-(N-methoxy)iminoethyl) phenoxyaniline HCl salt according to
Method A16. According to Method C1a, 4-chloro-3-(trifluorome-
thyl)phenyl isocyanate was reacted with 4-(4-acetylphenoxy)aniline
to afford the urea.
[0286] Entry 61: 4-(3-Carboxyphenoxy)-1-nitrobenzene was
synthesized according to Method A13, Step 2.
4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with
4-(2-aminoethyl)morpholine according to Method A13, Step 3 to give
4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)-1-nitrobenzene.
According to Method A13 Step 4,
4-(3-(N-(2-morpholinylethyl)carbamoyl)phe- noxy)-1-nitrobenzene was
reduced to 4-(3-(N-(2-morpholinylethyl)carbamoyl)- phenoxy)aniline.
According to Method C1a, 4-chloro-3-(trifluoromethyl)phen- yl
isocyanate was reacted with
4-(3-(N-(2-morpholinylethyl)carbamoyl)pheno- xy)aniline to afford
the urea.
[0287] Entry 62: 4-(3-Carboxyphenoxy)-1-nitrobenzene was
synthesized according to Method A13, Step 2.
4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with
1-(2-aminoethyl)piperidine according to Method A13, Step 3 to give
4-(3-(N-(2-piperidylethyl)carbamoyl)phenoxy)-1-nitrobenzene.
According to Method A13 Step 4,
4-(3-(N-(2-piperidylethyl)carbamoyl)pheno- xy)-1-nitrobenzene was
reduced to 4-(3-(N-(2-piperidylethyl)carbamoyl)phen- oxy)aniline.
According to Method C1a, 4-chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(3-(N-(2-piperidylethyl)carbamoyl)phenoxy)a- niline to afford the
urea.
[0288] Entry 63: 4-(3-Carboxyphenoxy)-1-nitrobenzene was
synthesized according to Method A13, Step 2.
4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with
tetrahydrofurfurylamine according to Method A13, Step 3 to give
4-(3-(N-(tetrahydrofurylmethyl)carbamoyl)phenoxy)-1-nitrobenzene.
According to Method A13 Step 4,
4-(3-(N-(tetrahydrofurylmethyl)carbamoyl)- phenoxy)-1-nitrobenzene
was reduced to 4-(3-(N-(tetrahydrofurylmethyl)carb-
amoyl)phenoxy)aniline. According to Method C1a,
4-chloro-3-(trifluoromethy- l)phenyl isocyanate was reacted with
4-(3-(N-(tetrahydrofurylmethyl)carbam- oyl) phenoxy)aniline to
afford the urea.
[0289] Entry 64: 4-(3-Carboxyphenoxy)-1-nitrobenzene was
synthesized according to Method A13, Step 2.
4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with
2-aminomethyl-1-ethylpyrrolidine according to Method A13, Step 3 to
give 4-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)-1-
-nitrobenzene. According to Method A13 Step 4,
4-(3-(N-((1-methylpyrrolidi-
nyl)methyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to
4-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)aniline.
According to Method C1a, 4-chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)- aniline
to afford the urea.
[0290] Entry 65: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 4-aminothiophenol according to Method A2, Step 4
to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. According to
Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was
reacted with 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to
afford the urea.
[0291] Entry 66: 4-Chloropyridine-2-carbonyl chloride was reacted
with isopropylamine according to Method A2, Step 3b. The resulting
4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-isopropylcarbamoyl)-4-pyri- dyloxy)aniline. According to
Method C1a, 4-chloro-3-(trifluoromethyl)pheny- l isocyanate was
reacted with 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)ani- line to
afford the urea.
[0292] Entry 67:
N-(4-Chloro-3-(trifluoromethyl)phenyl-N'-(4-ethoxycarbony- lphenyl)
urea was synthesized according to Method C1e.
N-(4-Chloro-3-(trifluoromethyl)phenyl-N'-(4-ethoxycarbonylphenyl)
urea was saponified according to Method D3 to give
N-(4-chloro-3-(trifluoromet- hyl)phenyl-N'-(4-carboxyphenyl) urea.
N-(4-Chloro-3-(trifluoromethyl)pheny- l-N'-(4-carboxyphenyl) urea
was coupled with 3-methylcarbamoylaniline according to Method D1b
to give N-(4-chloro-3-(trifluoromethyl)phenyl-N'--
(4-(3-methylcarbamoylphenyl)carbamoylphenyl) urea.
[0293] Entry 68: 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione
was synthesized according to Method A9. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione to afford the
urea.
[0294] Entry 69: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 3-aminothiophenol according to Method A2, Step 4
to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. According to
Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was
reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to
afford the urea.
[0295] Entry 70:
4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)anili- ne was
synthesized according to Method A10. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline to
afford the urea.
[0296] Entry 71: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
4-Chloro-3-(trifluoromethyl)-2-metho- xyphenyl isocyanate was
reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)an- iline according
to Method C1a to afford the urea. N-(4-Chloro-3-(trifluoro-
methyl)phenyl)-N'-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea
was saponified according to Method D4, Step 1, and the
corresponding acid was coupled with 4-(2-aminoethyl)morpholine to
afford the amide.
[0297] Entry 72: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a
to afford the urea. N-(5-(Trifluoromethyl)-2-meth-
oxyphenyl)-N'-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was
saponified according to Method D4, Step 1, and the corresponding
acid was coupled with methylamine according to Method D4, Step 2 to
afford the amide.
[0298] Entry 73: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was
synthesized according to Method A14.
4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a
to afford the urea. N-(5-(Trifluoromethyl)-2-meth-
oxyphenyl)-N'-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was
saponified according to Method D4, Step 1, and the corresponding
acid was coupled with N,N-dimethylethylenediamine according to
Method D4, Step 2 to afford the amide.
[0299] Entry 74: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with 2-hydroxyethylamine according to Method A2, Step 3b to
form
4-chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide.
4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide was
reacted with triisopropylsilyl chloride, followed by 4-aminophenol
according to Method A17 to form
4-(4-(2-(N-(2-triisopropylsilyloxy)ethylc-
arbamoyl)pyridyloxyaniline. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)
pyridyloxyaniline to afford
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(4-(2-(N-(2-triisopr-
opylsilyloxy) ethylcarbamoyl)pyridyloxyphenyl) urea.
[0300] Entry 75: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1f
to afford the urea, which was coupled with 3-aminopyridine
according to Method D1c.
[0301] Entry 76: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy) aniline according
to Method C1f to afford the urea, which was coupled with
N-(4-acetylphenyl)piperazine according to Method D1c.
[0302] Entry 77: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
4-fluoroaniline according to Method D1c.
[0303] Entry 78: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
4-(dimethylamino)aniline according to Method D1c.
[0304] Entry 79: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
N-phenylethylenediamine according to Method D1c.
[0305] Entry 80: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
2-methoxyethylamine according to Method D1c.
[0306] Entry 81: 4-(3-Carboxyphenoxy) aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
5-amino-2-methoxypyridine according to Method D1c.
[0307] Entry 82: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11 14-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
4-morpholinoaniline according to Method D1c.
[0308] Entry 83: 4-(3-Carboxyphenoxy)aniline was synthesized
according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl
isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according
to Method C1f to afford the urea, which was coupled with
N-(2-pyridyl)piperazine according to Method D1c.
[0309] Entry 84: 4-Chloropyridine-2-carbonyl chloride HCl salt was
reacted with 2-hydroxyethylamine according to Method A2, Step 3b to
form
4-chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide.
4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide was
reacted with triisopropylsilyl chloride, followed by 4-aminophenol
according to Method A17 to form
4-(4-(2-(N-(2-triisopropylsilyloxy)ethylc-
arbamoyl)pyridyloxyaniline. According to Method C1a,
4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with
4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline
to give
N-(4-chloro-3-((trifluoromethyl)phenyl)-N'-(4-(4-(2-(N-(2-triisoprop-
ylsilyloxy)ethylcarbamoyl)pyridyloxyphenyl) urea. The urea was
deprotected according to Method D5 to afford
N-(4-chloro-3-((trifluoromethyl)phenyl)--
N'-(4-(4-(2-(N-(2-hydroxy)ethylcarbamoyl)pyridyloxyphenyl)
urea.
[0310] Entry 85: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was
synthesized according to Method A2.
4-Bromo-3-(trifluoromethyl)aniline was converted to
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0311] Entry 86:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was
synthesized according to Method A6.
4-Bromo-3-(trifluoromethyl)anilin- e was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluorometh- yl)phenyl
isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridylox-
y)-2-chloroaniline to afford the urea.
[0312] Entry 87: According to Method A2, Step 4,
4-amino-2-chlorophenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline.
4-Bromo-3-(trifluoromethyl)aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline to afford
the urea.
[0313] Entry 88: 4-Chloropyridine-2-carbonyl chloride was reacted
with ethylamine according to Method A2, Step 3b. The resulting
4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-ethylcarbamoyl)-4-pyridylo- xy)aniline.
4-Bromo-3-(trifluoromethyl)aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0314] Entry 89: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was
synthesized according to Method A2, Step 3a, was reacted with
3-aminophenol according to Method A2, Step 4 to form
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
4-Bromo-3-(trifluoromethy- l)aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluorometh- yl)phenyl
isocyanate was reacted with 3-(-2-(N-methylcarbamoyl)-4-pyridylo-
xy)aniline to afford the urea.
[0315] Entry 90: According to Method A2, Step 4,
5-amino-2-methylphenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline.
4-Bromo-3-(trifluoromethyl)aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl
isocyanate was reacted with
3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline to afford
the urea.
[0316] Entry 91: 4-Chloropyridine-2-carbonyl chloride was reacted
with dimethylamine according to Method A2, Step 3b. The resulting
4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
4-Bromo-3-(trifluoromethyl)aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl
isocyanate was reacted with
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0317] Entry 92: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 4-aminothiophenol according to Method A2, Step 4
to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
4-Bromo-3-(trifluoromethyl- )aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluorometh- yl)phenyl
isocyanate was reacted with 4-(4-(2-(N-methylcarbamoyl)phenylthi-
o)aniline to afford the urea.
[0318] Entry 93: 4-Chloro-N-methylpyridinecarboxamide was
synthesized as described in Method A2, Step 3b. The chloropyridine
was reacted with 3-aminothiophenol according to Method A2, Step 4
to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
4-Bromo-3-(trifluoromethyl- )aniline was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluorometh- yl)phenyl
isocyanate was reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthi-
o)aniline to afford the urea.
[0319] Entry 94:
4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)anili- ne was
synthesized according to Method A10.
4-Bromo-3-(trifluoromethyl)ani- line was converted into
4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method
B1. According to Method C1a, 4-bromo-3-(trifluorometh- yl)phenyl
isocyanate was reacted with 4-(2-(N-(2-Morpholin-4-ylethyl)carba-
moyl)pyridyloxy)aniline to afford the urea.
[0320] Entry 95: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was
synthesized according to Method A2.
4-Chloro-2-methoxy-5-(trifluoromethyl- )aniline was synthesized
according to Method A7. 4-Chloro-2-methoxy-5-(tri-
fluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromet- hyl)phenyl isocyanate according
to Method B1. According to Method C1a,
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted
with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the
urea.
[0321] Entry 96:
4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was
synthesized according to Method A6.
4-Chloro-2-methoxy-5-(trifluorome- thyl)aniline was synthesized
according to Method A7.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according
to Method B1. According to Method C1a,
4-chloro-2-methoxy-5-(trifluoromethyl- )phenyl isocyanate was
reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-
-2-chloroaniline afford the urea.
[0322] Entry 97: According to Method A2, Step 4,
4-amino-2-chlorophenol was reacted with
4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized
according to Method A2, Step 3b, to give
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized
according to Method A7.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according
to Method B1. According to Method C1a,
4-chloro-2-methoxy-5-(trifluoromethyl- )phenyl isocyanate was
reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-
-3-chloroaniline to afford the urea.
[0323] Entry 98: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was
synthesized according to Method A2, Step 3a, was reacted with
3-aminophenol according to Method A2, Step 4 to form
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
4-Chloro-2-methoxy-5-(tri- fluoromethyl)aniline was synthesized
according to Method A7.
4-Chloro-2-methoxy-5-trifluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according
to Method B1. According to Method C1a,
4-chloro-2-methoxy-5-(trifluoromethyl- )phenyl isocyanate as was
reacted with 3-(-2-(N-methylcarbamoyl)-4-pyridyl- oxy)aniline to
afford the urea.
[0324] Entry 99: 4-Chloropyridine-2-carbonyl chloride was reacted
with ethylamine according to Method A2, Step 3b. The resulting
4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N-ethylcarbamoyl)-4-pyridylo- xy)aniline.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized
according to Method A7.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according
to Method B1. According to Method C1a, 4-chloro-2-methoxy-5-(tr-
ifluoromethyl)phenyl isocyanate was reacted with
4-(2-(N-ethylcarbamoyl)-4- -pyridyloxy)aniline to afford the
urea.
[0325] Entry 100: 4-Chloropyridine-2-carbonyl chloride was reacted
with dimethylamine according to Method A2, Step 3b. The resulting
4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 to give
4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized
according to Method A7.
4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into
4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according
to Method B1. According to Method C1a,
4-chloro-2-methoxy-5-(trifluoromethyl- )phenyl isocyanate was
reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyl- oxy)aniline to
afford the urea.
[0326] Entry 101: 4-Chloro-N-methyl-2-pyridinecarboxamide, which
was synthesized according to Method A2, Step 3a, was reacted with
3-aminophenol according to Method A2, Step 4 to form
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
2-Amino-3-methoxynaphthal- ene was synthesized as described Method
A1. According to Method C3, 2-amino-3-methoxynaphthalene was
reacted with bis(trichloromethyl) carbonate followed by
3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to form the
urea.
[0327] Entry 102: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was
synthesized according to Method A2.
5-tert-Butyl-2-(2,5-dimethylpyrrolyl)- aniline was synthesized
according to Method A4. 5-tert-Butyl-2-(2,5-dimeth-
ylpyrrolyl)aniline was reacted with CDI followed by
4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline according to Method
C2d to afford the urea.
[0328] Entry 103: 4-Chloro-N-methyl-2-pyridinecarboxamide was
synthesized according to Method A2, Step 3b.
4-Chloro-N-methyl-2-pyridinecarboxamide was reacted with
4-aminophenol according to Method A2, Step 4 using DMAC in place of
DMF to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
According to Method C2b, reaction of 3-amino-2-methoxyquinoline
with CDI followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline
afforded bis(4-(2-(N-methylcarbamoyl)-4-pyridlyoxy)phenyl)urea.
[0329] Listed in the Tables below are compounds which have been
synthesized according to the Detailed Experimental Procedures given
above:
TABLES
[0330] The compounds listed in Tables 1-6 below were synthesized
according to the general methods shown above, and the more detailed
exemplary procedures are in the entry listings above and
characterizations are indicated in the tables.
2TABLE 1 3-tert-Butylphenyl Ureas 77 TLC Mass mp HPLC TLC Solvent
Spec. Synth. Entry R (.degree. C.) (min.) R.sub.f System [Source]
Method 1 78 0.22 50% EtOAc/ 50% hexane 418 (M + H) +(HPLC ES-MS)
A13 C3 2 79 0.58 50% EtOAc/ 50% hexane 403 (M + H) +(HPLC ES-MS)
A13 C3 3 80 133-135 0.68 100% EtOAc 448 (M + H) +(FAB)
[0331]
3TABLE 2 5-tert-Butyl-2-methoxyphenyl Ureas 81 TLC Mass mp HPLC TLC
Solvent Spec. Synth. Entry R (.degree. C.) (min.) R.sub.f System
[Source] Method 4 82 5.93 448 (M + H) +(HPLC ES - MS) A13 B1 C1a 5
83 120-122 0.67 100% EtOAc 478 (M + H) +(FAB) A8 C2d 6 84 0.40 50%
EtOAc/ 50% hexane 460 (M + H) +(HPLC ES - MS) A3 C2d 7 85 0.79 50%
EtOAc/ 50% hexane 446 (M + H) +(HPLC ES - MS) A12 C2d
[0332]
4TABLE 3 5-(Trifluoromethyl)-2-methoxyphenyl Ureas 86 TLC Mass mp
HPLC TLC Solvent Spec. Synth. Entry R (.degree. C.) (min.) R.sub.f
System [Source] Method 8 87 250 (dec) 460 (M + H) +(FAB) A13 C2a 9
88 206-208 0.54 10% MeOH/ 90% CH2Cl2 446 (M + H) +(HPLC ES - MS) A3
step 2, A8 step 4, B1, C1a 10 89 0.33 50% EtOAc/ 50% pet ether 445
(M + H) +(HPLC ES - MS) A13 C3 11 90 0.20 2% Et3N/ 98% EtOAc 461 (M
+ H) +(HPLC ES - MS) A2 C4 12 91 0.27 1% Et3N/ 99% EtOAc 447 (M +
H) +(HPLC ES - MS) A2 C4 13 92 0.62 100% EtOAc 461 (M + H) +(FAB)
A2 C2a 14 93 114-117 0.40 1% Et3N/ 99% EtOAc 447 (M + H) +(FAB) A2
C4 15 94 232-235 0.54 100% EtOAc 490 (M + H) +(FAB) A8 C2d 16 95
210-213 0.29 5% MeOH/ 45% EtOAc/ 50% pet ether 475 (M + H) +(HPLC
ES - MS) A5 B1 C1c 17 96 187-188 0.17 50% EtOAc/ 50% pet ether 495
(M + H) +(HPLC ES - MS) A6 B1 C1a 18 97 0.48 100% EtOAc 475 (M + H)
+(HPLC ES - MS) A2 step 4, B1 C1a 19 98 194-196 0.31 5% MeOH/ 45%
EtOAc/ 50% pet ether 475 (M + H) +(HPLC ES - MS) A2 B1 C1a 20 99
214-216 0.25 5% MeOH/ 45% EtOAc/ 50% pet ether 495 (M + H) +(HPLC
ES - MS) A2 C1a 21 100 208-210 0.30 50% EtOAc/ 5% hexane 481 (M +
H) +(HPLC ES - MS) A19 C2a 22 101 188-190 0.30 70% EtOAc/ 50%
hexane 447 (M + H) +(HPLC ES - MS) A15, step 4, C1a 23 102 0.50 70%
EtOAc/ 30% hexane 472 (M + H) +(FAB) A3 B1 C1a 24 103 203-205 0.13
100% EtOAc 479 (M + H) +(HPLC ES - MS) A2 B1 C1a 25 104 0.09 75%
EtOAc/ 25% hexane 458 (M + H) +(HPLC ES - MS) A12 C2d 26 105
169-171 0.67 50% EtOAc/ (50% pet ether 474 (M + H) +(HPLC ES - MS)
A13 step 1, A13 step 4, A16, B1 C1a 27 106 218-219 0.40 50% EtOAc/
50% pet ether 477 (M + H) +(HPLC ES - MS) A2 step 3b, A2 step 4,
B1, C1a 28 107 212-214 0.30 40% EtOAc/ 60% hexane A9 B1 C1a 29 108
0.33 50% EtOAc/ 50% pet ether 474 (M + H) +(HPLC ES - MS) A2 step
3b, A2 step 4, B1, C1a 30 109 210-211 A2 B1 C1a 31 110 210-214 0.43
10% MeOH/ CH2Cl2 A14 B1 C1a D4 32 111 247-249 0.57 10% MeOH/ CH2Cl2
A14 B1 C1a D4 33 112 217-219 0.07 10% MeOH/ CH2Cl2 A14 B1 C1a D4 34
113 0.11 70% EtOAc/ 30% hexane A11 B1 C1f D1c 35 114 0.38 70%
EtOAc/ 30% hexane A11 B1 C1f D1c 36 115 0.77 70% EtOAc/ 30% hexane
A11 B1 C1f D1c 37 116 0.58 70% EtOAc/ 30% hexane A11 B1 C1f D1c 38
117 0.58 70% EtOAc/ 30% hexane A11 B1 C1f D1c 39 118 0.17 70%
EtOAc/ 30% hexane A11 B1 C1f D1c 40 119 0.21 70% EtOAc/ 30% hexane
A11 B1 C1f D1c
[0333]
5TABLE 4 3-(Trifluoromethyl)-4-chlorophenyl Ureas 120 TLC Mass mp
HPLC TLC Solvent Spec. Synth. Entry R (.degree. C.) (min.) R.sub.f
System [Source] Method 41 121 163-165 0.08 50% EtOAc/ 50% pet ether
464 (M + H) +(HPLC ES - MS) A13 C3 42 122 215 0.06 50% EtOAc/ 50%
pet ether 465 (M + H) +(HPLC ES - MS) A2 C1a 43 123 0.10 50% EtOAc/
50% pet ether 451 (M + H) +(HPLC ES - MS) A2 C1a 44 124 0.25 30%
EtOAc/ 70% pet ether 451 (M + H) +(HPLC ES - MS) A2 C1a 45 125 0.31
30% EtOAc/ 70% pet ether 465 (M + H) +(HPLC ES - MS) A2 C1a 46 126
176-179 0.23 40% EtOAc/ 60% hexane 476 (M + H) +(FAB) A3 C1a 47 127
0.29 5% MeOH/ 45% EtOAc/ 50% pet ether 478 (M + H) +(HPLC ES - MS)
A5 C1c 48 128 206-209 A15 C1a 49 129 147-151 0.22 50% EtOAc/ 50%
pet ether 499 (M + H) +(HPLC ES - MS) A2 C1a 50 130 0.54 100% EtOAc
479 (M + H) +(HPLC ES - MS) A2 C1a 51 131 187-189 0.33 5% MeOH/ 45%
EtOAc/ 50% pet ether 479 (M + H) +(HPLC ES - MS) A2 C1a 52 132 219
0.18 5% MeOH/ 45% EtOAc/ 50% pet ether 499 (M + H) +(HPLC ES - MS)
A2 C1a 53 133 246-248 0.30 50% EtOAc/ 50% hexane 485 (M + H) +(HPLC
ES - MS) A19, C1a 54 134 196-200 0.30 70% EtOAc/ 30% hexane) 502 (M
+ H) +(HPLC ES - MS) A15 C1a 55 135 228-230 0.30 30% EtOAc/ 70%
CH2Cl2 466 (M + H) +(HPLC ES - MS) 56 136 238-245 57 137 221-222
0.75 80% EtOAc/ 20% hexane 492 (M + H) +(FAB) C1d D1a 58 138 247
0.35 100% EtOAc C1d D1a D2 59 139 198-200 0.09 100% EtOAc 479 (M +
H) +(HPLC ES - MS) A2 C1a 60 140 158-160 0.64 50% EtOAc/ 50% pet
ether 61 141 195-197 0.39 10% MeOH/ CH2Cl2 A13 C1a 62 142 170-172
0.52 10% MeOH/ CH2Cl2 A13 C1a 63 143 168-171 0.39 10% MeOH/ CH2Cl2
A13 C1a 64 144 176-177 0.35 10% MeOH/ CH2Cl2 A13 C1a 65 145 130-133
487 (M + H) +(HPLC ES - MS) A2 B1 C1a 66 146 155 A2 C1a 67 147
225-229 0.23 100% EtOAc C1e D3 D1b 68 148 234-236 0.29 40% EtOAc/
60% hexane A9 C1a 69 149 0.48 50% EtOAc/ 50% pet ether 481 (M + H)
+(HPLC ES - MS) 70 150 0.46 5% MeOH/95% CH2Cl2 564 (M + H) +(HPLC
ES - MS) A10 C1a 71 151 199-201 0.50 10% MeOH/ CH2Cl2 A14 C1a D4 72
152 235-237 0.55 10% MeOH/ CH2Cl2 A14 C1a D4 73 153 200-201 0.21
50% MeOH/ CH2Cl2 A14 C1a D4 74 154 145-148 75 155 0.12 70% EtOAc/
30% hexane 527 (M + H) +(HPLC ES - MS) A11 C1f D1c 76 156 0.18 70%
EtOAc/ 30% hexane A11 C1f D1c 77 157 0.74 70% EtOAc/ 30% hexane A11
C1f D1c 78 158 0.58 70% EtOAc/ 30% hexane A11 C1f D1c 79 159 0.47
70% EtOAc/ 30% hexane 569 (M + H) +(HPLC ES - MS) A11 C1f D1c 80
160 0.18 70% EtOAc/ 30% hexane 508 (M + H) +(HPLC ES - MS) A11 C1f
D1c 81 161 0.58 70% EtOAc/ 30% hexane 557 (M + H) +(HPLC ES - MS)
A11 C1f D1c 82 162 0.37 70% EtOAc/ 30% hexane 611 (M + H) +(HPLC ES
- MS) A11 C1f D1c 83 163 0.19 70% EtOAc/ 30% hexane A11 C1f D1c 84
164 179-183 A2 A17 C1a D5
[0334]
6TABLE 5 3-(Trifluoromethyl)-4-bromophenyl Ureas 165 TLC Mass mp
HPLC TLC Solvent Spec. Synth. Entry R (.degree. C.) (min.) R.sub.f
System [Source] Method 85 166 186-187 0.13 50% EtOAc/ 50% pet ether
509 (M + H) +(HPLC ES - MS) A2 B1 C1a 86 167 150-152 0.31 50%
EtOAc/ 50% pet ether 545 (M + H) +(HPLC ES - MS) A6 B1 C1a 87 168
217-219 0.16 50% EtOAc/ 50% pet ether 545 (M + H) +HPLC ES - MS) A2
B1 C1a 88 169 183-184 0.31 50% EtOAc/ 50% pet ether 525 (M + H)
+(HPLC ES - MS) A2 B1 C1a 89 170 0.21 50% EtOAc/ 50% pet ether 511
(M + H) +(HPLC ES - MS) A2 B1 C1a 90 171 0.28 50% EtOAc/ 50% pet
ether 525 (M + H) +(HPLC ES - MS) A2 B1 C1a 91 172 214-216 0.28 50%
EtOAc/ 50% pet ether 522 (M + H) +(HPLC ES - MS) A2 B1 C1a 92 173
0.47 50% EtOAc/ 50% pet ether 527 (M + H) +(HPLC ES - MS) A2 step
3b, A2 step 4, B1, C1a 93 174 0.46 50% EtOAc/ 50% pet ether 527 (M
+ H) +(HPLC ES - MS) A2 step 3b, A2 step 4, B1, C1a 94 175 145-150
0.41 5% MeOH/ 95% CH2Cl2 A10 B1 C1a
[0335]
7TABLE 6 5-(Trifluoromethyl)-4-chloro-2-methoxyphen- yl Ureas 176
TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (.degree. C.)
(min.) R.sub.f System [Source] Method 95 177 140-144 0.29 5% MeOH/
45% EtOAc/ 50% pet ether 495 (M + H) +(HPLC ES - MS) A2 A7 B1 C1a
96 178 244-245 0.39 5% MeOH/ 45% EtOAc/ 50% pet ether 529 (M + H)
+(HPLC ES - MS) A6 A7 B1 C1a 97 179 220-221 0.25 5% MeOH/ 45%
EtOAc/ 50% pet ether 529 (M + H) +(HPLC ES - MS) A2 B7 B1 C1a 98
180 0.27 5% MeOH/ 45% EtOAc/ 50% pet ether 495 (M + H) +(HPLC ES -
MS) A2 A7 B1 C1a 99 181 180-181 0.52 5% MeOH/ 45% EtOAc/ 50% pet
ether 509 (M + H) +(HPLC ES - MS) A2 A7 B1 C1a 100 182 162-165 A2
A7 B1 C1a
[0336]
8TABLE 7 Additional Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth.
Entry R (.degree. C.) (min.) R.sub.f System [Source] Method 101 183
162-165 A1 A2 C3 102 184 0.10 50% EtOAc/ 50% hexane 442 (M + H)
+(HPLC ES - MS) A2 A4 C2d 103 185 125-130 0.24 40% EtOAc/ 60%
hexane 512 (M + H) +(FAB) A2 C2b
[0337] The preceding examples can be repeated with similar success
by substituting the generically or specifically described reactants
and/or operating conditions of this invention for those used in the
preceding examples.
[0338] From the foregoing description, one skilled in the art can
easily ascertain the essential characteristics of this invention
and, without departing from the spirit and scope thereof, can make
various changes and modifications of the invention to adapt it to
various usages and conditions.
* * * * *